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Abstract 
Huntington’s disease (HD) is a devastating, incurable inherited neurodegenerative disorder that 
commonly affects adults in mid-life. Despite encouraging results from in vitro and animal trials, 
disease-modifying therapeutic trials in HD are limited by a lack of tools to track disease progression. 
HD is clinically heterogeneous, and current clinical rating scales lack sensitivity and specificity, 
particularly over relatively short time periods. Improvements in the precision of objective 
measurement of disease progression in HD could lead to state markers (biomarkers) better able to 
predict onset, detect progression and measure the effects of therapeutic intervention. Biomarkers 
capable of detecting disease-related changes in premanifest gene carriers will be essential for 
clinical trials of treatments to delay onset.  Imaging, clinical and cognitive assessment as well as 
laboratory markers have all been proposed as biomarkers, but few measures have been quantified 
over short time intervals or shown to be predictive of clinical change over longer periods. 
A robust panel of biomarkers from a number of modalities will be necessary to progress to 
interventional clinical trials of disease-modifying therapies in HD, using biomarkers to measure the 
success or failure of an intervention. Such cross-validation requires simultaneous multimodal 
biomarker evaluation within a suitable cohort of subjects studied longitudinally. 
This thesis describes a multi-modal approach to the discovery and evaluation of potential 
biomarkers for Huntington's disease in a large cohort of human volunteers. After reviewing the 
relevant features of Huntington's disease and current state of biomarker research in Huntington's 
disease, several approaches to, and outcomes from, biomarker discovery and evaluation are 
described, including proteomic profiling, targeted ELISA, multiplex inflammatory profiling and 
measurement of whole-brain atrophy by longitudinal magnetic resonance imaging. The thesis draws 
together these different approaches and summarises the contributions to both biomarker research 
and our understanding of the neurobiology of HD that the work has generated. 
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He shall suffer whatever events his own fate and 
the stern Spinners twisted into his thread of destiny 
when he entered the world and his mother bore him. 
Homer, Odyssey. Book viii, 193ff. 
 
 
 
 
The Three Fates, Jacob Matham (1587). 
The thread of life was spun by Clotho and 
finally severed by Atropos; but it was Lachesis, 
‘the measurer’, who determined its length. 
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Chapter I Introduction 
I.1 Huntington’s disease 
 
 
It is spoken of by those in whose veins the seeds of the disease are 
known to exist, with a kind of horror, and not at all alluded to except 
through dire necessity, when it is mentioned as ‘that disorder’. 
 
 
O WROTE GEORGE Huntington in 1872 in his Medical and Surgical Reporter paper On chorea, 
the initial report of the disease that came to bear his name (Huntington 1872). It is difficult to 
do justice, in describing it, to the diversity and magnitude of the effects of Huntington’s disease 
(HD) on its sufferers, those who know they are destined to develop it, those who do not know 
whether they have inherited it, and their loved ones. An illustration of its horrors can be had from 
descriptions of HD in the usually sober scientific literature where, in addition to setting out its major 
features — ‘neurodegenerative’, ‘progressive’, ‘inherited’, ‘severe’, ‘fatal’ — more vivid descriptions 
go some way towards depicting the influence of HD, seen through the eyes of the researcher: 
‘devastating’, ‘dramatic’, ‘incurable’, ‘inexorable’. 
Prose cannot convey the overwhelming power of HD to destroy lives and families. This introductory 
chapter will nonetheless set out the basic epidemiological, clinical and pathological facts of HD, 
before going on to review some of the reasons why there is hope for disease-slowing treatments in 
the near future, finally discussing the current state of biomarkers for HD, and why and how such 
markers may enable treatments to reach the patients and gene carriers so desperately in need of 
them.  
S 
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I.1.1 Clinical features 
I.1.1.1 General description 
... hardly ever manifesting itself until adult or middle life, and then 
coming on gradually but surely, increasing by degrees, and often 
occupying years in its development, until the hapless sufferer is but a 
quivering wreck of his former self ...  
(Huntington 1872) 
The classical triad of clinical features of HD consists of movement disorders, psychiatric 
abnormalities and cognitive decline (Bates et al. 2002). In addition, manifestations of HD outside 
the central nervous system are increasingly seen as having direct relevance to the disease course 
(e.g. Björkqvist et al. 2006; Robbins et al. 2006). These aspects are discussed in turn below. 
While, as Huntington himself described chillingly, HD generally is a disease affecting young adults, 
with a mean age at onset of around forty years, one of the striking features of the disease is its 
heterogeneity, in both age at onset and clinical phenotype, capable of beginning at any time from 
early childhood to old age (McCusker et al. 2000; Rasmussen et al. 2000). With exceptions, HD 
generally progresses slowly, especially in comparison with some of the more common 
neurodegenerative diseases such as Alzheimer’s disease. The median interval between clinical 
diagnosis and death is typically given as 15 to 20 years (Roos et al. 1993), though it is to be hoped 
that the modern multidisciplinary care of HD patients is capable of sustaining good quality life for 
longer than this. 
HD is caused by a CAG triplet repeat expansion in the IT15 gene, encoding the protein huntingtin 
(The Huntington’s Disease Collaborative Research Group 1993). The disease is inherited in an 
autosomal dominant manner and the length of the expanded CAG repeat tract is a determinant of 
the age at onset. Repeat lengths of 39 and over are associated with full penetrance. In the 
expanded range, the length of the CAG repeat predicts about 50-70% of the age at clinical onset, 
with larger repeat lengths tending to result in earlier onset (Andrew et al. 1993; Duyao et al. 1993; 
Snell et al. 1993). 
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I.1.1.2 Neurological features 
The most striking neurological feature of HD is the movement disorder chorea; indeed, until 
recently HD was known as Huntington’s chorea. From the Greek κορεια (koreia), the term means 
literally ‘a dance’. Chorea is a hyperkinetic movement disorder characterised by excessive 
spontaneous movements that are irregularly timed, randomly distributed and abrupt. It ranges in 
severity from restlessness with mild, intermittent exaggeration of gesture and expression, through 
fidgety movements of the hands and unstable dance-like gait, to a continuous flow of disabling and 
violent movements (Barbeau et al. 1981). Chorea is typically a relatively early motor feature and is 
seen in about 90% of adult-onset cases, but does not progress linearly: rather it tends to peak after 
a few years then gradually recede in advanced disease (Young et al. 1986). 
Non-choreic movement disorders, including hypokinetic abnormalities such as rigidity and 
bradykinesia as well as dystonia (sustained involuntary contraction of muscle groups) and 
impairment of voluntary motor function are less prominent in very early disease but are almost 
ubiquitous by moderate-stage disease and, unlike chorea, tend to increase more linearly over time, 
to predominate by advanced disease (Thompson et al. 1988). While chorea is often the most 
obvious feature — and the most distressing to friends and relatives — non-choreic movement 
disorders, with their tendency to disrupt gait, balance and function, are generally more disabling 
than chorea, to which many patients are in fact strangely oblivious (Snowden et al. 1998). Indeed, 
symptomatic treatment of chorea with neuroleptic medications often does not produce functional 
improvement, because of worsening of hypokinetic features (Shoulson 1981). Rigidity and other 
hypokinetic features are usually prominent in juvenile-onset HD, which also carries an increased risk 
of seizures. About 10% of adult patients have an early bradykinetic phenotype with minimal chorea: 
this is known as the Westphal variant (Westphal 1883; Louis et al. 2000). 
Oculomotor disturbance is a cardinal feature of HD: it is near-universal and frequently present as a 
very early, though subtle, manifestation. The key features in early disease are delayed initiation of 
saccadic eye movements and inability to suppress reflexive fixation on novel stimuli; later, the 
saccades become slowed and are accompanied by blinking or head-thrusts; in advanced disease, 
broken pursuits, gross saccadic slowing and gaze restriction are seen. Oculomotor abnormalities 
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imply a progressive degeneration of frontal-subcortical networks and, as some of the earliest 
changes seen in HD, are appealing as a source of potential biomarkers (Lasker et al. 1997). 
Other neurological abnormalities include hyperreflexia, which is present in 90% of patients in early 
disease and implies involvement of the pyramidal tracts (Young et al. 1986). Dysarthria and 
dysphagia are very common from moderate-stage disease onwards and the latter is a major cause 
of morbidity and mortality. By end-stage disease, patients are almost totally disabled, fully 
dependent and unable to communicate. Death in Huntington’s disease is most commonly caused 
by infection, malnutrition or suicide (Lanska et al. 1988).  
A standardised clinical rating system for HD was first introduced in 1979 in an attempt to produce a 
scale capable of quantifying the main clinically-relevant disease features, both for clinical use and to 
standardise clinical measures between studies (Shoulson et al. 1979). Initially it consisted of a 
functional scale, to which motor and psychiatric components were added (Shoulson 1981) until 
formally codified as the unified Huntington’s disease rating scale, with motor, behavioural, 
functional and cognitive components (The Huntington Study Group 1996). 
The UHDRS is widely used, both clinically and in observational and interventional studies of HD. It 
is not without its weaknesses, however. It is virtually impossible to standardise its application 
completely, so it is subject to considerable inter-rater and intra-rater variability (Hogarth et al. 2005). 
More importantly, it cannot be considered to be an accurate reflection of the totality of the disease 
process. Certain key features, such as weight loss, are omitted altogether, while others seem to have 
undue prominence: of a possible 124 points on the motor scale, hyperkinetic movement disorders 
(dystonia and chorea) contribute 48 points while the impairment of voluntary movements 
contributes only 32 and bradykinesia 16, even though the latter two categories are each 
independently more important than chorea in contributing functional disability (Shoulson 1981; 
Thompson et al. 1988). 
A key area of contention in neurological assessment in HD is the concept of ‘motor onset’, also 
known as ‘phenoconversion’. In the clinical setting, and in most studies, HD is officially diagnosed 
as having occurred when a trained specialist examines a patient and declares “the unequivocal 
presence of an otherwise unexplained extrapyramidal movement disorder (e.g., chorea, dystonia, 
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bradykinesia, rigidity)” (The Huntington Study Group 1996; Hogarth et al. 2005). The UHDRS motor 
scale incorporates a diagnostic confidence score (Table 1) that can be scored between 0 and 4, a 
score of 4 being required for the formal diagnosis of HD.  
Description Score 
Normal (no abnormalities) 0 
Non-specific motor abnormalities (less than 50 % confidence) 1 
Motor abnormalities that may be signs of HD (50 - 89 % confidence) 2 
Motor abnormalities that are likely signs of HD (90 - 98 % confidence) 3 
Motor abnormalities that are unequivocal signs of HD (≥ 99 % confidence) 4 
Table 1 UHDRS diagnostic confidence score 
Thus defined, motor onset is one of the most reliably identifiable points in the course of the disease 
and is certainly of great value in the clinical setting in terms of establishing a ‘moment’ of clinical 
onset and its attendant prognostic predictions. Motor onset has relatively high inter-rater agreement: 
in one study of 75 clinicians shown video recordings of HD subjects, the proportion of agreement 
(expressed as κ scores) was 0.67 for diagnostic confidence scores of 4. However, for lesser scores 
agreement was poor — only 0.32 (Hogarth et al. 2005). Since virtually all ‘premanifest’ gene carriers 
(that is, those with diagnostic confidence scores less than four) have full functional capacity, motor 
onset is currently the only ‘hard’ diagnostic criterion that could be used to power clinical trials in 
HD. Because the emergence of “unequivocal” motor scores takes many years on average, and 
because of imperfect inter-rater agreement, the sample size requirements generated by the use of 
motor onset are enormous: a four-year trial capable of detecting a 20% disease-slowing effect in 
premanifest HD would require over 3,000 participants (Paulsen et al. 2006). 
Moreover, ‘phenoconversion’ defined by the onset of specific motor features overlooks the crucial 
fact that for many subjects, motor abnormalities are not the first or dominant features of the illness. 
While 90% of adult-onset patients do develop chorea at some point during the illness, many of the 
most severely affected (juvenile and Westphal-variant cases) never do; meanwhile, many patients 
experience many years of cognitive or behavioural disturbances that, in retrospect, can be seen to 
have been the earliest manifestations of HD. In a study of 960 patients diagnosed as having 
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undergone ‘motor onset’, motor abnormalities were retrospectively felt by the clinician to have 
been the earliest disease symptom or sign in only 56%. Psychiatric, cognitive and multifactorial 
presentations were almost as common and there is no reason to suppose that subjects with such 
presentations lacked neuropathology of a degree comparable with that seen in patients with early 
motor signs. 
Motor
56%
Psychiatric
22%
Cognitive
14%
Mixed
9%
Other
0.5%
 
Figure 1 Initial presenting feature of HD, determined retrospectively by clinician in 960 patients 
with ‘manifest’ disease 
(Adapted from Marder et al. 2000.) 
Thus, while ‘motor onset’ has value to the physician and to the patient, as a means of determining 
mutually that the stage of progressive functional decline has begun, as a surrogate measure of 
neuropathological equivalence, it leaves much to be desired. Sadly, there is no unified measure of 
the fundamental severity of HD that can be used to compare all HD gene carriers — both with and 
without motor signs — directly. This highlights the need for measures that can be applied 
agnostically across all gene carriers to give an objective measure, related to neuropathology, and 
have clinically relevant predictive value: a central aim of the search for biomarkers and of this thesis. 
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I.1.1.3 Psychiatric features 
The tendency to insanity, and sometimes that form of insanity which 
leads to suicide, is marked ... As the disease progresses the mind 
becomes more or less impaired, in many amounting to insanity, while 
in others mind and body both gradually fail until death relieves them 
of their sufferings. 
(Huntington 1872) 
Psychiatric manifestations of Huntington’s disease constitute some of the most disabling features, 
yet are sometimes among the more treatable, at least symptomatically. As alluded to by Huntington, 
the emergence of psychiatric disturbances at some point during the illness is near-universal but 
varies greatly in severity (Paulsen et al. 2001).  
Many patients become depressed and, while the social and lifestyle effects of living with the effects 
of an incurable degenerative disease in oneself and one’s family are far from negligible, there is 
consensus that depression in HD has its basis in neurodegeneration (Mindham et al. 1985) The 
cross-sectional prevalence of depression in HD high, around 50% (compared with 4% in the 
general population), and the onset of depression frequently predates the diagnosis of manifest HD 
by several years (Folstein et al. 1983; Folstein et al. 1987; Pflanz et al. 1991). As expected with such 
a high prevalence of depression, suicide, attempted suicide and self-harm are common: in one study 
suicide as a cause of death (likely an underestimate of all cases) was four times more common in 
HD patients than in the population (Farrer 1986). 
Anxiety disorder is a frequent accompaniment of depression in HD and can also occur in isolation 
and be disabling. Irritability and apathy are well-recognised clinically and by family members and 
carers, and can be highly challenging behaviours for all concerned (Paulsen et al. 2001). Other 
psychiatric disorders such as psychotic illness and mania appear to be more common in HD than in 
the general population (Pflanz et al. 1991). Sexual disinhibition and inappropriate behaviour are 
probably less common than generally held, because of the excessive tendency of such behaviours 
to be reported. The commonest sexual dysfunctions in HD are in fact hypoactive sexual desire and 
inhibited orgasm (Fedoroff et al. 1994). 
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The optimal assessment of psychiatric features in HD is a matter of debate. Psychiatric phenomena 
—disturbances of thought and mind — are by definition impossible to assess objectively, so 
behavioural measures, based on reports and outward manifestations of psychiatric disturbance, 
must be relied upon. Traditional formal clinical criteria for the diagnosis of psychiatric abnormalities, 
such as the International Classification of Diseases (ICD) and Diagnostic and Statistical Manual 
(DSM), specifically preclude diagnosis of individual syndromes in the presence of an organic brain 
disease such as HD (World Health Organization 1992; American Psychiatric Association 1994). 
Generic scales such as the Beck Depression Inventory (Beck et al. 1996) and Hospital Anxiety and 
Depression Scale (Zigmond et al. 1983) lack questions about important behavioural manifestations 
of HD, such as irritability, or ask questions that may be confounded by non-behavioural features, as 
in the BDI’s question about weight loss, that may render the results unreliable. 
The UHDRS behavioural assessment, used in the REGISTRY study, is a semi-structured interview 
that seeks to quantify the severity and frequency of symptoms in each of the following domains: 
depressed mood; low self-esteem/guilt; anxiety; suicidal thoughts; disruptive or aggressive 
behaviour; irritable behaviour; perseverative/obsessional thinking; compulsive behaviour; delusions; 
hallucinations; apathy; and behavioural milestones (The Huntington Study Group 1996; Euro-HD 
Network REGISTRY Steering Committee 2003-8). However, the UHDRS behavioural assessment, 
while widely used, is also widely criticised for lacking precise operational criteria (vague terms like 
“seldom”, “sometimes” or “frequently”, for example) and for a poorly capturing the spectrum of 
behavioural impairments in HD. For instance, perseverative/obsessional behaviour and compulsive 
behaviour are often impossible to dissociate in HD, in which the persistent, recurrent thoughts and 
behaviours are better described as ‘perseverative’ rather than in the terminology of obsessive-
compulsive disorder. The Problem Behaviours Assessment (Craufurd et al.) stemmed from an 
attempt to re-evaluate the behavioural features of HD based on theoretical features of interest from 
publications of disorders of the frontal lobes, symptoms mentioned during clinical consultations and 
features from the literature in HD. The result was a forty-point questionnaire that, while thorough 
and evidence-based, was also redundant and too long in the administration for use in a multimodal 
assessment study such as this.  
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The Behavioural Phenotype Working Group of the Euro-HD network has as a central aim the 
development and improvement of available behavioural assessment tools. Working collaboratively, 
the working group has developed the Short Behavioural Assessment, a questionnaire intended to 
replace the UHDRS behavioural assessment as a quickly-administered assessment encompassing 
the main domains of behavioural dysfunction in HD in a comprehensive yet parsimonious tool that 
can be administered in 15-30 minutes. It combines features of both the UHDRS behavioural 
assessment with refinements derived from the longer PBA. It takes the form of a structured 
interview and is accompanied by consensus guidelines for its administration and scoring, as well as 
a formalised training programme to improve standardisation. 
I.1.1.4 Cognitive features 
Progressive multi-domain cognitive decline, amounting to a form of dementia, is a universal feature 
of HD, frequently emerging early in the clinical course or even several years before the emergence 
of neurological signs (Craufurd et al. 2002; Johnson et al. 2007; Solomon et al. 2007). In keeping 
with the distribution of pathology (and, by retrograde extension, neuronal dysfunction), the 
cognitive phenotype of HD is generally described as a frontal-subcortical syndrome, with abnormal 
activity in the frontal cortex and basal ganglia likely contributing throughout the illness (Brandt et al. 
1986). Cognitive decline is a major source of concern for patients and carers, and a leading 
predictor of functional impairment (Marder et al. 2000). 
Executive function impairment is the most striking cognitive feature of HD. Difficulty with multi-
tasking, impaired concentration, impulsivity, excessively rigid thinking and psychomotor slowing are 
features of the dysexecutive syndrome, the severity of which correlates with striatal and insular 
atrophy (Peinemann et al. 2005). Unlike disorders selectively affecting frontal cortical function, HD 
is also characterised by psychomotor slowing, and in contrast to other causes of dementia, 
language, visuospatial and visuoperceptual function tend to be relatively preserved (Craufurd et al. 
2002). Apparent deficits in memory are generally due to problems of organisation and attention 
rather than an amnestic syndrome per se (Lundervold et al. 1994). 
The cognitive phenotype of the longitudinal imaging study cohort described in this work has been 
characterised in detail in another thesis, so is not reported in detail here (Henley 2008). 
 24 
I.1.1.5 Systemic features 
The clinical features of HD are seldom confined to the central nervous system. Huntingtin is 
expressed ubiquitously and it is therefore perhaps unsurprising that the mutant protein should 
produce a phenotype outside the CNS as well as within it. Prominent weight loss, sometimes 
amounting to cachexia, is an invariable feature of advanced HD but is also frequently seen earlier in 
the disease course (Sanberg et al. 1981; Farrer et al. 1985; Morales et al. 1989; Aziz et al. 2008). 
Low weight (i.e. low body mass index) is associated with more rapid progression of HD (Myers et al. 
1991). The additional calorific burden of the hyperkinetic movement disorder appears inadequate 
to explain the weight loss of HD, which may relate to an underlying energy utilisation deficit 
(Mochel 2007). Weight loss is often accompanied by muscle wasting (Sanberg et al. 1981), which is 
probably at least partially due to direct effects of the mutation on muscle cells (see section I.1.4.4). 
HD patients appear to have decreased beat-to-beat variability of the heart rate (Sharma et al. 1999), 
suggesting cardiovascular involvement in HD. The endocrine system represents a nexus between 
the CNS and peripheral tissues and endocrine disturbances, not entirely explicable by hypothalamic 
dysfunction, are a feature of HD: the prevalence of diabetes mellitus appears to be higher than in 
the general population (Farrer 1985) and testicular size and hormonal profile are altered (Markianos 
et al. 2005; Van Raamsdonk et al. 2007). 
Many of these peripheral features contribute to HD patients’ morbidity and mortality directly, and 
may also contribute indirectly to CNS dysfunction. The notion of exploiting these peripheral disease-
related changes as a possible source of biomarkers is discussed in sections I.1.4.4 and I.2. 
I.1.2 Genetics of Huntington’s disease 
When either or both the parents have shown manifestations of the 
disease ... one or more of the offspring almost invariably suffer from the 
disease, if they live to adult age. But if by any chance these children go 
through life without it, the thread is broken and the grandchildren and 
great-grandchildren of the original shakers may rest assured that they 
are free from the disease. 
(Huntington 1872) 
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That IT15 (‘interesting transcript 15’), the gene encoding the huntingtin protein, is the cause of HD, 
was discovered in 1993 after a major and unprecedented international collaborative effort (The 
Huntington’s Disease Collaborative Research Group 1993). The causative mutation is an expansion 
of a CAG triplet repeat tract in exon one, from the normal range of up to 29 repeats into the 
disease range of over 39 repeats. In the disease range, the mutation is essentially fully penetrant, 
with 100% of HD patients expected to develop disease manifestation unless they die prematurely 
from another cause. The expansion is now seen as fully sensitive and specific for HD, such that HD-
like disorders in patients lacking it are referred to as HD phenocopies and alternative causes for 
their condition are sought, and no condition other than HD is known to be caused by the mutation. 
As mentioned above, the length of the CAG repeat tract has a significant impact on the disease 
course, specifically on the likely age at which disease signs will emerge. The correlation was 
discovered shortly after the gene itself and repeat length appears to account for between 50 and 
70% of the variation in age at onset (Andrew et al. 1993; Duyao et al. 1993; Snell et al. 1993). These 
findings have been confirmed in many large cohorts and the relationship between CAG repeat 
length and onset was recently comprehensively examined by Langbehn and colleagues. As shown 
in Figure 2, repeat lengths of 40 and above are associated with over 90% lifetime probability of 
motor onset, assuming a life expectancy of 80 years. Each successive CAG repeat shifts the 
cumulative onset probability curve to the left, indicating earlier likely ages at onset, but the effect is 
not linear, so that the age difference from 40 to 42 is greater than that from 54 to 56. Conversely, 
the curves are steeper for higher repeats, indicating a tighter range of likely onset ages. So, for an 
individual with 40 repeats, the probability of onset increases from 10% to 90% over a period of 27 
years; for someone with 56 repeats, that probability range spans just 15 years (Langbehn et al. 
2004). 
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Figure 2 Cumulative probability of motor onset for a given age, by CAG repeat length 
(Reproduced from Langbehn et al. 2004 by permission of Wiley, Inc.) 
Figure 3, based on data from the same study, shows the relative frequencies of each pathological 
repeat length. The most common length is 43 triplets, and the majority of alleles are tightly 
distributed with repeats between 42 and 45, towards the lower end of the observed sizes, in the 
range where the range of likely ages of onset is very wide. The study also gave rise to the now 
widely-used formula for the calculation of an individual’s probability of motor onset over a chosen 
interval, given that he or she is currently without motor signs. This calculation, which is of great 
value in assessing the extent to which a candidate biomarker is associated with known genetic 
predictors of disease, is discussed in detail in chapter II.11. 
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Figure 3 Frequency of expanded alleles in 3452 subjects from 40 centres 
(Adapted from Langbehn et al. 2004.) Grey shaded bars represent those allele sizes falling in the 25th 
to 75th percentiles. 
Almost all cases of juvenile-onset HD occur patients with large CAG repeats, typically over 50, and 
juvenile patients usually have a rapidly progressive akinetic-rigid presentation (Telenius et al. 1993; 
Sánchez et al. 1996). Juvenile HD apart, CAG repeat length is a poor predictor of phenotypic 
characteristics other than age at onset. Sources of the great clinical heterogeneity of HD, such as 
the balance of motor and non-motor symptoms, cannot be predicted based on CAG repeat length 
(MacMillan et al. 1993). Whether CAG repeat length influences rate of progression is a 
controversial topic, subject as it is to the analytical hazards of the inextricably-linked 
interrelationships between repeat length, onset age and disease duration discussed in chapters 
II.3.1.3 and II.11.10. It is clear that subjects whose disease manifests at a younger age progress 
more quickly, but proving an additional effect of CAG repeat length on rate of progression that 
survives statistical correction for age at onset per se is problematic. Early studies failed to find an 
effect at all (e.g. Kieburtz et al. 1994) while others found a trend that did not survive correction for 
the effect of age at onset (Brandt et al. 1996). However, more recent studies using larger subject 
numbers and standardised clinical measures do suggest an effect of CAG repeat length on clinical 
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and functional progression independent of age-at-onset (Mahant et al. 2003; Ravina et al. 2008). 
Unsurprisingly, there appears to be an effect of CAG repeat length on the severity of pathology, 
after correction for age at onset, a finding that led to the ‘disease burden score’ calculation 
discussed in chapter II.11.10 (Penney et al. 1997). Several proposed biomarkers of progression 
across assessment modalities have been shown to correlate independently with CAG repeat length; 
section I.2 below mentions these in turn. 
That HD is caused by a triplet repeat expansion is the explanation for the phenomenon of 
anticipation, which describes the tendency for an inherited disease to emerge earlier, or with a 
more severe phenotype, with each successive generation. Anticipation in HD is caused by a 
combination of the causative relationship of CAG repeat length with age at onset, and the tendency 
for the length pathogenic expansions to increase, on average, with each generation (Andrew et al. 
1993; Duyao et al. 1993; The Huntington’s Disease Collaborative Research Group 1993). 
Interestingly, intergenerational repeat-length expansions are sexually dimorphic: while small changes 
of up to seven repeats are seen in both male and female transmissions, with an overall mean 
change of zero, transmissions from male expansion carriers are disproportionately prone to large 
changes in repeat length, producing a mean intergenerational increase of +4 repeats from paternal 
inheritance. Moreover, the larger the parental repeat length, the more likely is a large expansion on 
transmission. This explains why the majority of juvenile HD cases are inherited from an affected 
father (Ranen et al. 1995). The mechanisms underlying the male-specific expansion of HD alleles are 
poorly understood. Clearly males are differentially susceptible to unfavourable germ-line mutations 
and it has been suggested that the CAG repeat tract allowing ‘slippage’ of the DNA replication 
apparatus, combined with the greater number of cell divisions in spermatogenesis compared with 
oogenesis, may underlie the phenomenon. However, other triplet-repeat diseases such as fragile X 
syndrome and spinocerebellar ataxia type 7 tend to expand through the maternal line, so this is 
clearly an incomplete explanation (Pearson 2003). 
Whereas repeat lengths of 39 and above may be considered fully penetrant, and those under 29 
repeats are normal, lengths between these values are a cause for diagnostic uncertainty. The lower 
end of the range — 29 to 35 repeats — is usually referred to as the ‘intermediate allele’ range. 
Between 1% and 4% of the general population carries alleles in this range. While they do not cause 
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a clinical phenotype themselves — reported exceptions remain controversial (Kenney et al. 2007; 
Semaka et al. 2008) — there is concern that they may expand into the pathogenic range in future 
generations (Semaka et al. 2006). Repeat lengths in the range of 36 to 39 are referred to as 
‘reduced penetrance’ alleles and may or may not produce a clinical HD syndrome during an 
individual’s natural life (Langbehn et al. 2004). As shown in Figure 2, the distinction between these 
and ‘fully penetrant’ alleles is purely quantitative and, unlike alleles of fewer than 36 repeats, it is 
likely that they would eventually produce a clinical phenotype if the subject were to live sufficiently 
long. 
The co-existence of anticipation and intermediate and reduced-penetrance alleles is the likely 
explanation for the continued prevalence of HD, despite its apparently self-terminating tendency. 
Were it not for the ability of normal alleles to expand into the intermediate range, and for subjects 
lacking a clinical phenotype thereby to pass on an expanded allele to their offspring, each HD 
pedigree would tend to cease with a case of juvenile HD resulting in no offspring. There appears to 
be an inexhaustible supply of fresh mutations and new pedigrees with each passing generation. 
I.1.3 Epidemiology 
... the disease exists, so far as I know, almost exclusively on the east 
end of Long Island ... confined to certain and fortunately a few 
families. 
(Huntington 1872) 
Sadly, on the epidemiology of HD, George Huntington was mistaken. It is now known to be the 
third most common inherited neurological disorder in the United Kingdom, after type I 
neurofibromatosis and Charcot-Marie-Tooth disease (MacMillan et al. 1991). Worldwide, HD has 
been found in every population where it has been sought, and tends to have a prevalence (for 
manifest disease) of 2.5-10 per 100,000, with the consensus from the most reliable studies settling 
around 4 per 100,000 (Bates et al. 2002). Pockets of low (Japan, Finland) and high (Tasmania, 
Venezuela) prevalence are known to exist (Narabayashi 1973; Young et al. 1986; Palo et al. 1987; 
Pridmore 1990). Prevalence in the United Kingdom lies in the typical range for Western Europe 
(Bates et al. 2002), meaning that there are between 2400 and 6000 individuals with HD in the UK. 
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Half of those with an affected parent will inherit an expanded allele, but the disease generally 
remains asymptomatic for many years, only a minority of those at risk undergo testing, and some 
mutation carriers are unaware of their at-risk status. There are therefore many more individuals at 
risk, or gene-positive but prior to clinical diagnosis, than there are manifest HD patients. Estimates of 
the prevalence of the mutation (summarised in Figure 4) suggest that for every ten people with 
manifest disease, there are forty at-risk individuals, of whom fifteen carry the mutation (Walker et al. 
1981; Conneally 1984). Overall there are around 12,000 at-risk individuals (including gene-
negatives, premanifest gene carriers and manifest HD patients) in the UK. 
Manifest
HD:
2400
Premanifest
gene carriers:
3600
Gene-negative:
6000
At-risk subjects:
12000
Gene-positive:
6000
 
Figure 4 Prevalence estimates for the United Kingdom for subjects at risk of HD, gene negative 
individuals, premanifest carriers and manifest HD patients 
Estimates are based on the lower end of the range for UK prevalence of 4 per 100,000 and a low-end 
population estimate of 60 million. 
Large though these prevalence figures are, they cannot, of course, do justice to the collateral 
damage that HD continues to wreak: the psychosocial cost to those at risk of inheriting it of 
witnessing, often during their childhood, the slow, unremitting decline and death of at least one 
relative; the effect of the knowledge that they are at risk of the same condition; and the impact of 
the disease over many years on those left to care for the patients. Overall it is clear that HD casts a 
long shadow over very many families. 
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I.1.4 Pathobiology of Huntington’s disease 
But even if we take it for granted that we have discovered the sedes 
morbi we are still left in ignorance in regard to the nature of the 
derangement. And here we must leave the interesting subject of the 
pathology of this disease, and trust that the science, which has 
accomplished such wonders, through the never-tiring devotion of its 
votaries, may yet ‘overturn and overturn, and overturn it,’ until it is 
laid open to the light of day. 
(Huntington 1872) 
While knowledge that HD is caused by a single, fully penetrant mutation has led in the past fifteen 
years to a dramatic illumination of its molecular and cellular pathobiology, it cannot yet be 
considered “laid open to the light of day” and much remains unknown about the processes that lie 
between the mutation and its ultimate manifestations. A full review of the pathobiology of HD is 
beyond the scope of this thesis; after summarising the main features, this section will concentrate 
on aspects of pathology relevant to the search for HD biomarkers and the specific work presented 
in later chapters. 
I.1.4.1 Macroscopic pathology 
 
Figure 5 Comparison of coronal slices from fixed cerebral hemispheres of an HD patient and 
matched control subject 
HD patient on left, control subject on right. White arrowheads, caudate nuclei; black arrowheads, 
putamina. Image courtesy of Harvard Brain Tissue Resource Center. 
 32 
Macroscopically, HD brains weigh 10-20% less overall than matched control brains and it is obvious 
on inspection of gross specimens from advanced cases (Figure 5) that brain atrophy in HD is 
widespread and marked. The combined volume of both striata in an adult control seldom exceeds 
30mL (Aylward et al. 2004), less than 3% of the total brain volume of a typical adult (around 
1200mL). Thus, 70-90% of atrophy in HD must be extrastriatal. This consideration, with its 
implications for the ease and accuracy of measurement of whole-brain volume loss, as well as the 
likely clinical effects of that degree of extrastriatal atrophy, argues for the study of whole-brain 
atrophy, as discussed in Chapter VII, as a biomarker of HD progression. Despite these impressive 
whole-brain changes, it is clear that the striatum is differentially affected by atrophy. The caudate 
and putamen are virtually abolished by end-stage HD (Figure 5) and are the earliest structures to 
lose volume (Forno et al. 1979). Many of the early clinical abnormalities of HD, such as chorea, 
dystonia and the typical ‘subcortical’ dysexecutive cognitive syndrome, are explicable by striatal 
atrophy but would be expected to be worsened by cell death in other brain regions, especially 
those having connections with the striatum (Albin et al. 1989). Crucially for the discussions of 
Chapter VI and Chapter VII, measurement of atrophy using volumetric MRI can provide a marker of 
neuronal loss (Fox et al. 1996). 
I.1.4.2 Microscopic pathology 
Echoing the macroscopic picture, the neostriatum is most severely affected on the microscopic level 
in HD, with neuronal loss and astrogliosis (Figure 6). The widely-used pathological grading system of 
Vonsattel and colleagues is based on the severity of pathology in the striatum and divides subjects 
into five grades (0 to 4) based on the extent of macroscopic atrophy, neuronal death and 
astrocytosis in the caudate, putamen, globus pallidus and nucleus accumbens (Vonsattel et al. 
1985). 
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Figure 6 Microscopic HD pathology in the striatum 
A. HD striatum showing neuronal loss and astrocytosis (dark coloured processes). B. Striatum from 
age-matched control subject showing healthy neurons and a uniform background without astrocytosis. 
Haematoxylin and eosin stain. Image courtesy of Harvard Brain Tissue Resource Center. 
Within the striatum there is differential involvement of cell populations. Worst affected are the 
inhibitory GABAergic medium spiny neurons, which project to the globus pallidus and substantia 
nigra (Reiner et al. 1988). Why these cells should be selectively involved remains unclear but 
differential influences such as growth factors, excitotoxicity, neurotransmitter gene expression, 
somatic CAG repeat expansion and afferent anatomical connections have been suggested to 
contribute (Sieradzan et al. 2001; Gonitel et al. 2008) 
Beyond the striatum, most brain regions show pathological involvement to some extent. The 
cerebral cortex displays neuronal loss, affecting primarily layers III, IV and VI (Tellez-Nagell et al. 
1973). As has since been confirmed by MRI cortical thickness measurement (Rosas et al. 2002; 
Rosas et al. 2008), cortical atrophy is relatively uniform by end-stage, with relative sparing of the 
medial temporal lobes, and correlates with both CAG repeat length and the degree of striatal 
atrophy (Halliday et al. 1998). The frontal and prefrontal cortex, with its connections to the striatum, 
has long been known to be affected in HD and cortical cell loss has sometimes been considered 
secondary to striatal atrophy (Cudkowicz et al. 1990). However, recent work suggests that the 
pattern of regional neuropathology differs between clinical phenotypes, with predominantly motor 
cases having more cell loss in the motor cortex and predominantly psychiatric cases having greater 
loss in the cingulates and secondary visual cortex (Thu et al. 2008). Such region-specificity in cortical 
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pathology between different presentations argues for selective cortical pathology as a primary and 
clinically-relevant determinant of phenotype, a possibility investigated in Chapter VII. Other brain 
regions with potentially important functional links to phenotypic characteristics of HD have been 
found to be involved, including the cerebellum (Jeste et al. 1984), hypothalamus (Kremer et al. 
1991) and subcortical white matter (Halliday et al. 1998). Importantly, CAG repeat length is not 
constant throughout the brain, but displays regional mosaicism, and those areas where 
neuropathology is most pronounced, including the striatum and cerebral cortex, tend to be those 
where repeat length variability is greatest (Telenius et al. 1994). 
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Figure 7 Neuropil aggregates in premanifest HD 
Images taken from (A) striatum and (B) cortex of a premanifest HD mutation carrier. 
Immunohistochemical staining with EM48, an antibody to the N-terminal region of huntingtin. 
(Reproduced from Gutekunst et al. 1999 by permission of The Society for Neuroscience.) 
Immunohistochemical studies have shown that the huntingtin protein is widely expressed in 
neurons throughout the normal brain (Gutekunst et al. 1995). Areas of most severe pathology 
generally have high levels of normal huntingtin expression, though the converse is not true: 
huntingtin expression does not predict neuropathology (Ferrante et al. 1997). Mutant huntingtin 
forms ubiquitinated intracellular aggregates (Figure 7), to which other proteins are recruited. These 
aggregates can be in the neuropil, cytoplasmic, perikaryal or intranuclear. Curiously, while they are 
abundant in the cerebral cortex and elsewhere, aggregates are relatively sparse in the striatum 
(Gutekunst et al. 1999). Consequently there is much debate over whether mutant huntingtin 
aggregates are harmful, protective or benign. On the one hand, injecting aggregates into cells 
recapitulates the toxic effects of expressing mutant huntingtin (Yang et al. 2002) while on the other, 
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aggregates sequester mTOR, activating the autophagy pathway that may enhance the removal of 
toxic polyglutamine species (Ravikumar et al. 2004). 
Neuronal tissues have understandably been a focus of study in HD. However, key contributions of 
glial cells are increasingly being recognised. Chapter III and Chapter IV discuss a possible role for 
inflammation in the pathogenesis of HD and suggest a prominent role for microglial cells, the CNS 
equivalent of peripheral monocytes and macrophages. Microglial activation has been demonstrated 
in HD brain (Figure 8) and microglia have been shown to come into direct contact with neuronal 
cells containing huntingtin aggregates (Sapp et al. 2001). 
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Figure 8 Microglial activation in HD brain demonstrated using Tβ4 immunostaining 
Microglia (arrowheads) are only faintly labelled in control brain but prominent activation is seen in HD 
in both caudate and cortex, where the activated microglia adopt differing morphologies. (Reproduced 
from Sapp et al. 2001 by permission of Wolters Kluwer / LWW.) 
I.1.4.3 Molecular and cellular pathology 
Though pathogenic roles have been proposed for mutant huntingtin DNA and RNA (e.g. Galvao et 
al. 2001), the consensus view is that the mutant huntingtin protein is the toxic species that causes 
HD. Huntingtin is a 348kDa protein, expressed widely in tissues and in most intracellular 
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compartments. After fifteen years of intensive study, though its normal function is incompletely 
understood, it is thought to have diverse functions in vesicle transport, cytoskeletal anchoring, 
neuronal transport, postsynaptic signalling, cytoprotection and transcriptional regulation (reviewed 
in Imarisio et al. 2008). While embryonic knockout of huntingtin is lethal in mice, hemizygosity does 
not produce a disease phenotype in humans (Landles et al. 2004), and HD homozygotes do not 
possess a more severe phenotype than heterozygotes (Wexler et al. 1987); most researchers have 
therefore focused on the hypothesis that HD is caused by a toxic gain of function of mutant 
huntingtin. 
The presence of the CAG repeat sequence in the IT15 gene encodes a polyglutamine (polyQ) tract 
in the huntingtin protein. An expanded polyQ domain in the N-terminal portion of the protein 
induces conformation changes in the protein that result in inclusion formation. However, the n-
terminal fragment is sufficient to cause selective HD-like pathology, indicating that interactions of 
the polyglutamine tract prior to aggregate formation may be central to HD pathogenesis (Li et al. 
2000). 
That mutant huntingtin can cause death of neurons is clear, but the relationship between clinical 
phenotype and neuronal death is not straightforward. In one study, five patients with end-stage 
clinical HD had grade 0 pathology post-mortem (Myers et al. 1988). In the R6/2 HD mouse model, 
there is minimal striatal cell death despite a pronounced, progressive neurological phenotype 
(Carter et al. 1999). It is therefore clear that a long period of neuronal dysfunction precedes cell 
death and is sufficient to produce the disease phenotype. This has clear implications for the search 
for both disease-modifying therapies and biomarkers of progression. Treatments that prevent cell 
death, or biomarkers that signal cell death, are unlikely to be as useful as treatments that slow or 
reverse dysfunction, and biomarkers that can detect it. Finally, a conditional mouse model of HD 
has demonstrated that if the pathogenic processes arising from the expression of mutant huntingtin 
can be halted, both pathological and clinical progression are not only halted but reversed, 
suggesting that disease-modifying treatments have the potential to bring about clinical improvement 
well into the symptomatic phase of the disease (Yamamoto et al. 2000). 
The intracellular interactions and effects of mutant huntingtin are diverse, and numerous 
complementary pathways likely contribute synergistically to its detrimental effects (reviewed in 
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Landles et al. 2004). As summarised in Figure 9, the main mechanisms of dysfunction are felt to be 
gene transcriptional dysregulation, disordered protein folding, and deficient protein degradation. 
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Figure 9 Summary of the cellular pathogenesis of HD 
htt, huntingtin; Ub, ubiquitin. (Adapted from Landles et al. 2004 by permission of Nature publishing 
group; modifications after Imarisio et al. 2008.) 
Huntingtin, in both wild-type and mutant forms, not only interacts with a wide variety of 
transcription factors with key roles in neuronal function and survival (reviewed in Sugars et al. 2003) 
but also binds directly to DNA, altering the function of gene promoters in a polyglutamine-
dependent manner (Benn et al. 2008). Among the specific pathways deranged are the cAMP-
responsive element (CRE) and specificity protein 1 (SP1) pathways, critical to neuronal survival 
(Sugars et al. 2003), and the neuron-restrictive silencer element (NRSE) system that enables the 
cortex to provide trophic support to the striatum via the axonal delivery of brain-derived 
neurotrophic factor (BDNF) (Zuccato et al. 2003). Critically to the findings discussed in Chapter IV, 
mutant huntingtin has been shown to activate the IκB kinase complex, allowing nuclear entry of 
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NFκB — an important transcriptional activator of inflammatory genes — and enhancing the toxicity 
of mutant huntingtin (Khoshnan et al. 2004). More generally, the function of essentially any cellular 
pathway may be deranged directly or indirectly by transcriptional dysregulation and microarray 
studies have shown that gene expression in HD is widely deranged (Hodges et al. 2006). 
The ubiquitin-proteosome system is responsible for degrading unwanted small cellular proteins into 
amino acids. Mutant huntingtin aggregates are ubiquitinated, indicating that they are targeted for 
removal by the proteosome but cannot be degraded by it (Ciechanover et al. 2003). The 
proteosome cannot process peptides containing polyglutamine tracts (Venkatraman et al. 2004), 
and the UPS is almost completely inhibited in the presence of polyQ-containing mutant huntingtin 
fragments (Bence et al. 2001). The loss of function of this key system could cause widespread 
dysfunction of other cellular processes. 
Chaperone proteins are responsible for ensuring the correct folding of cellular proteins. As well as 
the polyglutamine tract conferring an abnormal structure on huntingtin per se, aggregates have 
been shown to sequester key chaperone proteins (Hsp70 and Hsp40) whose expression might 
otherwise be beneficial for cell survival (Bonini 2002; Hay et al. 2004). 
A number of other interactions of huntingtin highlight potential pathogenic pathways and suggest 
possible therapeutic approaches. Huntingtin is cleaved by caspases, specifically caspase 3 and 6, 
and prevention of caspase-6 cleavage prevents neurodegeneration and clinical decline (Graham et 
al. 2006), possibly through prevention of nuclear entry (Warby et al. 2008). The autophagy pathway 
is capable of degrading proteins that the proteosome cannot, including mutant huntingtin 
aggregates, which in fact appear to activate autophagy directly (Ravikumar et al. 2002; Ravikumar et 
al. 2004). Further apparent effects of mutant huntingtin include impairments of endocytosis (Li et al. 
2004), mitochondrial function (Panov et al. 2002) and vesicular trafficking (Zala et al. 2008). 
Importantly, these pathogenic mechanisms have been demonstrated in neuronal cells — so-called 
‘cell-autonomous’ effects. But as mentioned above (section I.1.4.2), far from existing in isolation, 
neurons are inextricably linked, both physically and functionally, with the glial cells that outnumber 
them by ten to one, regulate the CNS milieu, perform immune functions and modulate 
neurotransmission. Increasingly, far from being mere bystanders in neurodegenerative diseases, glial 
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cells are recognised as having critical roles in the reaction to, and progression of, 
neurodegeneration (Lobsiger et al. 2007). Support for a crucial role for microglia comes from the 
demonstration that the enzyme kynurenine monooxygenase (KMO), from an pathway linked to 
oxidative damage that is exclusive to microglia, is a therapeutic target in yeast (Giorgini et al. 2005). 
Chapter IV of this thesis will suggest that, because of the ubiquitous expression of huntingtin across 
cell types, the contributions of non-neuronal cells to neuropathogenesis may be exaggerated by the 
effects of the mutant protein within such cells (effects that are cell-autonomous to the glial cell but 
non-autonomous to the neuron), amplifying their influence or even turning a protective response 
into a maladaptive, harmful one. 
I.1.4.4 Non-CNS pathology 
Conceivably, the peripheral phenotype of HD could be brought about by CNS pathology exerting 
indirect effects on peripheral tissues: for instance, cachexia could be brought about via endocrine 
effects of hypothalamic dysfunction, the autonomic nervous system or altered food intake due to 
behavioural change. However, though huntingtin levels are highest, and pathology most 
pronounced, in brain, expression of mutant huntingtin, including the formation of aggregates, has 
been found in every tissue where it has been sought (Strong et al. 1993; Sathasivam et al. 1999). In 
human patients, peripheral tissues have been less well studied but muscle displays functional, 
biochemical and pathological changes in HD (Arenas et al. 1998; Lodi et al. 2000) while testicular 
degeneration is accompanied by reduced numbers of germ cells and abnormal seminiferous tubule 
morphology (Van Raamsdonk et al. 2007), while increased density of adenosine A2A receptors in 
brain is also seen in peripheral leukocytes (Varani et al. 2003; Varani et al. 2007). 
As seen in section I.1.1.5, the peripheral cellular pathology of HD is accompanied by sometimes 
dramatic clinical features, and is therefore of importance in its own right. A therapy that did not 
enter the CNS but could halt weight loss could nonetheless bring about improvement in quality or 
even quantity of life even if CNS pathology remained unaltered. The peripheral pathology of HD 
has two other important ramifications, however. First, it is unlikely that pathology in peripheral tissue 
remains locally confined. Dysfunctioning and dying peripheral cells are likely to release molecules 
that can have distant effects on other cell types, and may directly or indirectly cross the blood-brain 
barrier and influence CNS pathology for better or worse. Second, even if the CNS and peripheral 
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processes were each confined entirely to their own compartments, the pathology in both cases 
begins with mutant huntingtin and is likely to share a number of fundamental features. In reality, the 
likely scenario is that both forms of interplay exist: that CNS and peripheral tissues share parallel 
pathogenic pathways, and are linked by two-way interplay across the blood-brain barrier. This 
model is central to the arguments presented in Chapter IV. 
I.1.5 Emerging therapeutics 
I have never known a recovery or even an amelioration of symptoms in 
this form of chorea; when once it begins it clings to the bitter end. No 
treatment seems to be of any avail, and indeed nowadays its end is so 
well-known to the sufferer and his friends, that medical advice is 
seldom sought. It seems at least to be one of the incurables. 
(Huntington 1872) 
The advances in our understanding of the pathogenesis of HD since 1993 have been dramatic. 
Concerted and international efforts are now in place to study therapeutic targets, screen and 
rationally develop treatments, and test candidate disease-modifying therapies in animals and 
humans. There is a consensus that the coming years will see an expansion in the number of 
therapies shown to be effective in animal models that are put forward for clinical testing in human 
subjects (Handley et al. 2006). At the time of writing (2009), there are four registered clinical trials 
of putative disease-modifying therapies for HD active in the United States; a further sixteen are 
currently recruiting or preparing for recruitment (US National Institutes of Health 2008). This section 
will review the most promising approaches to disease-modification before discussing some logistical 
issues and introducing the role of biomarkers in HD clinical trials. While the focus of this thesis is on 
biomarkers and disease-modification, it should be noted that improved access to symptomatic 
treatments and expert multidisciplinary care are already improving the quality of life, and probably 
life expectancy, of HD patients and the wider availability of such interventions is a pressing 
imperative for healthcare provision. 
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I.1.5.1 Therapeutic candidates 
Gene silencing refers to a number of strategies used to prevent the translation of huntingtin mRNA 
into the mutant protein, by means of intracellular nucleotide molecules designed to target the 
huntingtin message. Preventing production of the protein is clearly an appealing approach that 
could theoretically mitigate all the detrimental effects of the mutation. Moreover, gene silencing 
treatments have already shown promise in human trials in macular degeneration and respiratory 
syncytial virus infection and are currently in phase III trials (Arjamaa 2006; Sah 2006). Trials of RNA 
interference in HD animal models have shown promise, with RNA targeting mutant huntingtin 
delivered by viral vector injected into the striatum producing clinical and pathological improvement 
(Harper et al. 2005). Delivery and brain penetration of gene silencing therapies are challenging 
issues, but recent promising trials with DNA oligonucleotide therapies infused into the CSF space in 
other neurodegenerative diseases (Smith et al. 2006) suggest that they may be surmountable. 
Cysteamine is an inhibitor of transglutaminases, which have been shown to be involved in the 
recruitment of mutant huntingtin into aggregates (Kahlem et al. 1998).  Cystamine, a cysteamine 
precursor, was shown to slow progression and improve motor function in the R6/2 mouse 
(Dedeoglu et al. 2002) and is safe and well-tolerated in humans but awaits large-scale study 
(Dubinsky et al. 2006). 
Histone deacetylase (HDAC) inhibitors are aimed at ameliorating transcriptional dysregulation in 
HD, by enhancing the availability of gene promoter sites. Suberoylanilide hydroxamic acid, an 
orally-administered HDAC inhibitor, produced pathological and motor improvement in the R6/2 
mouse but has an unfavourable toxicity profile (Hockly et al. 2003). Work is underway to identify 
less toxic, selective HDAC inhibitors (Thomas et al. 2008). 
Caspase inhibitors could prevent generation of toxic N-terminal fragments and nuclear entry of 
huntingtin. Minocycline has some caspase-inhibiting activity and has shown promise in animal 
studies but has yet to demonstrate efficacy in a randomised, double-blind placebo-controlled trial in 
human patients (Bonelli et al. 2004) and more potent, selective inhibitors, especially of caspase 6, 
are being sought. 
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Autophagy enhancers could improve the removal of mutant huntingtin from cells. The enzyme 
mTOR (‘mammalian target of rapamycin’) downregulates autophagy and mTOR inhibition with 
rapamycin reduces aggregate formation and improves motor deficits in fly and mouse models 
(Ravikumar et al. 2004). A novel mTOR-independent autophagy pathway may yield additional 
therapeutic targets (Williams et al. 2008). 
Fetal stem cell transplantation has shown promise but is currently limited by technical, ethical and 
legislative concerns. In one study, three of five patients maintained or slightly improved motor and 
cognitive function after transplantation but the improvement was not sustained (Bachoud-Levi et al. 
2006). 
Microglial modulation treatments aim to mitigate the apparent harmful effects of microglial 
activation in HD. The KMO pathway (page 39), which was identified as a therapeutic target in yeast 
(Giorgini et al. 2005), has recently been targeted by a small-molecule inhibitor and preliminary 
results suggest that KMO inhibitors may be capable of dramatically improving survival in the R6/2 
mouse (Muchowski 2008). Bone marrow transplantation, aimed at replacing the microglial 
population with wild-type cells, is also under investigation. 
Mitochondrial enhancers are generally widely-available dietary supplements such as creatine, 
coenzyme Q and fish oil derivatives, aimed at improving the efficiency of cellular energy utilisation 
(Panov et al. 2002). Such agents have been tested in large trials and none has convincingly shown 
disease-modifying efficacy (e.g. Tabrizi et al. 2005), though enthusiasm persists for re-trialling them 
on a larger scale, at higher doses and in combination.  Dimebon, an antihistamine with actions as an 
NMDA receptor antagonist and mitochondrial membrane stabiliser, has shown promise in trials of 
Alzheimer’s disease (Doody et al. 2008) and clinical trials are now underway in HD. 
I.2 Biomarkers for HD 
I.2.1 Introduction 
From the previous section, it is apparent that there is confidence that disease-modifying therapies 
can be developed for HD. A genetic test can reliably predict which at-risk people will develop the 
disease, and in such individuals there is a potentially valuable window of opportunity after genetic 
diagnosis during which the slowing of pathology would be expected to delay the onset of disease 
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symptoms. The natural history of the disease, however, raises major hurdles to the translation of 
potential treatments to human patients. HD progresses very slowly and causes a diverse range of 
signs, symptoms and rates of progression. As discussed in section I.1.1.2, the clinical rating scales 
used to assess progression, such as the UHDRS, are subject to intra- and inter- rater variability and 
lack the ability to distinguish disease modification from symptom relief. Moreover, in premanifest 
expansion carriers — the very group that stands to benefit most from disease-slowing treatments — 
there are typically for several decades no unequivocal outward signs by which to judge the success 
or failure of a potential therapy. Clinical trials in premanifest subjects based on current clinical 
outcome measures would require vast subject numbers over unfeasibly long periods (Paulsen et al. 
2006). Reducing the sample size requirement for clinical trials is a key aim of the development of 
biomarkers for Huntington’s disease. 
A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention (Biomarkers Definitions Working Group 2001). In many fields, such as 
Alzheimer’s disease, biomarkers are used alongside clinical outcome measures (e.g. Fox et al. 2005), 
while in some diseases such as HIV, biomarkers are used instead of clinical measures, as surrogate 
endpoints (e.g. Delta Coordinating Committee 2001). Roles and characteristics of ideal biomarkers 
for HD are outlined in Table 2. 
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Roles that an ideal set of biomarkers for HD would fulfil: 
• Accurate prediction of age at onset of disease manifestations; 
• Prediction of rate of disease progression after onset; 
• Prediction of likely clinical manifestations; 
• Unequivocal diagnosis of disease onset; 
• Measurement of all aspects of disease progression; 
• Determination that a putative treatment has reached and activated its target 
(pharmacodynamic biomarkers); 
• Assessment of efficacy of putative disease-modifying interventions. 
Characteristics of an ideal biomarker (after Henley et al. 2005): 
• Quantifiable reliably, reproducibly and minimally invasively; 
• Subject to minimal variation in the general population; 
• Unaffected by comorbidity or symptomatic medication; 
• Linearly altered by disease progression; 
• Subject to predictable alteration when the disease is modified by an intervention  
Table 2 Potential roles and ideal characteristics of biomarkers for HD 
The more closely a biomarker is mechanistically linked to disease pathogenesis — and the better 
understood the links are — the more likely it is to fulfil the final two criteria. 
A conceptual outline for the evaluation of the potential utility of candidate biomarkers is shown in 
Figure 10. 
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Figure 10 Outline of the evaluation of the utility of potential biomarkers 
Ideal biomarker candidates may achieve complete separation cross-sectionally between HD patients 
and controls (A). If a successful treatment could be expected to return the biomarker to control levels, 
such a marker may be considered for use directly as a surrogate endpoint in an interventional trial (B). 
Some biofluid markers may fall into this category. If there is incomplete separation cross-sectionally 
(C), or if a successful treatment would not be expected to return the biomarker to control levels, it is 
necessary to study the biomarker in patients and controls longitudinally (D), to establish that the rate 
of change in patients is significantly different from that in controls. If it is (1), the marker may then be 
used longitudinally in an interventional trial, the surrogate endpoint being the alteration of the rate of 
change in treated patients towards the rate previously observed in controls (2). Most imaging and 
quantitative motor markers will likely fall into this category. 
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To date, disease-modification trials in HD have generally been of low-potency agents such as dietary 
supplements, tested in cohorts of manifest HD subjects, monitored using clinical endpoints, and 
have had negative outcomes (e.g. Tabrizi et al. 2003; Tabrizi et al. 2005; Hersch et al. 2006; e.g. 
Biglan et al. 2007; Amarin Neuroscience Ltd et al. 2008). Where biomarkers have been employed in 
such trials it has been as pharmacodynamic markers of drug entry to the CNS or target occupancy 
(Bender et al. 2005; Hersch et al. 2006). 
Until markers of progression can be found for premanifest individuals, treatment trials of agents 
expected to influence disease progression are likely to continue to take place in manifest HD, 
because of the established role of clinical endpoints and need for clear links between biomarkers 
and ‘hard’ clinical endpoints (Figure 11). The demonstration that the clinical and pathological 
phenotype can be reversed in adulthood in HD mice if the expression of mutant huntingtin is 
stopped (Yamamoto et al. 2000) reinforces the validity of this approach, since a putative treatment 
that did not at least slow clinical progression in a suitably powered clinical trial could reasonably be 
deemed unlikely to be disease-modifying. Clinical measures may then be used as primary endpoints 
with candidate biomarkers employed in parallel as secondary endpoints, following the model of 
other diseases such as HIV (Delta Coordinating Committee and Virology Group 1999; Delta 
Coordinating Committee 2001) and Alzheimer’s disease (Fox et al. 2005), enabling the parallel 
evaluation of biomarker candidates, the assessment of therapies and the investigation of the 
relationships between disease, biomarker and therapy.  
The ultimate aim of HD therapeutics development is to identify treatments that can be shown to 
ameliorate the very earliest pathological changes in premanifest disease, delaying clinical onset and 
securing additional years of impairment-free living, in addition to increased life expectancy (Figure 
11). Once this has been achieved, it becomes merely a qualitative matter to defer clinical onset to a 
time beyond the individual’s natural life expectancy, amounting to a de facto cure. Such treatment 
of premanifest individuals has two prerequisites: first, a panel of biomarkers capable of predicting 
onset and measuring the efficacy of treatments in a manner that predicts clinical outcomes; and 
second, a treatment that interacts as expected with both pathobiology and biomarkers, with a 
favourable profile of benefit to adverse effects so as to ensure long-term compliance. 
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Figure 11 Schematic showing the likely evolution of disease-modifying therapies for HD 
The disease trajectory is shown in terms of a putative disease marker (vertical axis) capable of tracking 
progression from premanifest disease to death. The earliest treatments (n) are likely to be licensed for 
initiation in manifest disease. Such an approach would increase life expectancy and is likely to 
improve quality of life overall, with the caveat that patients will inevitably be sustained in a state where 
they have a degree of impairment. If treatments can be demonstrated to be effective in slowing 
pathology, and sufficiently safe for administration to premanifest gene carriers, much more favourable 
outcomes will likely result, from deferring clinical onset and hence securing extra impairment-free 
years, in addition to increased life expectancy (o) to, ultimately, a deferral of disease onset to beyond 
the individual’s natural life expectancy — a de facto cure (p). 
This section will review the current state of biomarker research in HD, focusing on the four areas 
most likely to produce useful biomarkers for HD: neuroimaging, biofluids, quantitative motor 
assessment and cognitive measures. It concludes with a discussion of the substantial remaining 
challenges to the conduct of biomarker-powered treatment trials in HD. 
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I.2.2 Imaging 
I.2.2.1 Introduction 
Modern neuroimaging techniques such as magnetic resonance imaging (MRI) enable high quality 
images of brain structure and function to be obtained, while advanced image analysis techniques 
allow robust measurement of differences between subjects and change within individuals. As well 
as being relatively non-invasive, its clear relevance to neuropathology (Fox et al. 1996) makes 
neuroimaging an appealing source of biomarkers. 
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Figure 12 Potential imaging biomarkers for HD 
A. Volumetric assessment of basal ganglia structures (Aylward et al. 2003). B. Cortical thickness 
measurement showing regions of cortical thinning in premanifest HD (Rosas et al. 2005). C. 
Measurement of whole brain atrophy using the boundary shift integral. Boundary regions undergoing 
atrophy in early HD are highlighted in red (Henley et al. 2006). D. Diffusion tensor imaging fractional 
anisotropy map showing areas of increased (red-yellow) and decreased (blue) white matter 
organisation in premanifest HD (Rosas et al. 2006). E. Functional MRI map showing regionally 
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decreased activation in premanifest HD in response to disgusted facial expressions (Hennenlotter et al. 
2004). F. Positron-emission tomography (PET) map showing regions where D2 dopamine receptor 
binding decreased significantly over 29 months (Pavese et al. 2003). 
I.2.2.2 Serial volumetric MRI 
Volumetric imaging enables the volumes of brain regions to be estimated. T1 volumetric MRI is the 
most established technique in HD. 
I.2.2.2.1 Striatal morphometry 
The GABAergic medium spiny neurons of the striatum have long been known to bear the burden of 
cell death in early Huntington’s disease (Bates et al. 2002). The basal ganglia have extensive cortical 
connections that could account for the motor, cognitive and behavioural dysfunction of the disease 
(Alexander et al. 1986). 
Basal ganglia structures have been shown, by manual outlining, to have reduced volume in early 
HD (Harris et al. 1992) and premanifest disease (Aylward et al. 1994) (Figure 12A). Cross-sectional 
caudate volume has been shown to correlate with estimated disease onset probability based on 
CAG repeat length (Aylward et al. 1996) and performance on some cognitive tests (Brandt et al. 
1995). 
Because of overlap between HD patients and controls, and the fact that even a successful 
intervention may not restore lost brain volume (see Figure 10), cross-sectional volumetric imaging 
may be less likely to provide useful biomarkers than longitudinal measurement of brain volume loss. 
Studies using volume subtraction of manually segmented caudates have demonstrated significantly 
faster atrophy in early disease (Aylward et al. 1997) and in premanifest gene carriers as far as 11 
years from predicted onset, over a mean inter-scan interval of 4 years (Aylward et al. 2000; Aylward 
et al. 2004). More recent exploratory studies have proposed automated techniques for improving 
the reliability of regional atrophy measures (Rosas et al. 2001; Hobbs et al. 2007). 
I.2.2.2.2 Cortical and whole-brain morphometry 
Although basal ganglia structures are affected by atrophy relatively more than other brain regions, 
measurement of a small change in a large volume, rather than a large fractional change in a small 
region, may, if the measurements are more precise, generate data less susceptible to segmentation 
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inaccuracy. The majority of atrophy in HD is extrastriatal (see section I.1.4.1) and the relative 
contributions to disease manifestations from striatum and cortex are not known, so treatments 
aimed at preserving striatal function may fail to ameliorate the disease (Rosas et al. 2004); 
conversely, disease modification brought about by a treatment aimed at cortical function may be 
missed by measures of striatal atrophy. 
In cross-sectional studies, Rosas and colleagues have confirmed by a semi-automated technique that 
numerous extrastriatal brain areas are atrophied in HD (Rosas et al. 2003). They have used an 
automated technique to demonstrate cortical thinning cross-sectionally in early HD (Rosas et al. 
2002) and premanifest gene carriers (Rosas et al. 2005) that correlates with changes in cognition 
(Figure 12B). Longitudinal studies of cortical thinning in HD are underway. 
The boundary shift integral (BSI) is a semi-automated method by which changes in brain volume can 
be calculated from registered scan pairs. Semi-automated segmentation of the baseline region is 
followed by automated calculation of the volume change based on the movement of its boundary. 
It has been shown to be more reliable than simple volume subtraction (Freeborough et al. 1997) 
and is widely used in observational and interventional trials of Alzheimer’s disease (Fox et al. 2005). 
Using the BSI, Henley and colleagues demonstrated that whole-brain atrophy was significantly faster 
in early HD than controls, over a short 6-month period (Henley et al. 2006) (Figure 10C). 
Voxel-based morphometry (VBM) and tensor-based morphometry (TBM) are automated techniques 
for analysing regional morphological differences between groups of MRI scans. Cross-sectionally, 
VBM has identified brain regions differentially affected between different disease groups and 
controls (Thieben et al. 2002; Kassubek et al. 2004; Kassubek et al. 2005) but it has not yet been 
applied longitudinally in HD. TBM has demonstrated increased atrophy over 2 years in premanifest 
HD (Kipps et al. 2005). Though the insights from these techniques are useful in enhancing our 
understanding of HD and directing subsequent regional atrophy studies, some loss of statistical 
power is inevitable when from deriving regionalising information from whole-brain comparisons 
without pre-defined regions of interest. As such, the main value of VBM and similar techniques may 
be in identifying regions of interest for directed study as potential biomarkers. 
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I.2.2.3 Diffusion tensor imaging  
Diffusion tensor imaging (DTI) uses the ability of water to diffuse along axons to produce maps of 
white matter fibre tracts and quantitative measures of damage to axonal integrity. It can detect 
abnormalities in disorders such as multiple sclerosis where conventional MRI scans appear normal 
(Werring et al. 1999). Consequently DTI is appealing as a potential means of measuring 
neuropathology earlier in HD than other techniques. 
Reading and colleagues identified several regions of decreased fractional isotropy (FA, a measure of 
axonal organisation) compared with controls in premanifest HD (Reading et al. 2005). Rosas and 
colleagues demonstrated several regions where FA correlated with cognitive performance in 
premanifest HD and found more widespread abnormalities in manifest HD (Rosas et al. 2006) 
(Figure 10D). Klöppel and colleagues used DTI tractography to measure connections between the 
basal ganglia and frontal cortex, enabling the correct classification of 82% of scans as coming from 
premanifest HD subjects or controls. They further demonstrated that the loss of such fibres 
correlates with impairment of saccadic eye movements in HD (see also section I.2.4.1) (Klöppel et 
al. 2008). 
DTI shows promise as a potential biomarker capable of detecting change in HD earlier than other 
imaging measures. As a relatively new technique, however, its robustness remains to be tested 
across populations and longitudinally in HD. 
I.2.2.4 Functional MRI 
Functional MRI (fMRI) uses changes in regional blood flow during neuronal activity to identify brain 
regions active during performance of experimental tasks. It has the potential to reveal early 
abnormalities in HD due to neuronal dysfunction. Because neuronal dysfunction is more likely to be 
reversible than cell death, fMRI measures may not require longitudinal measurement to be useful as 
surrogate endpoints (see Figure 10). 
Several fMRI studies have demonstrated regional functional abnormalities in early HD (Clark et al. 
2002; Aron et al. 2003; Thiruvady et al. 2007). In premanifest subjects, region-specific alterations in 
functional activity have been shown to correlate with estimated time to onset (Hennenlotter et al. 
2004; Paulsen et al. 2004). One study comparing volumetric and functional MRI data found that 
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regions with altered activity were not those experiencing the most atrophy, suggesting that fMRI 
abnormalities may reflect dysfunction in basal ganglia output pathways or recruitment of secondary 
populations of neurons (Gavazzi et al. 2007). 
While fMRI is appealing as a marker of neuronal dysfunction in HD, there are more technical 
hurdles to its adoption as a biomarker for clinical trials. The equipment and expertise to perform 
fMRI studies are less widespread than conventional MRI techniques and scanning times are typically 
longer. fMRI is highly susceptible to apparently trivial differences in conditions (such as ambient 
light or sound levels) and therefore difficult to standardise across sites as required for large clinical 
trials. It is unknown to what extent observed fMRI changes reflect of neuropathology per se, rather 
than psychological factors in patients (e.g. performance anxiety in subjects who know they are 
destined to develop HD). 
I.2.2.5 MR Spectroscopy 
MR spectroscopy (MRS) can non-invasively quantify the biochemical composition of tissues 
including brain. Lactate levels have been shown to be elevated in the striatum in premanifest 
disease (Jenkins et al. 1998; Reynolds et al. 2005) and early HD (Koroshetz et al. 1997; Jenkins et al. 
1998; Reynolds et al. 2005) and appear to respond to treatment with coenzyme Q10, a treatment 
aimed at brain energy metabolism (Koroshetz et al. 1997). However, the finding of increased lactate 
has not been reproduced across all studies (Hoang et al. 1998). MRS has identified cross-sectional 
changes in N-acetylaspartate and creatine (Sanchez-Pernaute et al. 1999; Reynolds et al. 2005) and 
in one study, these changes were shown to correlate with motor dysfunction (Sanchez-Pernaute et 
al. 1999). A sequence of metabolite changes may be detectable with disease progression, with N-
acetylaspartate reductions the earliest feature, giving way to reduced creatine followed by elevation 
of glutamate and lactate after motor onset (Reynolds et al. 2005). More recently, MRS has been 
used in a trial of creatine therapy to demonstrate that the compound entered the brain — that is, as 
a pharmacodynamic biomarker (Hersch et al. 2006). The utility of MRS is limited by long scan times, 
the small number of molecules it can accurately detect, its relative insensitivity and the use of 
metabolite ratios which may obscure individual metabolite changes. Nonetheless, its ability to 
glimpse the biochemical milieu of the central nervous system gives it promise as a source of 
pharmacodynamic biomarkers in HD.  
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I.2.2.6 Positron-emission Tomography 
Positron-emission tomography (PET) uses positron emission by radioisotopes to identify regional 
functional variations in vivo. While fMRI has largely supplanted PET imaging in the visualisation of 
regional brain activity, the ability of PET to highlight receptor density selectively by the use of 
radiolabelled ligands is of value. 
Post-mortem studies have shown 50% loss of dopamine receptors in the striatum by end-stage HD 
(Cross et al. 1983). Dopamine receptors have been widely studied using the PET ligands 11C-
raclopride (which binds D2 receptors) and 
11C-SCH23390 (which binds D1 receptors). Dramatically 
reduced D1 and D2 binding is seed in manifest HD (Turjanski et al. 1995) and correlates with the 
duration of motor manifestations (Ginovart et al. 1997). In premanifest HD, reductions in dopamine 
receptor binding are more variable but significant (Weeks et al. 1996) and correlate with CAG 
repeat length (Antonini et al. 1998), estimated time to motor onset (van Oostrom et al. 2005) and 
subtle cognitive changes (Lawrence et al. 1998). Longitudinal studies have shown consistent 
decreases in D2 binding of around 5-6% annually in manifest disease (Pavese et al. 2003) and 
around 4% in premanifest disease, with faster rates of loss in those approaching motor onset 
(Andrews et al. 1999), suggesting that 11C-raclopride binding may detect both progression and 
incipient motor onset. Recently 11C-raclopride binding has been used to monitor fetal striatal grafts 
(Furtado et al. 2005). One potential weakness of dopamine receptor binding studies using PET is 
that they are more sensitive to striatal than extrastriatal pathology. However, statistical parametric 
mapping has recently shown that there is also loss of D2 receptor binding in the other brain regions 
(Pavese et al. 2003). 
Microglial activation is seen post-mortem in HD brain (Messmer et al. 1998; Sapp et al. 2001) and 
microglia have been implicated as a potential source of tissue damage in HD (Giorgini et al. 2005).  
The PET ligand 11C-R-PK11195 binds benzodiazepine receptors expressed selectively by activated 
microglia. It has demonstrated increased microglial activation in the striatum in manifest HD that 
correlates with reduced 11C-raclopride binding, UHDRS motor scores and CAG repeat length 
(Pavese et al. 2006). Microglial activation is also seen in premanifest disease where it correlates with 
onset probability (Tai et al. 2007). These findings suggest that microglial activation is an early and 
consistent marker of HD pathogenesis. 
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PET scanning offers early visualisation and quantification of pathological abnormalities in HD, and 
thus shows promise as a source of biomarkers in HD.  PET imaging is already used as a biomarker 
clinically and in disease-modifying trials in Alzheimer’s disease (Nordberg 2007). However, a 
number of drawbacks limit its utility in HD: the cost of PET scanning is very high and the availability 
of PET scanning equipment and expertise is limited; the radioactive ligands are potentially 
hazardous and difficult to prepare and manipulate; scans are time-consuming; and, being ligand-
based, PET scanning is susceptible to influence by medications commonly used in HD (such as 
neuroleptics, which bind D2 receptors). 
I.2.3 Biofluid biomarkers 
I.2.3.1 Introduction 
Molecular biomarkers that can be quantified in biofluids such as blood or urine are appealing 
because of the minimal requirement for patient involvement, opportunity for rapid bulk processing 
of specimens, availability of reliable assays and because several analyses can be carried out on a 
single sample. Approaches to the discovery of potential markers have ranged from hypothesis-
driven searches investigating pathways known to be deranged in HD (e.g. Hersch et al. 2006; e.g. 
Ciammola et al. 2007), to the application of ‘omics’ technologies to find differences between HD 
patients and controls (e.g. Borovecki et al. 2005; Dalrymple et al. 2007; Runne et al. 2007).  
The ideal peripheral blood biomarker of HD would be a direct product of neuronal dysfunction, 
normally absent from blood, that leaked across the blood-brain barrier and became detectable in 
blood. However, attempts to find such markers in blood have hitherto been unsuccessful. Most of 
the potential biomarkers studied to date are likely wholly or largely produced by peripheral tissues 
as a result of effects of the ubiquitously-expressed mutant huntingtin. As discussed in section I.1.4.4, 
some such changes may represent peripheral processes that recapitulate CNS pathogenic 
pathways. In other cases, signalling molecules may cross the blood-brain barrier from the CNS and 
produce peripheral changes. These mechanistic differences will inevitably influence the utility of 
each potential marker: for instance, a peripherally produced marker that reflects CNS pathogenesis, 
but does not measure it directly, would not be useful as a pharmacodynamic marker of CNS target 
occupancy but may be useful for prediction of disease onset or response to treatment. This 
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underscores the importance of understanding the place of each potential marker with respect to the 
pathogenic pathways of HD. 
Another problem universal to biomarker identification that particularly affects biofluid studies is the 
possible effect of medications. Ideally, biomarker discovery work would be performed using only 
unmedicated subjects. However, such patients are likely to be unrepresentative of the HD 
population and the results of such studies may not be applicable to the many subjects taking 
medications for symptomatic relief or concomitant illnesses, who would need to be included in 
therapeutic clinical trials. It may therefore be more practicable to ensure that medications are 
recorded and attempts made to identify and account for possible medication artefacts on biomarker 
discovery. 
The potential biofluid biomarkers reported to date are summarised in Table 3. 
 57 
Marker Alteration Tissue Key reference 
Oxidative stress 
8OH2’dG Increased Serum (Hersch et al. 2006) 
Malondialdehyde Increased Plasma (Chen et al. 2007) 
GPx and Cu/Zn-SOD Reduced Erythrocytes (Chen et al. 2007) 
Metabolic markers 
Panel of 17 metabolites Mixed Serum (Underwood et al. 2006) 
Valine, leucine and isoleucine Reduced Plasma (Mochel 2007) 
Cholesterol biosynthetic 
pathway 
Reduced Cultured cells (Valenza et al. 2005) 
Transcriptomic markers 
Panel of 12 transcripts Increased Blood (Borovecki et al. 2005) 
IER3 Increased Blood (Runne et al. 2007) 
Signalling pathways 
BDNF Reduced Serum (Ciammola et al. 2007) 
FAAH Reduced Lymphocytes (Battista et al. 2007) 
Anandamide Increased Lymphocytes (Battista et al. 2007) 
A2A receptors Increased Lymphocytes (Varani et al. 2007) 
Endocrine markers 
Cortisol Increased Urine (Björkqvist et al. 2006) 
Ghrelin Increased Plasma (Popovic et al. 2004) 
Leptin Decreased Plasma (Runne et al. 2007) 
Testosterone (males only) Decreased Plasma (Markianos et al. 2005) 
CART Increased CSF (Björkqvist et al. 2007) 
Table 3 Summary of published biofluid biomarker candidates identified to date in HD 
8OH2’dG, 8-hydroxy-2-deoxy-guanosine; GPx, glutathione peroxidase; Cu/Zn-SOD, copper-zinc 
superoxide dismutase; IER3, immediate early response 3; BDNF, brain-derived neurotrophic factor; 
FAAH, fatty acid amide hydrolase; IL6, interleukin 6; CART, cocaine- and amphetamine-regulated 
transcript. 
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I.2.3.2 Markers of oxidative stress 
8-hydroxy-2-deoxyguanosine (8OH2’dG) is formed when DNA is subjected to oxidative damage. It 
has been shown to be increased in brain, urine and plasma of amyotrophic lateral sclerosis patients 
and HD mice (Bogdanov et al. 2001). Serum levels in HD were found to be dramatically elevated 
compared with controls and fell significantly in a group of patients given the antioxidant treatment 
creatine rather than a placebo (Hersch et al. 2006). Since 8OH2’dG levels could be reduced 
directly by the antioxidant effect of creatine, rather than by any effect on huntingtin-mediated 
toxicity, in this setting 8OH2’dG is a pharmacodynamic marker. This clear separation of patients 
from control subjects (as in Figure 10A) is promising, but a recent attempt to reproduce it in 
another population was unsuccessful, possibly because of baseline differences in consumption of 
antioxidant supplements (Biglan et al. 2007). 
Another group examining oxidative damage found increased 8OH2’dG levels in HD leukocytes but 
did not measure serum levels. They also found increases in plasma malondialdehyde, a marker of 
lipid peroxidation, reduced activity of two erythrocyte enzymes (GPx and Cu/Zn-SOD) and 
abnormalities of mitochondrial DNA (mtDNA) (Chen et al. 2007). Oxidative damage to mtDNA in 
HD has recently been shown by another group (Liu et al. 2007). 
I.2.3.3 Metabolic markers 
Huntingtin is ubiquitously expressed (Sathasivam et al. 1999) and, in addition to neurological 
features, the peripheral phenotype of HD includes weight loss and there may be an energy 
utilisation deficit (Farrer et al. 1985; Mochel 2007). Two groups have used metabolic profiling to 
examine HD-associated differences in metabolite levels in peripheral blood. 
Underwood and colleagues used gas chromatography / time-of-flight / mass spectrometry (GC-TOF-
MS) to quantify the levels of 1275 metabolites in serum from humans and R6/2 mice, followed by 
multivariate statistical modelling to identify the most consistently altered metabolites. They identified 
a pro-catabolic pattern of changes (see Table 4) which was similar in both mice and humans, and 
present even in  premanifest subjects (Underwood et al. 2006). 
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Metabolite Function 
Glycerol Product of triglyceride breakdown 
Monosaccharides Carbohydrate metabolism 
Lactate Anaerobic metabolism 
Alanine Amino acid 
Leucine Branched chain amino acid 
2-amino-n-butyrate Intermediate in pyrimidine metabolism 
Ethylene glycol Glycerol metabolite 
Alpha-hydroxybutyric acid Unknown 
Valine Branched chain amino acid 
Monosaccharide Carbohydrate metabolism 
Malonate Unknown 
Urea Nitrogen excretion 
Table 4 Metabolites identified by GC-TOF-MS as contributing, with 5 unidentified others, to the 
signal discriminating HD patients from controls 
(Underwood et al. 2006.) The branched chain amino acids leucine and valine were found by 1H-NMR 
to be downregulated in a separate population (Mochel 2007). 
Using proton nuclear magnetic resonance (NMR) spectroscopy to quantify a different subset of 
metabolites, Mochel and colleagues found that controls, premanifest gene carriers, and patients at 
different disease stages were distinguishable by decreasing levels of the branched chain amino acids 
(BCAA) valine, leucine and isoleucine (Mochel 2007). These findings echoed the results of much 
earlier metabolic studies (e.g. Phillipson et al. 1977) and more recent work by others (Underwood et 
al. 2006), but in the Mochel study, BCAA levels were found to correlate with UHDRS motor scores, 
CAG repeat length and retrospectively determined weight loss, suggesting a hypermetabolic state 
early in HD. Possible effects of medications were not accounted for in this study and its findings 
have yet to be validated in a second population (Mochel 2007). 
Another group investigating the cholesterol biosynthetic pathway in human HD cells derived from 
peripheral blood identified reductions in sterol regulatory element-binding proteins, which regulate 
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the pathway (Valenza et al. 2005). The techniques used to isolate and study the cells in this study 
would be difficult to apply to large cohort studies but the pathway is of interest in future biomarker 
work. 
I.2.3.4 Transcriptomic markers 
Transcriptional dysregulation is a feature of HD (Cha 2000) and thus it is reasonable to expect 
altered gene transcription that is detectable outside the central nervous system. One group 
identified transcriptional changes in muscle in HD patients consistent with a change in fibre type 
(Strand et al. 2005). However, muscle is a relatively inaccessible tissue and serial biopsies for 
biomarker analysis in clinical trials are unlikely to be feasible. 
Borovecki and colleagues used microarray profiling in whole blood to identify changes in gene 
expression. They identified a panel of 12 genes whose expression was significantly altered from 
controls and across disease stages, including early and late premanifest patients based on predicted 
onset. These changes were confirmed in a test set of samples and shown to respond to treatment 
with phenylbutyrate, a histone deacetylase inhibitor affecting transcriptional regulation that is 
neuroprotective in HD mice (Borovecki et al. 2005). However, when Runne and colleagues 
subjected blood samples from another population of HD patients to similar analysis, they found no 
significant changes in the 12 genes identified by Borovecki et al. This finding may be explained by 
genetic, environmental, medication or dietary differences between populations or the inherent 
statistical and technical challenges of transcriptomics. Indeed, when Runne and colleagues 
performed further discovery and evaluation experiments using both transcriptomic and pathway-
based approaches, they only identified one RNA (IER3) that was significantly upregulated in HD, 
and the difference in expression was modest (Runne et al. 2007). The apparent failure of gene 
expression profiling in blood to produce readily measured biomarkers is disappointing, but as the 
maturing technology is applied to different patient populations and in longitudinal studies, useful 
transcriptomic biomarkers may yet emerge. 
I.2.3.5 Signalling pathways 
I.2.3.5.1 BDNF 
Brain-derived neurotrophic factor (BDNF) is a growth factor that promotes survival of nerve cells, 
including striatal neurons, during development and after injury. BDNF levels are reduced in HD 
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brain, particularly in the striatum (Ferrer et al. 2000). BDNF concentrations are lower in serum in HD 
animal models, and increased by treatment with the neuroprotective agents cystamine and 
cysteamine (Borrell-Pages et al. 2006).  Significantly decreased BDNF levels were found in the serum 
of symptomatic HD patients (Ciammola et al. 2007) and serum BDNF is certainly interesting as a 
potential marker of progression. However, though BDNF does cross the blood-brain barrier, serum 
BDNF is largely derived from platelets, which are thought to acquire it from a number of sources 
including brain, peripheral nerve and vascular endothelium (Lommatzsch et al. 2005). The balance 
of central and peripheral contributions to altered serum BDNF levels in HD requires further study. 
I.2.3.5.2 Endocannabinoid system 
In a study examining the endocannabinoid system, which has been shown to be downregulated in 
the brain of R6/2 mice (Lastres-Becker et al. 2003), the activity of the enzyme fatty acid amide 
hydrolase (FAAH) in HD lymphocytes was decreased to 10% of control levels. Levels of its 
substrate, endocannabinoid anandamide, were correspondingly higher. These abnormalities were 
seen in both premanifest and manifest HD (Battista et al. 2007). 
I.2.3.5.3 Adenosine receptors 
Adenosine A2A receptors are expressed on striatal medium spiny neurons and peripheral blood cells, 
and are dysfunctional in HD cell models (Varani et al. 2001). In HD leukocytes, A2A receptors were 
shown to have increased density and affinity in manifest disease (Varani et al. 2003) and 
premanifest carriers (Varani et al. 2007) but no correlation with CAG repeat length or advancing 
disease stage has been shown. 
I.2.3.6 Endocrine markers 
Several features of HD, including depression, sleep disturbance and weight loss are also seen in 
hypothalamic dysfunction, and cell loss occurs in the hypothalamus in HD (Petersen et al. 2006). 
Several groups have identified alterations of endocrine function that may track with disease 
progression. 
The R6/2 mouse demonstrates several features of an overactive hypothalamic-pituitary-adrenal axis 
and urinary cortisol levels increase progressively with advancing HD in humans (Björkqvist et al. 
2006). Plasma (but not CSF) levels of the appetite-regulating hormones ghrelin and leptin were 
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respectively increased and decreased in HD, a pattern suggesting endocrine compensation for 
negative energy balance (Popovic et al. 2004). Lower plasma testosterone levels are seen in male, 
but not female, HD patients, and levels correlate with several cognitive scores (Markianos et al. 
2005; Markianos et al. 2007). Cocaine- and amphetamine-regulated transcript, a neuropeptide with 
that modulates appetite and mood, was shown to be increased in CSF in HD (Björkqvist et al. 
2007). 
These endocrine changes are of interest neuropathologically and clinically. They may also yield 
useful biomarkers. Some endocrine abnormalities such as hypotestosteronism may be amenable to 
treatment using existing therapies, which may have both central and peripheral benefits. If treatable, 
measures of endocrine dysfunction will become biomarkers of pharmacodynamics rather than of 
progression. Endocrine features are highly susceptible to influences other than pathology, such as 
drugs and depression; this must be borne in mind when assessing their utility as potential 
biomarkers. 
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I.2.4 Quantitative clinical measures 
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Figure 13 Some quantitative motor assessment tools proposed as biomarkers for Huntington’s 
disease 
A. Desk-mounted equipment for oculomotor assessment (e.g. Golding et al. 2006). B. Portable, 
forehead-mounted saccadometer (Ali et al. 2006). C. Apparatus for measurement of grip force 
(Gordon et al. 2000). D. Wrist-mounted actigraphy device (Hurelbrink et al. 2005).  
Clinical rating scales such as the UHDRS (The Huntington Study Group 1996) are the current 
standard for the assessment of progression in Huntington’s disease. However, even in experienced 
hands, all clinical measures are subject to inter-rater variability which contributes, along with the 
imperfect ability of motor measures to capture disease progression, to the large sample size 
requirements for clinical trials based on such measures (Paulsen et al. 2006). Attention has therefore 
focused on automated techniques aimed at detecting subtle motor abnormalities earlier in 
premanifest HD and increasing the reliability of motor measures in manifest disease. 
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I.2.4.1 Oculomotor assessment 
Disorders of eye movements are an established and consistent feature of HD (Bates et al. 2002). 
Oculomotor abnormalities are subtle, and therefore difficult to assess and quantify accurately. 
Nonetheless, because of the involvement of frontal-striatal circuits in oculomotor control, eye 
movement abnormalities are an appealing source of insight into pathways implicated in premanifest 
and early HD. 
Computerised quantitative eye movement measurement has demonstrated a number of 
reproducible oculomotor abnormalities in HD that may function as biomarkers. In manifest HD, 
saccade initiation is delayed and the ability to repress reflexive saccades is impaired; in premanifest 
HD, subtle abnormalities were identified in saccade initiation and accuracy of memory-guided 
saccades (Blekher et al. 2004).  Golding and colleagues demonstrated that voluntary saccade 
initiation delay correlated with disease stage in manifest HD, and estimated pathological disease 
burden in premanifest subjects (Golding et al. 2006). These findings were demonstrated using 
expensive specialist eye-tracking equipment (see Figure 13A). Recently developed, inexpensive, 
portable ‘saccadometer’ devices (see Figure 10B) may greatly facilitate the assessment of 
oculomotor dysfunction as a biomarker and its integration into multi-centre clinical trials. Early 
results from these devices in HD have been promising (Ali et al. 2006). 
As mentioned in section I.2.4.1, a recent multimodal approach by Klöppel and colleagues combined 
automated oculomotor examination and DTI fibre tracking, affirming the neuroanatomical basis for 
both oculomotor assessment and DTI in tracking HD progression (Klöppel et al. 2008). 
I.2.4.2 Tapping tests 
Semi-quantitative finger-tapping assessment forms part of the UHDRS motor examination (The 
Huntington Study Group 1996), but tapping tasks are amenable to automated measurement and 
analysis. 
In one paradigm, subjects were instructed to tap as quickly as possible on a sensor. Tapping rates 
were significantly lower than controls in manifest HD patients but not premanifest gene carriers. 
Rates correlated with UHDRS motor scores and HD duration, but not with CAG repeat length (Saft 
et al. 2006). Longitudinally tapping rates declined significantly over 3 years in manifest HD, but this 
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interval was longer than required for the UHDRS motor score to increase significantly, indicating 
that tapping was less sensitive at detecting progression than the UHDRS motor score (Andrich et al. 
2007). 
Tasks of rhythmic tapping, where subjects tap at regular intervals with or without an auditory pacing 
signal, have shown more promise as a potential marker for motor onset emerging among the most 
promising psychomotor tasks from the baseline analysis of the Predict-HD study, where accuracy of 
unpaced tapping and variability of paced tapping correlated with the ‘soft’ motor signs that herald 
onset (Paulsen et al. 2006). Variability of paced tapping also correlated with probability of motor 
onset estimated from age and CAG length (Hinton et al. 2007). Longitudinal data from Predict-HD 
on tapping measures are awaited. 
I.2.4.3 Grip force 
Assessment of grip force is a test of non-repetitive voluntary movement encompassing sensorimotor 
integration and motor persistence. In a cross-sectional study, automated measurement (Figure 13C) 
revealed greater variability in force during static gripping in HD patients than controls that 
correlated with total functional capacity and cognitive scores (Gordon et al. 2000). Longitudinally, 
grip force variability increased in 100% of subjects over 3 years (Reilmann et al. 2001). Preliminary 
data suggest increased grip force variability in premanifest HD (Reilmann et al. 2007). 
I.2.4.4 Actigraphy 
Several wrist-mounted devices (see Figure 13D) can produce long-term recordings of subjects’ 
overall activity (actigraphy) and have been studied in HD. In one study, 5-day recordings 
demonstrated reduced activity cross-sectionally in HD patients compared with controls, and no 
significant change in activity levels over a 2-year followup period (van Vugt et al. 2001). Another 
group studied less severely affected patients over 48 hours and showed increased motor activity 
while awake and sleeping (Hurelbrink et al. 2005). Actigraphy is appealing because it encompasses 
both motor and functional aspects of the illness; however, its utility as a marker of progression may 
be limited by the large stepwise changes in functional activity that occur as HD progresses. 
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I.2.4.5 Gait analysis 
Like oculomotor function, gait disturbance is a widespread feature of HD that has traditionally been 
studied using expensive specialist equipment. Such studies have revealed consistent changes in 
several gait parameters in HD. However, in order to be useful as a biomarker, measures need to be 
made quickly and consistently between centres. Easy-to-use instrumented carpet devices have 
recently become available. Using one such device, HD patients were shown to differ significantly 
from controls in all parameters of gait including velocity, stride length and cadence (Rao et al. 
2005). Such devices have not yet been tested in premanifest HD. 
I.2.4.6 Graphimetry 
Computerised writing analysis (graphimetry) quantifies a highly functional fine motor control task. 
Because no special equipment is required to perform the task, it can be performed in patients’ 
homes and therefore may be able to provide data with high temporal resolution. Preliminary results 
suggest that it may be capable of identifying premanifest gene carriers who are close to developing 
motor features of HD (Thanendrarajan et al. 2007). 
I.2.4.7 Tongue force 
Objective measurement of tongue force has been proposed as a marker of the motor phenotype of 
HD that may reflect a different subset of neuropathology from other quantitative measures because 
motor control of the tongue may be impaired in HD when other movements are normal. 
Preliminary data suggest that tongue force variability correlates with severity in manifest disease 
(Bohlen et al. 2007). 
I.2.5 Cognitive measures 
Cognitive abnormalities in HD are well described (e.g. Craufurd et al. 2002). Cognitive changes 
have the potential to identify premanifest HD gene carriers close to developing motor signs of the 
disease, and are also very important in their own right. Cognitive tasks are more subject than other 
classes of potential biomarker to practical limitations such as difficulty in standardisation across 
languages, practice effects and confounding influences of psychiatric and motor symptoms of HD. 
Nonetheless, head-to-head longitudinal comparisons of standardised cognitive batteries may yield 
useful information that will not be captured by other measures. The development of such batteries 
forms part of the aim of several large ongoing studies, including Predict-HD (Huntington Study 
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Group), PHAROS (Huntington Study Group), EHDN Registry and HD-Toolkit (Euro-HD Network 
REGISTRY Steering Committee 2003-8; Stout 2009). Longitudinal data from these studies are 
awaited. 
I.2.6 Discussion 
The pipeline presented in Figure 14, drawn from discussions within the Euro-HD network 
biomarkers working group, highlights the series of steps required for a potential marker to become 
an approved surrogate endpoint in a clinical trial of a putative disease-modifying therapy. Biomarker 
candidates identified to date have considerable overlap and require head-to-head evaluation in 
large, longitudinal, multi-centre studies having the features of clinical trials. 
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Figure 14 Pipeline for the establishment of biomarkers for HD as surrogate endpoints for clinical 
trials of disease-modifying therapies 
The challenges faced in establishing which biomarker candidates should be taken forward to 
biomarker-powered interventional trials are more than logistical. No single biomarker can be 
expected to encompass all aspects of HD and it is therefore likely that a combination of markers 
and compound measures from across all available modalities will be required to obtain a true 
picture of the disease process in an individual. Determining what combination of markers best 
captures the most significant aspects of the disease process in a sensitive and specific manner with 
minimal duplication is a major challenge that current and planned studies may answer only partially. 
Different biomarkers and combinations are likely to be required to fulfil the numerous roles for 
which biomarkers are needed (see Table 2), from prediction of age at onset to assessment of 
therapeutic efficacy. 
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Most importantly, perhaps, past efforts to use biomarkers as outcome measures for clinical trials 
demonstrate that a highly effective biomarker may behave unexpectedly when measured in concert 
with a putative therapeutic intervention. When whole-brain atrophy was used to assess the efficacy 
of beta-amyloid immunization therapy in Alzheimer’s disease, the expectation was that efficacy 
would be signalled by a reduction in atrophy rates. Unexpectedly, treated patients experienced 
more atrophy than those given placebo, despite favourable cognitive outcomes (Fox et al. 2005). 
Whatever the explanation for this, it is clear that interactions between disease, intervention and 
biomarker will likely be more complex than anticipated. A biomarker is never truly validated but 
rather undergoes a constant process of evaluation, of which measurement in clinical trials forms 
part. In parallel to the pipeline presented in Figure 14, each biomarker must therefore undergo 
extensive investigation to establish its place in the physiological and pathological mechanisms of the 
HD patient so that the effects of interventions may be better anticipated. 
Finally, there is unlikely to be one combination of markers that is best placed to measure the effects 
of every possible treatment. The intervention and biomarkers must be carefully chosen to provide 
both efficacy and pharmacodynamic information. For example, measures of peripheral inflammation 
would be pharmacodynamic if used with an anti-inflammatory drug, but may be markers of 
treatment efficacy if measured alongside a histone deacetylase inhibitor. 
I.3 Aims of this thesis 
I.3.1 Unmet needs 
It is to be hoped that the preceding discussion sets out adequately both the need, and the realistic 
hope, for disease-modifying treatments for HD in the near future. In addition, the argument has 
been made for the development of biomarkers capable of tracking progression in HD, to facilitate 
the conduct of clinical trials of such treatments. Numerous biomarker candidates have been 
proposed and these now require head-to-head comparison to determine their power and 
redundancy. This thesis focuses on three main areas of remaining need. 
First, though hypothesis-driven research has led to the identification of several candidates detectable 
in blood, there is a conspicuous lack of plasma proteins in the list of potential blood markers (Table 
3). The use of proteomic profiling, to identify in an unbiased manner those proteins whose plasma 
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levels are differentially altered in HD, has not previously been reported, and little work has focused 
on the targeted investigation of the underlying pathological basis for differences in plasma protein 
expression in HD. Meanwhile, some molecules with immediate relevance to neuropathogenesis, 
that have been shown to track with progression in other diseases, have not been tested as possible 
biomarkers for HD. 
Second, there are compelling reasons why a panel of biomarkers ought to include one or more 
volumetric imaging measures. To date, the bulk of imaging biomarker research has focused on 
striatal atrophy, or the examination of regional atrophy across the whole brain. Quantification of 
whole-brain atrophy using the robust BBSI technique has the potential to capture all pathological 
(and clinically-relevant) atrophy in a single measure but has only been reported as a small pilot 
study, and requires detailed study in a larger cohort over a longer interval, to determine both the 
rate and profile of whole-brain atrophy and the relationships between atrophy and existing clinical 
and genetic measures of severity and progression. 
Finally, as set out above, the head-to-head comparison of biomarker candidates will require the 
establishment of longitudinal cohorts of subjects in whom a variety of measures from several 
biomarker modalities will need to be applied simultaneously, and compared both within and 
between measures using suitable statistical frameworks with sufficient power to detect significant 
synergy between markers while discarding redundant measures. 
I.3.2 Hypothesis 
• Trials of potentially disease-modifying treatments will be needed in HD in the coming years. 
• The epidemiology and natural history of HD and likely number of agents requiring testing 
are such that enough sufficiently-powered trials will be difficult or impossible to conduct. 
• Biomarkers of HD may improve the efficiency of clinical trials by reducing subject numbers 
and duration, and potentially increasing the validity of the outcomes per se. 
• The existence of a sensitive and specific genetic test is capable of revealing subjects 
destined to develop HD and those with manifest disease: this enables completely accurate 
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clinical characterisation of cohorts and will facilitate the development of biomarkers despite 
the relative rarity of the disease. 
• Existing candidate biomarkers require evaluation in larger cross-sectional and longitudinal 
cohorts. 
• Novel techniques of analysing biofluids may reveal new biomarker candidates. 
• Mechanistic evaluation of biomarker candidates revealed by such methods, in terms of 
pathogenic pathways of HD, may provide insights into pathogenesis, the likely behaviour of 
biomarkers in clinical trials, and possibly novel therapeutic approaches. 
• Whole-brain atrophy measured using the BBSI has the potential to be a robust imaging 
biomarker of HD and requires further evaluation in a large, well-characterised cohort. 
I.3.3 Aims 
1. To establish and study a cohort of subjects with premanifest and early manifest HD and control 
subjects, and study them longitudinally over 2 years using volumetric MRI imaging, clinical and 
psychiatric assessment, genetic analysis and blood sample collection for biomarker 
development. 
2. To apply unbiased proteomic discovery techniques to analyse the blood samples collected from 
these subjects — in concert with further blood samples collected from a wider spectrum of 
patients attending a Multidisciplinary HD clinic — in order to identify novel plasma protein 
biomarker candidates. 
3. To use robust quantification techniques to evaluate biomarker candidates in terms of their 
reliability as markers, across disease stages cross-sectionally and with advancing disease 
longitudinally. 
4. To use a hypothesis-driven approach to investigate biomarker candidates in terms of their 
mechanistic role in the pathogenic pathways of HD, with a view to establishing the reasons why 
they appear to behave as biomarkers, as well as shedding light on incompletely understood 
pathogenic pathways and possibly revealing potential targets for disease modification. 
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5. To evaluate the use of whole brain atrophy, quantified using the brain boundary shift integral, as 
an imaging biomarker in presymptomatic gene carriers and patients with early disease over the 
period of study 
6. To use these volumetric imaging data to study anatomical correlates of salient clinical features 
of HD (motor and psychiatric manifestations), to determine to what extent regional atrophy 
measures may have promise as predictors of clinical burden. 
I.4 Publications relating to this chapter 
Sections of the review presented in this introductory chapter were published as: 
• Wild EJ and Tabrizi SJ (2006) Predict-HD and the future of therapeutic trials. Lancet 
Neurology 5(9): 724-725. 
• Wild EJ and Tabrizi SJ (2007) The differential diagnosis of chorea. Practical Neurology 7(6): 
360-373. 
• Wild EJ and Tabrizi SJ (2007) Huntington’s disease phenocopy syndromes. Current Opinion 
in Neurology 20(6): 681-687. 
• Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis 
MB and Tabrizi SJ (2008) Huntington’s disease phenocopies are clinically and genetically 
heterogeneous. Movement Disorders 23(5): 716-720. 
• Wild EJ and Tabrizi SJ (2008) Biomarkers for Huntington’s disease. Expert Opinion on 
Medical Diagnostics 2(1): 47-62. 
 
 72 
Chapter II General methods 
II.1 Structure and conduct of cohort studies 
HE WORK IN this thesis is drawn largely from two cohort studies, running in parallel. The 
longitudinal imaging study ran from October 2005-June 2008 and was a prospective, 
longitudinal study of volumetric imaging and clinical, behavioural and psychological assessment in 
premanifest and early HD. 81 subjects were enrolled (20 controls, 21 premanifest HD gene carriers 
and 40 patients with early manifest HD). This study had three major timepoints with full assessment 
at each: baseline, one year and two years. The year two timepoint, in practice, was delayed by three 
months for two reasons. Firstly, a study design with unequal assessment intervals allows each 
datapoint to contribute to both the slope and vertical intercept of a best-fit line. Second, a number 
of subjects were cross-recruited at the two-year timepoint into a complementary but larger study, 
TRACK-HD (TRACK-HD Steering Committee 2006-8) which, by design, used the same volumetric 
MRI sequence, in addition to 3T MRI imaging not reported here. Cross-recruited subjects therefore 
had combined visits at this timepoint, and the MRI and clinical data were shared between both 
studies. At recruitment, the intention was to perform a one-year, two-timepoint study but the project 
was extended to allow a third timepoint, and subjects were invited to extend their participation in 
the study by a year. 
The biofluid study began in 2003 and is a prospective project aimed at collecting biofluid samples 
from controls and HD gene carriers throughout the disease course, processing and storing them 
under standardised conditions and performing a variety of analyses to identify and further study 
biomarker candidates in HD. The inclusion criteria for the study are wider in order to maximise the 
number of samples collected and the extent of the disease spectrum captured. The study was 
designed and has been run with the ethos of a biobank (Medical Research Council et al. 2006), with 
an emphasis on consistency of sample collection, processing and storage, as well as rigorous 
stewardship of the sample database and associated metadata. Recruitment and sample collection 
for this study was carried out largely through the HD Multidisciplinary Clinic of the National 
Hospital for Neurology and Neurosurgery, so by necessity the clinical assessments carried out were 
less comprehensive. The biofluid study was both cross-sectional and longitudinal, though the focus 
of this thesis is, for the most part, the cross-sectional findings. Subjects were invited to donate 
T 
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samples of blood and urine at each clinic appointment, subject to the inclusion criteria. Longitudinal 
collection aimed to leave at least six months between consecutive donations. Samples of both 
blood and urine were collected and, while some preliminary metabolomics work has been carried 
out on the urine samples, this thesis only reports the findings from the study of blood. 
Cross-recruitment between the two studies was encouraged. Wherever subjects were willing, 
subjects in the longitudinal imaging study were invited to donate a blood sample for the biofluid 
study, which was processed and stored using the same techniques. Samples obtained from such 
cross-recruitment were accompanied by reliable clinical, behavioural, cognitive and imaging data, 
greatly enhancing their utility in the assessment of the pathogenic relevance of biofluid biomarker 
candidates. In addition, a subset of subjects gave samples on multiple occasions, enabling 
longitudinal study of the relationships between clinical, imaging and biofluid measures. 
II.2 Consent and ethical considerations 
All studies mentioned in this thesis were carried out at approved research institutions. The author’s 
own work was all carried out at University College London’s Institute of Neurology in conjunction 
with the National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Trust. 
All human experiments were carried out in accordance with the declaration of Helsinki. All human 
subjects gave informed, written consent to participate. Human subjects at UCL/UCLH were 
enrolled into either or both of two studies: UCLH/04/N008 (Identification of biomarkers that can be 
used to track the progression of Huntington’s disease) and UCLH/03/N009 (Use of serial magnetic 
resonance imaging to identify outcome measures for clinical trials that may be used to track the 
progression of Huntington’s disease (HD) – in early disease and in presymptomatic gene carriers). 
Both these studies were approved by University College London (UCL) / UCL Hospitals Joint 
Research Ethics Committee. 
No animal work was carried out by the author, but this thesis includes animal work carried out by 
others. All animal experiments were carried out in accordance with relevant legislation and 
approved by local and national regulatory authorities. These are specified in the relevant methods 
sections for each experiment. 
 74 
II.3 Subjects and inclusion criteria 
II.3.1 Longitudinal imaging study 
II.3.1.1 Source of volunteers 
Human volunteers for the longitudinal imaging study were recruited from three sources: 
• The National Hospital for Neurology and Neurosurgery (NHNN) Multidisciplinary HD 
Clinic research volunteer database (data held with subjects’ consent); 
• Direct prospective recruitment of volunteers by the author via the NHNN Multidisciplinary 
HD Clinic. 
• The Huntington’s Disease Multidisciplinary Clinic of Addenbrooke’s Hospital, Cambridge. 
Potential subjects were referred, with their permission, by Dr Roger Barker. 
Recruitment was carried out equally by the author and Dr Susie Henley, research psychologist. 
II.3.1.2 Inclusion criteria 
• Subjects were classified as controls, premanifest HD and manifest HD. 
• For all subjects, the inclusion criteria were all of the following: 
1. Able to give informed consent; 
2. Age over 18 at the time of enrolment; 
3. No contraindications to MRI scanning such as metal implants, and able to tolerate 
the procedure, i.e. not claustrophobic; 
4. English as first language (this was necessary for reliable cognitive testing); 
5. Absence of active major psychiatric disorder (for the purpose of cognitive testing 
and subject retention); 
6. Absence of significant active central nervous system or medical disorders (in order 
to avoid confounding effects on outcome measures). 
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For premanifest HD subjects the additional inclusion criteria were: 
7. Positive predictive genetic test for the HD CAG repeat expansion, performed by 
an accredited genetic testing laboratory; and 
8. Absence of features diagnostic of clinical onset of HD, as determined by a rating of 
<4 points on the diagnostic confidence scale of the UHDRS (The Huntington Study 
Group 1996). 
For manifest HD subjects, the additional inclusion criteria were: 
9. Positive genetic test for the HD CAG repeat expansion, performed by an 
accredited genetic testing laboratory; and 
10. Presence of features diagnostic of clinical onset of HD, as determined by a rating 
of 4 points on the diagnostic confidence scale; and 
11. Early stage Huntington’s disease, i.e. disease stage I or II according to the criteria of 
Shoulson and Fahn (Shoulson et al. 1979), as defined under the UHDRS as total 
functional capacity score >7. 
For control subjects the additional inclusion criteria were: 
12. Partner or spouse of premanifest or manifest HD subject (partner/spouse controls); 
or 
13. Individual previously at risk of inheriting HD, with a negative genetic test for the 
HD CAG repeat expansion, performed by an accredited genetic testing laboratory 
(gene-negative controls). 
II.3.1.3 Comments on inclusion criteria 
The inclusion criteria were designed to enable the study of the population likely to be eligible for 
clinical trials of potential disease-modifying treatments in HD (see section I.1.5), while considering 
pragmatic factors. The main aim was to validate, in a large cohort, pilot work  suggesting that whole-
brain atrophy rates were increased in early HD (Henley et al. 2006), over a longer period in order to 
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extend the duration of the trial to improve signal-to-noise ratios; and to obtain preliminary data on 
whole-brain atrophy in premanifest HD. 
It was considered that ability to complete this study — in particular, the ability of patients to attend 
appointments and tolerate scanning and assessment — would be influenced by a number of factors 
including functional ability, cognitive dysfunction, psychiatric disturbance and motor dysfunction. It 
was hoped that using early disease as an inclusion criterion in manifest HD would produce a cohort 
of subjects with a diverse range of HD features but who were at approximately the same level of 
functioning, and who were likely to be able to continue to attend assessments for the duration of 
the study. 
To an extent, the population defined by these criteria is by definition unrepresentative, as features 
such as major psychiatric disturbance and movement disorders are both relatively common in HD, 
but both would diminish subjects’ ability to complete the study, reducing its power. Nonetheless, 
these criteria allowed for a reasonable approximation of the population likely to be eligible for early 
clinical trials while encompassing much of the clinical diversity of the disease. 
Matching across groups for gender was carried out informally at the level of recruitment, with 
efforts to ensure a roughly even balance of males and females in each group. Matching age and 
CAG repeat length across groups was more challenging, because of the interactions between CAG 
repeat length, age and disease duration. For a given repeat length, subjects who are younger are 
less likely to have disease signs. So if the premanifest and manifest groups are to be matched for 
CAG repeat length, the premanifest group is likely to be younger on average than the manifest 
group. Conversely, if age-matching is sought, the CAG repeat lengths of the groups are likely to 
differ significantly, since for a given age, premanifest subjects will tend to have lower CAG repeat 
lengths than similarly-aged subjects with manifest disease. Thus, it was decided not to attempt to 
match these two groups on the basis of either age or CAG repeat length, but to recruit a wide 
range of both ages and CAG repeat lengths, and attempt to correct for differences statistically (see 
section II.10). Age-matching of the control group for both groups of mutation carriers was 
attempted, however, by ensuring that the control group spanned the full range of ages in both 
groups. 
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Control subjects for the longitudinal imaging study were drawn from two different populations: 
partners and spouses, and gene-negative family members. It was felt that these individuals were 
likely to share with the mutation carriers a number of environmental factors that could otherwise act 
as confounders, such as socioeconomic status, diet, sleeping habits and living conditions. A further, 
significant expected advantage was that, to a degree at least, the psychological burden of living with 
a genetic or clinical diagnosis of HD would be common to gene carriers and their partners and 
spouses, thus enabling a clearer discrimination of the direct and indirect effects of the HD mutation, 
especially on the cognitive, behavioural and neurological measures. The same was felt likely to hold 
(though perhaps to a lesser extent) for gene-negative subjects, previously at risk of carrying the 
mutation, since many such individuals remain carers for parents and siblings with HD. 
II.3.2 Biofluid study 
II.3.2.1 Source of volunteers 
Human volunteers for the longitudinal imaging study were recruited from two sources: 
• Direct prospective recruitment of volunteers via the NHNN Multidisciplinary HD Clinic. 
• Cross-recruitment of subjects from the longitudinal imaging project, to enable better 
phenotypic characterisation of subjects. 
II.3.2.2 Inclusion criteria 
• Subjects were classified as controls, premanifest HD or manifest HD. 
• Manifest HD subjects were further divided into early, moderate or advanced HD. 
• For all subjects, the inclusion criteria were all of the following: 
1. Able to give informed consent; 
2. Age over 18 at the time of enrolment; 
3. Absence of significant active central nervous system or medical disorders (in order to avoid 
confounding effects on outcome measures). 
For premanifest HD subjects the additional inclusion criteria were: 
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1. Positive predictive genetic test for the HD CAG repeat expansion, performed by an accredited 
genetic testing laboratory; and 
2. Absence of features diagnostic of clinical onset of HD, as determined by a rating of <4 points 
on the diagnostic confidence scale of the UHDRS (The Huntington Study Group 1996). 
For manifest HD subjects, the additional inclusion criteria were: 
1. Positive genetic test for the HD CAG repeat expansion, performed by an accredited genetic 
testing laboratory; and 
2. Presence of features diagnostic of clinical onset of HD, as determined by a rating of 4 points on 
the diagnostic confidence scale. 
Manifest HD subjects were subdivided into early, moderate and advanced stages as outlined in 
section II.5.2.  
For control subjects there were no additional inclusion criteria, though in practice the majority of 
control subjects were partners and spouses of mutation carriers. 
II.4 Genetic testing 
The majority of subjects in both studies underwent genetic diagnosis through the Neurogenetics 
Laboratory of the National Hospital for Neurology and Neurosurgery, London. However, the 
process of repeat length measurement has evolved in technique and improved in consistency since 
its introduction in 1994. Moreover, some subjects underwent clinical genetic testing in other 
laboratories.  
Where consent could be obtained, therefore, CAG re-sizing was carried out in order to move 
towards a reliable standard throughout the cohorts. 
CAG repeat length sizing were carried out by the Neurogenetics Laboratory of the National 
Hospital for Neurosurgery. DNA was extracted using standard techniques using an NA3000 
automated DNA extractor (AutoGen, MA). Repeat lengths were analysed by fluorescent PCR 
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amplifying the triplet repeat region followed by size fractionation and fragment sizing using an 
Applied Biosystems 3730XL genetic analyser and GeneMapper software (Applied Biosystems, CA). 
II.5 Clinical assessments 
II.5.1 Longitudinal imaging study 
Clinical assessment of subjects was based on that adopted by the Euro-HD Network REGISTRY 
study, a Europe-wide clinical database project that aims to define the phenotype of HD 
comprehensively (Euro-HD Network REGISTRY Steering Committee 2003-8). 
Clinical assessments were as follows: 
• Demographic questionnaire (Appendix A) 
• Medical history questionnaire (Appendix B) 
• HD history questionnaire (Appendix C) 
• UHDRS motor scale (Appendix D) 
• UHDRS functional scales (Appendix E) 
At the baseline and one-year timepoints, these assessments were carried out by the author after 
training and certification as an accredited motor rater by the Euro-HD Network. At the two-year 
timepoint, because of cross-recruitment of subjects into the TRACK-HD study, the clinical 
assessments in a subset of subjects were carried out by another trained rater (Dr Nayana Lahiri).  
II.5.2 Biofluid study 
Because the majority of samples for the biofluid study were collected through the outpatient clinic, 
the clinical data collected were by necessity less comprehensive. They consisted of: 
• Demographic data (Name, date of birth, gender) 
• Subject group (control or HD) 
• CAG repeat length (see section II.4) 
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• Significant comorbidities 
• Medications 
• Clinical stage (premanifest, early, moderate or advanced according to standard criteria 
defined by Total Functional Capacity (TFC) score (Shoulson et al.; Shoulson) and the 
UHDRS diagnostic confidence scale (The Huntington Study Group), as applied by trained 
raters (all neurologists or neurogeneticists) including the author: 
− Premanifest HD: UHDRS motor diagnostic confidence score < 4; 
− Early HD: UHDRS motor diagnostic confidence score = 4 and TFC between 13 and 7; 
− Moderate HD: UHDRS motor diagnostic confidence score = 4 and TFC between 6 
and 3 
− Advanced HD: UHDRS motor diagnostic confidence score = 4 and TFC between 3 
and 0 
• For subjects who were cross-recruited into both the longitudinal imaging study and the 
biofluid study, the more comprehensive assessments in section II.5.1 were carried out, 
enabling examination of the relationships between more quantitative clinical and 
behavioural scores and biofluid findings in a subset of subjects. 
II.6 Behavioural assessments 
At the time of the design of the longitudinal imaging study (November 2005), the shortcomings of 
the UHDRS Behavioural Assessment were clear so an alternative assessment was sought. The PBA 
was too long to consider for this study. However, the SBA was still in draft form and had not yet 
been validated formally. Nonetheless, because of the Europe-wide collaborative nature of its 
development, that draft was widely felt to be an improvement on the UHDRS measure. The draft 
SBA (Appendix G) was therefore adopted as the core behavioural measure of the study. However, 
because it had not yet been validated it was decided that the Beck depression inventory would be 
employed in parallel. This was important not only to gain information about the critical affective 
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behavioural axis, using a well-validated scale, but also to enable the SBA to be piloted alongside the 
more traditional measure. 
At the two-year timepoint, a slightly different, revised draft SBA was used instead, because of cross-
recruitment of subjects to TRACK-HD which uses the revised form as its standard behavioural tool. 
The revised form differs from the first draft in several ways: 
• More detailed questions about (dis)orientation in time, place and person; 
• The addition of a ‘worst’ dimension to each domain, capturing the worst severity that it has 
attained over the preceding month, enabling better assessment of fluctuating symptoms; 
• The addition of an irritability subscale which was absent from the first draft because of 
overlap with aggressive behaviour and difficulty differentiating between the two domains 
reliably; 
• Changes to suggested prompts. 
Subjects in the biofluid study did not undergo behavioural testing, unless they were cross-recruited 
to the longitudinal imaging study. 
II.7 Magnetic resonance imaging 
II.7.1 Acquisition 
Subjects underwent 1.5T T1-weighted volumetric imaging on a General Electric scanner using an IR 
prepared FAST spoiled GRASS sequence with 24 x 18cm field of view and 256 x 256 matrix 
providing 124 contiguous 1.5mm-thick coronal slices. In-plane voxel dimensions: 0.9375 by 0.9375 
mm.  Acquisition parameters: TR = 13ms; TE = 5.2ms; flip angle = 13°; inversion time = 650ms; 
receiver bandwidth = 16kHz, NEX=1.  The scan acquisition time was approximately 9 minutes. 
Subject to available time and subject agreement, two consecutive (‘back-to-back’) scans were 
obtained to maximise scan quality. 
II.7.2 Pre-processing 
Image processing and analysis was carried out using Medical Image Display and Analysis Software 
(MIDAS) (Freeborough et al. 1997). Automated bias correction was performed to correct for 
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magnetic field inhomogeneities (Boyes et al. 2008). This fully automated process removes some of 
the effects of differences in head position within the scanner on regional image intensity. Bias-
corrected scans were checked for quality by a blinded expert rater. Where back-to-back scans were 
available, the scan with fewer artefacts was selected for analysis. 
II.8 Blood sample acquisition and processing 
Blood samples were collected from the antecubital fossa between 2pm and 4pm. For protein-based 
analyses, samples were collected into 6ml EDTA-coated Vacutainer™ tubes (BD, Oxford, UK). All 
samples were processed within 2 hours of collection. 
The blood fractionation procedure was designed to obtain good quality plasma, as well as 
preserving white cell pellets for future analysis of intracellular changes. An established technique, 
gradient density centrifugation, was employed (Boyum 1968). Histopaque® Accuspin™ tubes 
(Sigma, Dorset, UK) consist of two chambers separated by a porous high-density polyethylene 
barrier (‘frit’). The lower chamber contains Histopaque®-1077, an aqueous solution of a high 
molecular weight polysaccharide and sodium diatrizoate, an iodinated nonionic compound, 
adjusted to a density of 1.077 ± 0.001. On contact with this reagent, erythrocytes aggregate and 
granulocytes become slightly hypertonic, increasing their sedimentation rate, resulting in pelleting at 
the bottom of the tube. Lymphocytes and other mononuclear cells (including monocytes) remain at 
the interface between plasma and the reagent. Plasma may be collected from above this layer and 
the mononuclear layer may be collected separately. Contamination of plasma and the mononuclear 
layer by erythrocytes and granulocytes is avoided by the barrier between the chambers. 
Fractionation was carried out at room temperature. Histopaque® Accuspin™-1077 tubes were 
centrifuged for one minute at 1000g to ensure that the reagent was confined to the lower chamber. 
Whole blood was added gently to the upper chamber and the tubes centrifuged for 10 minutes at 
1000g. Two plasma aliquots of ~1mL were removed from above the mononuclear layer using a 
sterile pipette, avoiding the cell layer by 5mm. The remaining plasma, mononuclear cells and 
reagent were removed, leaving 5mm above the frit to minimise erythrocyte contamination. The 
mononuclear layer was diluted to 10mL with PBS (Sigma) and centrifuged at 250g for 10 minutes. 
The supernatant was decanted, resuspended to 10mL with PBS and centrifuged at 2500g for 12 
minutes. The two resulting cell pellets and plasma were frozen at -70°C. Plasma aliquots were 
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thawed once, over ice, and divided into 100μL aliquots which were re-frozen at -70°C until 
required. 
II.9 Cerebrospinal fluid collection, processing and storage 
CSF donors were recruited through the University of British Columbia HD Medical Clinic. Gene-
positive subjects were staged early or moderate according Independence Score as assessed by an 
experienced rater (100-80, early; 75-60, moderate) (The Huntington Study Group 1996). CSF was 
obtained by lumbar puncture, examined by microscopy and centrifuged to remove cells and the 
acellular portion was frozen at -80°C. There was no significant contamination of CSF by blood cells 
(median erythrocyte count 0.5×106/L, range 0-171; median leukocyte count 1.0×106/L, range 0-
17). Blood samples were obtained within an hour of lumbar puncture in EDTA tubes. Plasma was 
extracted by 2-stage centrifugation and frozen at -80°C. 
II.10 Cognitive assessment 
Subjects in the longitudinal imaging study underwent, at each assessment timepoint, a battery of 
cognitive tests lasting about 2 hours. Details are given in Appendix H. Cognitive outcomes from 
these subjects are reported elsewhere and do not form a focus of this thesis. At the two-year 
timepoint, the majority of subjects were cross-recruited into the TRACK-HD study, which had a 
different cognitive battery that was incompatible with the longitudinal imaging study assessment. As 
a result, the subject numbers undergoing cognitive assessment at the two-year time point were 
considerably reduced. Subjects in the biofluid study did not routinely undergo cognitive assessment. 
II.11 Statistical methods 
II.11.1 Overall approach 
This section sets out the statistical framework used to analyse the data contributing to this thesis, 
and the rationale for the approach used. The discussion here is limited to topics of relevance to 
both studies, or those applying to many aspects of one study. Specific analyses confined to one 
aspect of a single study are discussed separately in the statistical methods sections of the following 
chapters. 
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Data were collated in Microsoft® Excel 2003 (Microsoft Inc). Statistical analysis was carried out 
using Stata™ software versions 9 and 10 (Statacorp) and SPSS™ 14.0 (SPSS Inc). 
Raw data underwent basic processing to obtain meaningful values suitable for analysis. The general 
statistical approach to the evaluation of each candidate measure as a possible biomarker was then 
based on a stepwise, cumulative analysis to determine the extent to which the measure fulfilled a 
number of traits: 
1. Are there significant differences in the value of the measure between controls and HD patients? 
2. Are there significant differences in the value of the measure between other disease groups, e.g. 
premanifest and manifest HD or early and moderate HD? 
3. If there are sufficient numbers of clinical subgroups, is there a linear trend in the measure across 
all subject groups with increasing disease severity (i.e. does the measure track with 
progression)? 
4. To what extent does the measure correlate with established measures of clinical severity? 
5. To what extent does the measure correlate with what is known about the patient’s risk or 
objective disease severity, based on their CAG repeat length and age? 
6. Within the premanifest group, does the value of the measure correlate with estimated onset 
probability or time to predicted clinical onset? 
7. To what extent is the measure capable of predicting other key characteristics of subjects, e.g. in 
distinguishing between controls and premanifest HD, or between premanifest and manifest 
disease? 
8. Can the measure be combined with others to improve on the discriminating ability of the 
measures when applied individually? 
9. Does longitudinal observation of change in the measure improve its ability to answer these 
questions? 
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II.11.2 Tests for matching between groups 
Where possible, matching of groups for key demographic features was carried out at the level of 
recruitment. However, because of the progressive nature of HD and the relationships between 
CAG repeat length, age and disease duration, as well as limitations in the available pool of 
volunteers, differences between disease groups were almost inevitable (see section II.3.1.3). Tests 
were therefore performed to establish whether there were statistically significant differences 
between groups for the following key variables: 
• Age (two-tailed t-test) 
• Sex (Fisher’s exact test) 
• CAG repeat length between disease groups (two-tailed t-test) 
For longitudinal data, inter-group differences in the inter-visit interval were also tested using a two-
tailed t-test. Baseline IQ was tested between groups for the analysis of cognitive data, but not for 
other outcomes. 
II.11.3 Covariates 
The presence of a statistically significant difference in a potential confounding variable between 
groups is an important indicator of the need to correct for such differences in any subsequent 
analysis. However, the absence of such a statistically significant difference when groups are 
compared directly does not rule out the possibility that the variable may still exert a significant effect 
on other analyses. For example, a group of premanifest and early HD patients may differ slightly but 
not statistically significantly in terms of age, but if there is a large effect of age on brain atrophy rate, 
this might produce a spurious positive result when atrophy rates are compared between groups. 
Thus, it is necessary to identify in advance those variables that might theoretically be expected to 
have a systematic effect on the value of measures of interest. Linear regression analysis allows these 
‘nuisance’ variables to be adjusted for statistically. In addition, where required (e.g. for graphical 
display), the linear regression model can be used to generate values for the variable of interest, 
adjusted for the effect of the nuisance variable. In effect, this standardises each value to what it 
would be if the value of the nuisance variable were equal throughout the subject group: for 
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instance, using this technique to adjust atrophy rates for age produces individual values for what 
each subject’s atrophy rate would be if all subjects were the same age. This model allows each 
covariate to have a different effect on the outcome measure but does rely on the assumption that 
the relationship between each nuisance covariate and the outcome measure is linear. 
In general, age and gender were used as covariates in all linear regression analyses, while IQ was 
added when cognitive variables were analysed. The use of age is clear-cut, as most biological 
processes are affected to some extent by age, and age differences between groups were expected. 
Deciding whether to adjust all analyses, or some, for a possible effect of gender is less 
straightforward. On the one hand, there is no firm evidence to suspect that the pathogenesis or 
clinical progression of HD differs between males and females (Marder et al. 2000; Bates et al. 2002) 
and, of relevance to the longitudinal imaging study, there are no gender-related differences in brain 
atrophy due to normal ageing (Good et al. 2001) or in neurodegenerative disease (Schott et al. 
2005). In addition, each covariate added to a linear regression model increases the degrees of 
freedom which increases the size of resulting confidence intervals and increases the chance that a 
true effect will be missed. On the other hand, gender does exert diverse effects and could be 
theorised a priori to influence most possible marker candidates in HD. In addition, there are certain 
features of HD that do appear to be gender-specific such as endocrine phenotype (Markianos et al. 
2005; Markianos et al. 2007) and the increased propensity of CAG repeats to expand during 
gametogenesis (Pearson 2003), which might conceivably be recapitulated in the somatic tissues. 
Overall it was felt that gender effects were unlikely but that a gender effect was sufficiently plausible 
that gender was used as an additional covariate in the linear regression analyses. 
II.11.4 Tests for normality of data 
Linear regression modelling and other parametric statistics rely (among other requirements) on the 
data in question having a normal (Gaussian) distribution. Formal statistical testing for whether data 
are normally distributed can be performed, but such tests can fail to detect non-normality in small 
data sets and in larger data sets may falsely infer that a small or localised deviation from the normal 
distribution is ‘not significant’. Instead, visual comparison of the distribution of the data was used to 
establish normality or otherwise, by inspection of simple histograms and comparisons of data 
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quantiles against those of a normal distribution with equivalent parameters. Examples of such plots 
are given in Figure 15. 
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Figure 15 Examples of normal and non-normal data from the longitudinal imaging study 
(A-B) histograms with normal overlay and (C-D) inverse normal quantile plots for (A, C) total 
intracranial volume (TIV) and (B, D) UHDRS motor score at the baseline of the longitudinal imaging 
study. Inspection of such plots was used to determine whether assumptions of normal distribution 
were warranted (as in the case of TIV) or not (as in the case of UHDRS motor score, which is skewed 
towards lower scores but also shown by the normal quantile plot to fit poorly throughout the range of 
scores). In a normal quantile plot, a hypothetical normal distribution is calculated, having the same 
mean and variance as the sample data. For each sample data point, the quantile of that point is used 
to calculate the value of the corresponding quantile of the normal distribution. The two quantiles are 
plotted against each other and compared with a line of unity. Rather than showing raw quantile 
values, the horizontal axis is labelled with ‘inverse normal’ values, back-calculated from the normal 
distribution quantiles into the original units of measurement, so that each axis is labelled with values 
meaningful for the data set under comparison. 
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II.11.5 Handling of non-normal data 
Three options were available for the statistical analysis of data that were not normally distributed. 
Non-parametric tests of hypothesis can be used but these are more likely to produce false negative 
results, cannot be used with covariates to adjust for the effect of nuisance variables and cannot be 
compared directly with the results of equivalent parametric tests. Simple mathematical adjustment 
of data can be attempted to transform the data into a normal distribution (e.g. log-transformation) 
but such transformation is not always possible. Finally, the data can be resampled using a 
bootstrapping technique. This involves repeatedly constructing a new sample set based on random 
resampling a subset of subjects within a sample to produce a new data set; some subjects may be 
sampled more than once and others may be omitted. This is repeated many times (typically 2-3000). 
It enables the use of the same parametric statistical models as were applied to normally distributed 
data, including covariates, without having to apply specific mathematical transformations. 
Bootstrapping was therefore used for the analysis of all non-normally distributed data. 3000 
repetitions were employed, with resampling on a per-group basis where appropriate, and 
confidence intervals were calculated with bias-correction (Thompson et al. 2000). 
II.11.6 Correction for multiple comparisons 
Over the two parallel projects contributing to this thesis, a large number of statistical comparisons 
was performed. The main contributor to the multiplicity of tests was the analysis of associations 
between candidate biomarkers and the numerous clinical measures (see section II.11.9) in which 
each potential marker was tested against each clinical measure, using up to three models per 
pairing. Performing a large number of statistical tests brings with it a risk of false-positive results. 
Opinion among statisticians is divided on whether or not to make Bonferroni-type corrections for 
multiplicity in analyses of this type, with some authors insisting that they should always be employed 
(e.g. Bender et al. 2001) but a number (e.g. Rothman 1990; Savitz et al. 1995; e.g. Perneger 1998; 
Thompson 1998) arguing against their use. Overall, the approach adopted in this thesis was in 
keeping with the overall consensus that they should only be routinely used when the associations 
being investigated are so ‘similar’ that they are not of independent scientific interest. Thus, it was 
necessary to use multiplicity correction when performing inter-group comparisons between the 
different clinical stages in the biofluid study (section II.11.7) because adjacent clinical stages differ in 
only a quantitative manner and there is overlap between groups; but since the battery of clinical 
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and cognitive tasks was designed to minimise redundancy while ensuring a reasonably 
comprehensive phenotypic coverage, multiplicity correction was not deemed necessary in general. 
For a few notable exceptions where there is considerable overlap in assessments (e.g. UHDRS total 
functional capacity and independence score), the number of tests was reduced by excluding the 
less useful measure from the analysis (in this cohort, IS). The use of proteomic discovery 
methodology (Chapter III) inevitably brings with it a necessity for multiple comparison testing and 
this is discussed separately in that chapter. 
II.11.7 Inter-group comparisons 
Inter-group comparisons of the mean value of candidate markers were used to address the first two 
general statistical questions (section II.11.1): 
• Are there significant differences in the value of the measure between controls and HD 
patients? 
• Are there significant differences in the value of the measure between other disease groups, 
e.g. premanifest and manifest HD or early and moderate HD? 
Where there were two or three groups of interest (as in the longitudinal imaging study) a linear 
regression model was used; when used to test for significant differences between pairs of groups, 
this model has the properties of a t-test but allows the use of covariates. Where there were more 
than two groups (as in the biofluid study), the number of inter-group statistical tests required was of 
concern. One option might have been to reduce the number of tests and only, say, test between 
adjacent groups (for a four-group study, this would reduce the number of tests from nine to three). 
However, it was felt that statistically differences between non-adjacent groups would also be of 
interest, so an alternative strategy was adopted. One-way analysis of variance (ANOVA) was used 
to determine whether the mean value in one or more groups differed significantly from that in the 
other groups. Where the ANOVA indicated that one or more means was sufficiently different, post-
hoc Tukey HSD (‘honestly significant difference’) tests were then employed to test for significant 
differences between all pairs of groups. The Tukey HSD test is a pairwise parametric mean-
comparison tests that is more-stringent than a t-test because it incorporates correction for multiple 
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comparisons (Kutner 2005). Where the ANOVA indicated that no group’s mean was significantly 
different from the others, no post-hoc tests were performed. 
II.11.8 Assessment of trends across groups 
Assessment of trends across groups aims to address the question: 
• If there are sufficient numbers of clinical subgroups, is there a linear trend in the measure 
across all subject groups with increasing disease severity (i.e. does the measure track with 
progression)? 
Testing whether a measure tracks with progression is a key facet of biomarker evaluation because 
markers that differ significantly between groups but do not proceed linearly with advancing disease 
(e.g. measures whose value rises early but then falls later) are more difficult to model and use as 
surrogate endpoints than those that track linearly. The inter-group tests above, while providing 
important information about individual groups and their relationships, do not make use of the full 
information available from the design of the study. A single test that could encode the known fact 
that, overall, disease severity increases in each group from premanifest to early to moderate HD 
would be desirable. In addition the control group may effectively be considered a model for gene 
carriers with no exposure to mutant huntingtin. 
Linear regression analysis was therefore used to construct a model for the four-group design of the 
biofluid study. Group membership was encoded by assigning integer values to each group: 
controls, 0; premanifest HD, 1; early HD, 2; and moderate HD, 4. Each variable of interest was then 
regressed against this group code, with age and sex as covariates. Because the group code values 
are arbitrary, the constant term of this analysis is not interpretable, but the partial correlation 
coefficient R can be used to quantify the goodness-of-fit of the pattern of the variable across all 
groups and, since the arbitrary group codes are the same for each analysis, it can be compared 
directly across groups. Like the constant term, the slope of the association is not meaningful in itself 
but the p-value for whether it differs significantly from zero is a valid measure of the significance 
level of the across-group linear trend. 
This approach was used to construct figures comparing the values of potential markers across 
groups in the biofluid study. It was felt that with three-groups or fewer, this test of linearity would be 
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susceptible to undue influence by one group, so this analysis was not performed for the longitudinal 
imaging study. 
II.11.9 Associations with clinical measures 
This analysis addresses the question: 
• To what extent does the measure correlate with established measures of clinical severity? 
Clear mechanistic associations with disease pathogenesis are a highly desirable feature of a 
candidate biomarker (see discussion in chapter I.2.6) and in their absence it may be impossible to 
predict how a biomarker may perform in concert with a putative disease-modifying treatment. Brain 
tissue cannot readily be obtained in vivo from human HD patients, so mechanistic connections 
must be explored indirectly. As discussed in I.2, existing clinical tools have substantial shortcomings 
but are the current ‘gold standard’ for clinical trials and many of them do, on a population level, 
show strong associations with both the severity of neuropathology and ‘hard’ clinical outcomes 
such as disability and death (Vonsattel et al. 1985; The Huntington Study Group 1996). Therefore it 
is desirable to establish whether the pattern of a candidate biomarker correlates well or poorly with 
other clinical measures. A strong correlation in the expected direction is relatively easy to interpret, 
as it suggests that the biomarker captures the disease process to a similar extent to the clinical 
marker. However, owing to the absence of a true ‘gold standard’ in HD weaker correlations, or 
those in a counter-intuitive direction, are harder to explain, as discrepancies may be due to one of 
several factors: a shortcoming of the new measure; a shortcoming of the traditional clinical 
measure; or simply that each measure is capturing a different but potentially important facet of the 
disease process. The latter two are the most dangerous pitfalls because they may lead to rejection 
of a valuable and genuine biomarker on the basis of a poor degree of association with an existing, 
and imperfect, clinical measure. Thus, clinical correlations alone cannot be used alone to establish 
the pathological relevance or clinical applicability of a potential biomarker, but do certainly 
contribute to the overall picture that ultimately establishes a marker’s utility over time. 
Clinical correlations with key clinical, psychiatric and cognitive variables were assessed using linear 
regression analysis, using age and sex as covariates, in the premanifest and manifest groups. Unlike 
the scores discussed above determined from age and triplet repeat length, most clinical scores are 
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expected to show different distributions between premanifest and manifest disease. A stepwise 
approach, from most to least stringent, was adopted to modelling the possible interactions, as 
outlined in Figure 16. The most complex model allowed for the association between the candidate 
marker and the clinical measure to have a different slope (and intercept) in each group. This model 
was adopted if the term for the interaction between group and the clinical measure was significantly 
different from zero at the p<0.05 level. If it was not, a model was examined in which the slopes of 
the associations did not differ, but the groups were allowed to have different intercepts, i.e. the 
value of the candidate marker was significantly different between groups for a given value of the 
clinical measure. This model was adopted if the term for the difference between groups was 
significantly different from zero at the p<0.05 level. If it was not, a final model was fitted in which 
the association between the candidate marker and clinical measure had the same slope across both 
groups, which were also not allowed to differ from each other in terms of absolute value. If the 
slope term was not significantly different from zero at the p<0.05 level, the model was rejected and 
no correlation was deemed to exist. 
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Figure 16 Linear regression models sequentially applied to clinical correlation analysis 
In the most complex model (A), the slope of the correlation between the candidate biomarker value 
(y) and the clinical measure (x) is different in the premanifest and manifest groups if the group×x 
interaction term (β3) is significantly different from zero. In the next model (B), the slope of the 
interaction is not allowed to differ between groups but the values are significantly different between 
groups overall, if the group term (β2) is significantly different from zero. In the final model (C), the 
association between x and y has the same slope and the two groups do not differ in value from each 
other. 
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II.11.10 Modelling genetic predictors of disease course 
As discussed in chapter I.1.1.2, there is no established measure of disease severity that can be used 
to place both premanifest gene carriers and patients with overt disease onto a single scale — a 
‘universal x-axis’ — to determine to what extent a putative biomarker tracks linearly with the 
progression of neuropathology. One approach is to use age on its own as the comparator, and 
certainly as age increases, so does the burden of pathology, but of course at a given age, different 
subjects will have not only different clinical phenotypes but also very different degrees of pathology. 
CAG repeat length is the only factor shown to have a consistent and quantifiable influence on both 
the age of motor onset  and severity of pathology (e.g. Duyao et al. 1993; Penney et al. 1997; e.g. Li 
et al. 1998) and, though it certainly does not account for the full range of phenotypic variability, in 
the absence of a direct measure of pathological severity, a calculation taking into account age and 
CAG repeat length could theoretically produce an estimate of an individual’s lifetime exposure to 
mutant huntingtin toxicity, with which the most promising putative markers would be expected to 
correlate. Such measures are necessary to address the question: 
• To what extent does the measure correlate with what is known about the patient’s risk or 
objective disease severity, based on their CAG repeat length and age? 
One such measure is the model of disease burden proposed by Penney and colleagues (Penney et 
al. 1997), who studied the relationship between CAG repeat length and the degree of striatal 
atrophy post-mortem in HD brains. They found that the severity of atrophy was a linear function of 
CAG repeat length and age at death and that the CAG repeat length at which no atrophy was 
predicted to occur was 35.5 repeats. From this they proposed the formula: 
striatal dysfunction = constant × age × (CAG - 35.5) 
Based on the authors’ inferences that “the rate of development of striatal pathology should solely be 
a function of the CAG repeat number” and that “striatal pathology should develop linearly from 
birth” this formula has since been adapted for generic use (Sanchez-Pernaute et al. 1999) as a 
theoretical measure of disease burden (with arbitrary units) in the form: 
disease burden = age × (CAG - 35.5) 
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There are a number of limitations of this approach, as has been pointed out by others (Rosenblatt et 
al. 1998). First, it is derived from cross-sectional post-mortem data, with its inevitable bias towards 
end-stage brain changes (which can only be avoided by limiting study to subjects who have died 
prematurely from causes unrelated to HD).  The validity of using such data to make inferences 
about the progression of pathology in vivo is limited. Second, the study of Penney et al. was based 
on quantification of caudate atrophy, which, based on MRI measurements, is certainly selectively 
increased early in the disease course but does not appear to increase linearly throughout the 
disease as Penney and colleagues propose (Aylward et al. 2004), nor is there any reason to believe 
that the trajectory of caudate atrophy is capable of acting per se as a universal marker of pathology. 
A more widely-accepted measure of the combined contributions of age and CAG is the conditional 
onset probability calculation of Langbehn and colleagues (Langbehn et al. 2004). Based on a very 
large cohort of 2913 individuals from 9 countries, it uses a parametric survival model to predict for 
a given subject the probability p that they will remain disease-free for a specified number of years 
(conventionally five): 
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Where agenow is the subject’s current age, ageonset is the projected disease-free age (e.g. agenow + 5) 
and CAG is the subject’s CAG repeat length. 
This can be rearranged to predict, for a given individual, the number of years of disease-free life that 
must elapse before they reach a conditional onset probability of interest (conventionally 50 or 
60%): 
now
CAGCAG
e
agee
ageee
p
e
onsettoyears
CAG
now
CAG
−+++×
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
−−
+×
=
×−×−+
+−−× ×−
×−
146.056.9327.072.17
55.35
54.21
3
54.2155.351
1
1ln3
327.072.17
146.056.9π
π
 
 96 
Where agenow is the subject’s current age, CAG is the subject’s CAG repeat length and p is the 
conditional onset probability of interest. 
Conditional onset probabilities calculated using this method have several advantages. First, they are 
based on genuine population data from a large sample using the most widely agreed-upon event in 
premanifest HD: diagnosis of motor onset. Second, they make no assumptions of linearity of 
progression but, rather, attempt to model the non-linearity of onset probability. Third, unlike models 
that simply use an individual’s CAG repeat length to predict their probability of onset at a given age, 
this conditional model makes use of the additional clinical information that the individual has 
survived to agenow without developing motor signs, to modify the onset probability. For example, an 
individual with a repeat length of 44 would be predicted, at birth, to have a 77% probability of 
onset by the age of 50 years; but if the same individual remained disease-free at 45, their 
conditional probability of onset by the age of 50 would be reduced to 53%, because of the 
information about their genotype-phenotype concordance encoded in 45 years’ disease-free 
survival. 
Because of these advantages, the Langbehn et al. model is widely used in the study of premanifest 
gene carriers (e.g. Paulsen et al. 2006). It was therefore used as a standard comparator in the 
analysis of biomarker candidates discussed in this thesis, for the premanifest cohort. However, 
though the modelling of the interaction between CAG and age is considerably more sophisticated 
than in the Penney et al. formula, because the model was developed in premanifest subjects, and 
moreover carries the assumption of a lack of motor signs at agenow, it would be meaningless if 
applied to subjects with manifest disease and cannot be used to carry out analyses across both 
groups. 
Nonetheless such analyses are certainly of interest, and the approach of Penney et al. was adapted 
to construct a linear regression model suitable for comparing across premanifest and manifest HD. 
Variables of interest were regressed against CAG repeat length, using age as a covariate, in 
premanifest and early HD. One way to interpret this model is that is asks what the effect of CAG 
would be on the value of the outcome measure, if all subjects had the same age; that is, what is the 
additional effect on the measure of each additional CAG triplet for a subject with a given age. This 
model makes two assumptions. First, it assumes that the effect of CAG repeat is linear. This is 
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certainly not true throughout the range of pathological CAG repeats, as the model of Langbehn et 
al shows; but it is a reasonable assumption within the range of repeat lengths to be expected from 
the studies’ inclusion criteria (section II.3.1.2). Second, it assumes that the effect of CAG is equal in 
premanifest and manifest HD — that is, there is nothing about having disease signs per se that 
influences the effect of CAG on the outcome measure. This assumption can be sidestepped by 
introducing an interaction term for an effect of CAG × group, but given that the aim of the model is 
to examine the pattern of the measure across all gene carriers, agnostic to disease status, this 
analysis was not attempted. 
II.11.11 Discriminatory ability of biomarker candidates and marker 
combinations 
One test of the utility of a biomarker is the degree to which it can be used in isolation to predict 
known phenotypic features of subjects that can be measured by other means. Assessing this aims to 
address the question: 
• To what extent is the measure, alone or in combination, capable of predicting other key 
characteristics of subjects? 
This analysis is complementary to that of associations between marker candidates and clinical 
measures (section II.11.9) and we would expect those measures that performed well in the latter to 
do so in the former. In a sense, it is a more demanding trial of the potential biomarker, since rather 
than making a statement about the strength of a given association, and whether that association is 
statistically significant, it tests the ability of the candidate marker to select the more likely of two 
choices that the investigator has determined to be of relevance, modelling some of the real-life 
functions biomarkers would be expected to fulfil, such as distinguishing between control subjects 
and premanifest gene carriers, or between premanifest and manifest HD. 
The approach adopted for this task was logistic regression analysis, which is used fairly routinely in 
medicine in the evaluation of potential biomarkers and their ability to assist in clinical and diagnostic 
decision-making (e.g. Yuen et al. 2007), and has been applied in the field of neurodegeneration 
(Teunissen et al. 2003). It is a form of generalised linear model in which the distribution of a variable 
in a sample is used to predict a dichotomous outcome. The contrasts tested were those key clinical 
outcomes for which outcomes could be determined reliably for each subject in these cohorts: 
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• Controls vs. premanifest HD carriers (testing whether the candidate marker can distinguish 
subjects that clinical assessments cannot); 
• Premanifest HD vs. manifest HD (testing the ability of the marker to diagnose motor onset - 
see discussion in chapter I.1.1.2); 
• Controls vs. all HD gene carriers (testing whether the marker can detect a generic signal 
present in all mutation carriers). 
In addition, it is of considerable interest to be able to analyse markers not only alone but in 
combination and it is likely that combining biomarkers in this way will be necessary to provide the 
power and breadth of scope necessary for the conduct of future clinical trials (see chapter I.2.6). 
The key question is 
• Can the measure be combined with others to improve on the discriminating ability of each 
measure applied individually? 
Where multiple measures are available on a single subject on given occasion, stepwise logistic 
regression can be used to test them systematically. Briefly, this is an algorithmic approach to the 
selection of significant predictors of an outcome a logistic regression analysis is performed on each 
variable of interest, and those variables that significantly improve the prediction the outcome are 
included in the model, which is re-tested after the addition of each ‘significant’ variable. Thus a final 
model is arrived at which combines the best predictive power of the variables of interest, giving an 
idea of the ‘added value’ of each measure over the others (Hanley et al. 1982). Stepwise logistic 
regression was therefore used to compare measures of interest within the multivariate biofluid 
study, and also to compare across modalities in analysing the discriminatory ability of combinations 
of biofluid and imaging markers. The use of stepwise logistic regression is not without its pitfalls and 
the method has been criticised for being too lenient, and performing multiple tests on the same 
data (Copas 1983). However, with judicious selection of the variables of interest and careful 
interpretation of the data, the technique can be a valuable way of assessing the real-life utility of 
markers and examining the possible value of combining them. 
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A stepwise logistic regression model can also be used to construct receiver operating characteristic 
(ROC) curves, a standard graphical representation of the characteristics of a clinical test with a 
dichotomous outcome. By convention, the results of such a test can be classified in four ways: true 
positives and true negatives (the test correctly assigns the subject to the ‘positive’ or ‘negative’ 
outcome; and false positives and false negatives (the test incorrectly assigns the subject). A ROC 
curve plots the true positive against the false positive diagnosis rate, such that for each subject 
whose status is determined by the test to be ‘positive’, a correct result causes the plotted line to 
deviate upwards, while an incorrect result causes it to deviate to the right. A test that assigned 
subjects randomly to either outcome would tend to produce a diagonal line, while a perfect test 
would produce a vertical line. In practice, most tests fall between the two extremes and it follows 
that the area under the curve (AUC) is one measure of the ability of the measure to classify cases 
correctly (i.e. the discrimination of the test): the closer the AUC is to 1, the better the discrimination. 
Indeed a system of classifying tests exists, according to their the AUC values they produce when 
ROC curves are plotted (Hanley et al. 1982): 
Area under the curve (AUC) Discrimination of the test 
More than 0.9 Excellent 
0.8 - 0.9 Good 
0.7 - 0.8 Fair 
0.6 - 0.7 Poor 
Less than 0.6 Fail 
Table 5 Classification of test discrimination according to the area under the ROC curve 
II.11.12 Sample size estimation 
For several measures of interest, it was desirable to calculate estimates of sample size requirements 
for clinical trials using modification of that measure as an outcome. In addition to providing useful 
information in themselves, samples size estimates have been published in the literature, or can be 
calculated from it, for some existing candidate biomarkers in HD (e.g. Aylward et al. 2003). 
Calculations of the sample size that would be required for an observational study to detect a simple 
difference in a measure between controls and a patient group were calculated using the formula: 
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Where: 
n is the estimated sample size required per group 
α is the desired significance level (typically 0.95 for ‘p<0.05’ results) 
1-β is the desired power (typically 0.9 for 90% power). Power is the probability of identifying a 
correlation if one exists 
zp is the ordinate for the normal distribution for a given probability p 
σ1 is the standard deviation of the measure in the control group 
σ2 is the standard deviation of the measure in the patient group 
μ1 is the mean value of the measure of the control group 
μ2 is the mean value of the measure of the patient group 
 
The calculation of sample size requirements for interventional clinical trials is more complex and 
depends on the manner in which we wish to model the effect of the intervention. The effect size of 
the treatment, E, is a value between zero and one that expresses the proportion by which the 
treatment is expected to reduce the change in the measure. The key decision rests on whether the 
effect of normal variability in controls is to be included in the model. If we omit control data from 
the model, the treatment is predicted to reduce the absolute value of the measure by E towards 
zero, and the sample size is given by: 
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For example, in the case of brain atrophy, with an effect size of 0.3, this would model a 30% 
absolute reduction in atrophy rate (including any atrophy due to normal ageing). However, if 
control data are included in the model, the treatment is modelled as having an effect of magnitude 
E on the difference between patients and controls for the measure and the sample size 
requirement is given by: 
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For the example of brain atrophy, this would mean reducing by 30% the excess atrophy caused by 
the disease process, above normal ageing. 
The difference is not trivial, because the sample size requirements generated by the two 
approaches can vary greatly. For instance, data from the pilot study of whole-brain atrophy in early 
HD (Henley et al. 2006) produce requirements of 268 subjects per arm if control atrophy is 
included, and 156 if it is excluded, for a 6-month trial of an intervention with 30% effect, at 90% 
power and 5% significance. The organisation of clinical trials will require a single reliable figure for 
funding, planning and recruitment. On the face of it, the latter (relative reduction) approach seems 
more biologically plausible, because no intervention would realistically be expected to act equally 
on a pathological process in patients and the ageing process in normal controls: in the example 
given it is unlikely a treatment would halt age-related brain atrophy. However, values for outcome 
measures obtained from observational trials already include a contribution from normal variability 
and ageing, by definition. Moreover, normal subjects are not generally included in clinical trials, 
because both trial arms typically consist of patients, one under active treatment and the other 
receiving a placebo, so the additional inclusion of normal variability appears less clearly warranted. 
In this thesis, sample size calculations are based on the absolute reduction in atrophy, excluding 
control data, but conservative effect sizes have been used, because the treatment would be 
expected to attain a smaller reduction in an absolute measure. 
Subject drop-out from longitudinal studies can also be taken into account for sample size 
estimations (e.g. Fox et al. 2000) and is usually estimated at 10% per year. 
II.11.13 Analysis of longitudinal data 
Both studies contributing to this thesis involve the longitudinal collection of data or samples from 
the same subjects over multiple timepoints. For measures that can be calculated cross-sectionally 
(e.g. most biofluid measures), the expectation is that longitudinal observation may reveal a stronger 
disease-related signal, because of the expectation that, within each subject group, the change in that 
measure over time is likely to be less variable than its baseline value, if the disease exerts a 
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differential, progressive effect on the biological processes underlying the measure that is greater in 
HD gene carriers than in controls (see Figure 10). 
II.11.13.1 Longitudinal data with two timepoints 
The majority of measures arising from the parallel studies were cross-sectional, but where serial 
measurement of such cross-sectional measures was performed, longitudinal rates of change were 
calculated by subtracting the baseline value from that at followup and, where necessary, dividing by 
the time interval between observations to produce an annualised rate of change: 
interval
baselinefollowupchangeofrate −=  
In calculating longitudinal change rates, one issue is whether the change score should be analysed 
as an absolute value or adjusted for the baseline value. A ten-point change in a given score over 
one year may have a different meaning depending on whether the baseline score was ten or ten 
thousand. On the other hand, given that the aim of measuring change longitudinally is to seek to 
eliminate some of the heterogeneity seen cross-sectionally, it may defeat the object to adjust for 
baseline score, especially if the cross-sectional values are highly variable within groups but do not 
differ greatly between groups. 
If adjustment for baseline values is to be attempted, different approaches can be considered. The 
first is to calculate the change value as a proportion of the baseline value, viz: 
ntervali
baseline
baselinefollowupchangeofrate ÷−=  
Alternatively, the change score can be analysed in its unadjusted form, using the baseline value as a 
covariate. 
Both of these approaches to adjustment for baseline value have a potential shortcoming in that a 
proportional adjustment may amplify or diminish change scores. Consider two subjects observed at 
two timepoints over one year. Subject A’s score halves from 200 to 100 while subject B’s score 
doubles from 200 to 400. The absolute change scores would be -100 and +200 respectively, while 
the proportional changes would be -50% and +100%. But if the nature of the change is such that it 
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acts directly on the baseline value — as in the case of brain atrophy, where the process of atrophy 
directly diminishes brain volume — a halving and doubling of volume could be seen as equivalent 
changes in different directions. Expressing the change logarithmically as 
interval
baseline
followupchange ÷⎟⎠
⎞⎜⎝
⎛= ln,δ  
gives values of -0.69 and +0.69 respectively, capturing the perceived equivalence of these changes. 
In practice, brain atrophy was the only outcome for which the outcome measure was felt to be a 
sufficiently immediate reflection of the process under observation, acting directly on the entity 
measured at baseline, to warrant such correction. Followup brain volume was calculated by 
subtracting the absolute volume change measured by the BBSI from the baseline brain volume. 
After analysis, logarithmic change rates were back-converted to meaningful atrophy rates using the 
formula 
( ) 1001 ×−= δerateatrophyannualised  
For other measures in the longitudinal imaging study, absolute change scores were used for the 
analysis. 
Once an appropriate annualised change rate was calculated, it was treated as a new measure and 
analysed as set out in sections II.11.2-II.11.11. For the analysis of associations with clinical measures, 
it was felt most useful to examine correlations between pairs of longitudinal measures, rather than 
examining, say, associations between baseline clinical score and longitudinal change in a candidate 
marker. 
II.11.13.2 Linear change over more than two timepoints 
The longitudinal imaging study had three timepoints, meaning that up to three values were available 
for all cross-sectional measures, with the caveats noted in section II.5. The longest interval would be 
expected to have the greatest signal-to-noise ratio, and therefore one approach would be to ignore 
the intermediate timepoint and calculate rates of change over this interval. However, given the 
asymmetry of inter-assessment interval, the likelihood that dropout will diminish subject numbers at 
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each successive timepoint, and the fact that each point value may be considered equally reliable, it 
is desirable to explore methods of modelling linear change that are capable of including multiple 
timepoints per subject in calculating rates of change. The method adopted was the generalised 
estimating equation (GEE), which is an extension of the generalised linear model that allows multiple 
observations per subject to be analysed against time to produce estimates and confidence intervals 
for rates of change (Liang et al. 1986). One feature of the GEE is that it accounts for the likelihood 
that subject dropout may be influenced the variable under scrutiny (i.e. to depend on disease 
severity), which would otherwise tend to bias the calculation towards lesser rates of change. 
For a three-timepoint study, the GEE uses three sequential cross-sectional values to calculate a rate 
of change. BBSI-derived atrophy rates, however, are calculated directly by analysing the change in a 
variable and are said to be a ‘direct measure of change’. Instead of three sequential values, the BBSI 
calculated over a three-timepoint study yields three non-sequential atrophy rates, between 
timepoints 1 and 2, timepoints 2 and 3, and timepoints 1 and 3. Because these do not correspond 
to sequential point values, the GEE cannot be used to combine all the available data to infer overall 
rates of change from such ‘direct’ measures. Some authors have successfully applied a linear mixed 
model to account for this difficulty (Frost et al. 2004).  Overall, however, it was felt that a key 
difference between direct and indirect measures of change was the precision of each measure. This 
is expected to be equal at each timepoint for serially-applied point measures such as clinical scores; 
but a direct measure calculated over one year is likely to be less precise than the same measure 
applied over two years. Therefore for the direct measure of BBSI-derived whole-brain atrophy, linear 
analysis was restricted to calculation of change over the longest measured interval for each subject. 
II.11.13.3 Linearity of change 
For the three-timepoint longitudinal imaging study, comparison of change over the first and second 
one-year intervals allowed an assessment of whether change in each measure was linear. 
Annualised change in each measure over the second interval was compared with that over the first 
by means of groupwise paired t-tests. For groupwise comparisons of linearity, an acceleration value, 
calculated by subtracting the first year’s annualised change score from the second, was compared 
between groups using linear regression, with age and sex as covariates, as described in section 
II.11.7. Clinical and genetic factors predicting non-linearity were assessed as described in sections 
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II.11.9 and II.11.10. For whole-brain atrophy, the first and second year’s directly measured atrophy 
values were used to in place of derived change scores for paired t-tests and to calculate the 
acceleration value. 
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Chapter III Inflammatory activation in HD revealed 
by proteomic discovery 
III.1 Introduction 
HE PATHOLOGICAL HALLMARK of HD is striatal neuronal cell loss but there are widespread 
changes in the CNS (Bates et al. 2002) and systemic abnormalities have been identified 
including endocrine dysfunction (Björkqvist et al. 2006) and immune activation (Leblhuber et al. 
1998). Peripheral abnormalities are of significance in their own right but may also reflect central 
pathology and, where implicated molecules cross the blood-brain barrier, may exert central effects 
on brain pathogenesis. 
In addition, because of its slow clinical progression and the limitations of standard clinical rating 
scales (The Huntington Study Group 1996), there is a need for biomarkers of onset and progression 
in HD to power clinical trials of potential disease-modifying treatments (Henley et al. 2005; Handley 
et al. 2006). Unlike in other degenerative diseases, diagnostic markers are not required because of 
the reliable genetic test for HD (Henley et al. 2005). Several candidate biomarkers in plasma have 
been proposed (Borovecki et al. 2005; Hersch et al. 2006) but no plasma proteins to date have 
been reported to be effective biomarkers for HD. Because of its ready accessibility, plasma is an 
appealing site for biomarker discovery and evaluation, while cerebrospinal fluid, while difficult to 
obtain, offers closer insights into the CNS milieu. 
Proteomic profiling has previously been applied to mouse models of HD and human brain tissue 
(Zabel et al. 2002) but has not been reported for human plasma or CSF. Using a multi-platform 
proteomic profiling approach with 2 different depletion techniques and protein identification 
methods, 18 candidate proteins were identified that were differentially expressed in human plasma 
at various stages of HD including pre-manifest gene carriers. Candidate proteins were assessed 
mechanistically in terms of known roles in the pathogenesis of HD and other neurodegenerative 
diseases. The most promising protein in this respect, clusterin, was evaluated further by 
immunoblotting and enzyme-linked immunosorbent assay (ELISA) quantification in plasma samples 
from 2 independent populations, as well as in matched CSF and plasma samples. To investigate the 
neuroinflammatory processes highlighted by the proteomic discovery, interleukin-6 (IL-6) levels were 
investigated in both human plasma and the R6/2 transgenic mouse model of HD using ELISA. 
T 
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III.2 Contributions and collaborations 
Collection and processing of matched CSF and plasma was performed by B Leavitt. 2D gel 
electrophoresis and corresponding statistical analysis was performed by A Dalrymple and R Joubert 
of Proteome Sciences Inc. Quantitative immunoblotting and human clusterin ELISA were performed 
by A Dalrymple. The Mouse IL-6 ELISA was performed by M Björkqvist of Lund University. Animal 
rearing and IL-6 ELISA was performed by K Sathasivam and G Bates of King’s College London. 
Subject recruitment and clinical characterisation, plasma processing, statistical analysis of 
immunoblotting and ELISA experiments, preparation of figures and drafting of the published 
manuscript were performed by the author. Study, design and interpretation and revision of the 
manuscript was shared between all collaborators including the author. 
III.3 Subjects and methods 
III.3.1 Ethical approval and subject recruitment 
Ethical approval and subject recruitment were as specified in Chapter II. 
III.3.2 Inclusion and exclusion criteria 
Subjects with concomitant CNS disorders, significant medical comorbidity, known liver dysfunction, 
recent alcohol or substance abuse, and those taking medications or supplements suspected or 
known to interfere with the experimental methods used, were excluded. In view of the likelihood of 
nutritional, infective and inflammatory disorders in advanced HD, such patients were not included 
in validation experiments.  
III.3.3 Collection and fractionation of blood samples 
Subjects were classified as controls, premanifest HD or early, moderate or advanced HD. Sample 
collection, fractionation and storage and CAG repeat sizing were carried out as outlined in Chapter 
II. Subjects’ clinical data are shown in Table 6. 
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Table 6 Clinical characteristics of subjects in each study for discovery and evaluation experiments 
a4 early, 4 moderate, 2 advanced HD patients. Independent sample sets were used for the two 
discovery experiments and CSF/plasma pairs; other plasma work was performed using a combination 
of overlapping and unique samples. 
Experiment Disease stage Number of 
subjects 
Female: 
male 
Mean age 
(range) 
Control 74 (43:31) 44 (21-74) 
Premanifest 42 (24:18) 40 (27-61) 
Early 58 (32:26) 46 (29-67) 
Moderate 66 (38:28) 51 (23-77) 
Overall subject pool 
Advanced 10 (2:8) 54 (40-68) 
Control 10 (8:2) 49 (29-67) 2D electrophoresis 
1st plasma study HD patients 10a (7:3) 51 (31-70) 
Control 55 (28:27) 43 (22-68) 
Premanifest 14 (7:7) 37 (30-46) 
Early 15 (9:6) 43 (29-51) 
Moderate 15 (9:6) 48 (24-62) 
2D electrophoresis 
2nd plasma study 
Advanced 10 (2:8) 54 (40-68) 
Control 15 (6:9) 47 (24-68) 
Premanifest 15 (7:8) 38 (30-46) 
Early 15 (9:6) 43 (29-51) 
Immunoblotting 
Plasma 
Moderate 15 (9:6) 48 (24-62) 
Control 18 (13:5) 42 (21-74) 
Premanifest 18 (12:6) 41 (27-61) 
Early 19 (10:9) 48 (29-63) 
Clusterin ELISA 
Plasma 
Moderate 18 (13:5) 55 (35-77) 
Control 9 (6:3) 45 (25-66) 
Early 9 (4:5) 51 (38-64) 
Clusterin ELISA 
Matched CSF and 
plasma Moderate 11 (1:10) 53 (38-72) 
Control 34 (19:15) 41 (21-67) 
Premanifest 16 (8:8) 38 (30-61) 
Early 23 (14:9) 44 (29-67) 
IL-6 ELISA 
Plasma 
Moderate 23 (13:10) 50 (23-69) 
 109 
III.3.4 Collection and fractionation of CSF samples 
CSF was collected, processed and stored as detailed in chapter II.9. 20 subjects with HD and 10 
control subjects, age-matched and lacking the HD mutation, were recruited (see Table 6). 
III.3.5 2D gel electrophoresis 
Two independent 2D gel electrophoresis (2DE) studies were performed using different depletion 
and identification techniques to maximize sensitivity. For the first study (minimal depletion), plasma 
samples from 10 HD patients and 10 controls (Table 2) were depleted of albumin and 
immunoglobulins using an antibody-based spin column (GE healthcare, UK). For the second study 
(stringent depletion), plasma samples from 55 HD patients and 55 matched controls (Table 2) were 
depleted of the 6 most abundant proteins using Multiple Affinity Removal System (MARS) HPLC 
columns (Agilent Technologies, CA). 
Depleted protein pellets were re-suspended in 2D gel lysis buffer composed of 9.5 M urea, 2% 
CHAPS (USB Corporation, OH), 1% dithiothreitol, 0.8% Pharmalyte (pH 3-10, GE healthcare) and 
Mini Complete Protease Inhibitor Cocktail (Roche, UK). The protein concentration of each plasma 
sample was determined using the Bradford assay (Bio-Rad, UK). Plasma samples (75 or 100μg in 
first and second study respectively) were loaded onto immobilized pH 3-10 non-linear gradient 
strips then separated in the second dimension using SDS polyacrylamide gels as described (Heinke 
et al. 1999; Weekes et al. 1999). 
Resultant 2DE gels were silver-stained with OWL silver stain (Insight Biotechnologies, UK) and 
image analysis performed using ProgenesisTM Workstation, (version 2003.02, Nonlinear Dynamics, 
UK). Images were processed using the automatic wizard for spot detection, warping and matching, 
followed by manual editing and optimal matching to the reference gel (>80% per gel). Following 
background subtraction and normalization to total spot volume, spot data from the first study were 
analyzed using student t-tests at the 95% confidence level. Spot data from the second study were 
imported into StatistiXL software (www.statistixl.com) and the mean of normalized volume, 
coefficient of variation, fold change and Mann-Whitney test determined (pairwise comparisons 
between groups). A program developed internally was used to select statistically significant spots 
automatically based on the following criteria: spots present within at least 60% of all gels (across all 
subject groups), ≥1.5-fold change and p<0.005. 
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Significant spots from the first study were excised, prepared and analyzed by LC/MS/MS as 
previously described (Standen et al. 2003). Proteins present in the spots were determined using 
Mascot search algorithm against the NCBI non-redundant (www.ncbi.nlm.nih.gov) and Swiss-Prot 
(expasy.org) databases. Significant spots from the second study were excised, prepared and 
analyzed using matrix-assisted laser desorption/ionisation-time of flight (MALDI-ToF) mass 
spectrometry as previously described (Joubert et al. 2001). Mass spectra were matched with the Ms-
Fit program (prospector.ucsf.edu) and the Swiss-Prot database was used to identify proteins. 
III.3.6 Evaluation of clusterin as a biomarker 
III.3.6.1 Semi-quantitative immunoblotting 
Based on the results of the first 2DE experiment, the availability of quality commercial ELISA kits and 
the identification in the literature of plausible mechanistic roles in HD pathogenesis for the proteins, 
both clusterin and beta-actin were selected for further analysis. The concentrations of α and β-
clusterin and β-actin were determined by semi-quantitative immunoblotting in 60 plasma samples 
(Table 6). Control experiments using a range of plasma dilutions and primary antibody dilutions 
were performed to ensure that quantification was within the linear range. For α and β-clusterin, 
undepleted plasma samples (2μg) were used; for β-actin, plasma samples were depleted using 
MARS HPLC columns and 20μg used.  Plasma was denatured in Laemmli sample buffer and size-
separated using 12% tris-glycine gels (National Diagnostics, UK). Following SDS-PAGE, proteins 
were transferred to polyvinylidene difluoride membrane (GE Healthcare). Transfer efficiency and 
equal loading of protein samples was assessed by incubating membranes with Ponceau red solution 
(Sigma) and gels post-transfer with EZblue solution (Sigma). Membranes were washed with PBS-T 
and incubated with blocking buffer, then with anti-α-clusterin (1:10000, 05-354, Upstate, UK), anti-β-
clusterin (1:40000, sc-6419, Santa Cruz Biotechnology, CA) or anti-β-actin (1:250, A5316, Sigma) 
antibodies, followed by horseradish peroxidase-conjugated sheep anti-mouse (α-clusterin and β-
actin, GE healthcare) or rabbit anti-goat secondary antibodies (β-clusterin, Jackson laboratories, ME). 
For protein band visualization and quantification, membranes were incubated with ECL-plus, 
scanned and analyzed using ImageQuant software (GE healthcare). Linear regression analysis with 
coded variables for each subject group (control=1, premanifest=2, early=3, moderate=4) was used 
to identify significant trends with advancing disease. Data were re-analyzed using age as a covariate 
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to account for any effect of age on clusterin concentration. Comparisons between individual subject 
groups were made using ANOVA with post-hoc Tukey HSD analysis. 
III.3.6.2 Human clusterin ELISA 
Clusterin concentrations in paired CSF and plasma samples (n=29, Table 1) and in a larger set of 
plasma samples (n=73, Table 1) were measured using a commercially available ELISA kit 
(RD194034200, BioVendor, Modrice, Czech Republic; manufacturer’s protocol). Absorbances were 
determined at 450nm. Clusterin concentrations were determined from standard curves. Statistical 
analysis was performed as described for immunoblotting experiments. 
III.3.7 Exploration of the acute phase response in HD 
III.3.7.1 Human IL-6 ELISA 
Plasma IL-6 concentrations in 96 samples (Table 6) were determined using IL-6 ELISA kits (EK-033-
31, Phoenix Pharmaceuticals, Belmont, CA; manufacturer’s protocol). Absorbance and 
concentration were determined and statistical analysis performed as for clusterin ELISA. 
III.3.7.2 Mouse IL-6 ELISA 
Affected mice were hemizygote R6/2 females (Induced Mutant Resource, Bar Harbor, ME), bred 
and reared by backcrossing R6/2 males to (CBA × C57BL/6) F1 females (Harlan Olac, UK). 
Transgenic animals were identified by PCR of tail-tip DNA. CAG repeat size determination 
(Woodman et al. 2007), housing conditions and environmental enrichment (Hockly et al. 2003) 
were as previously described. Animals had unlimited access to rodent breeding chow from a food 
hopper. Mice were subject to a 12h-light, 12h-dark cycle. Animals were culled by cervical 
dislocation and blood was withdrawn. After clotting, serum was obtained by centrifugation and 
snap-frozen. 50μL aliquots were used for the IL-6 ELISA (M6000B, R&D systems, UK; manufacturer’s 
protocol). Absorbance and concentration were determined and statistical analysis performed as 
described for clusterin ELISA. 
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III.4 Results 
III.4.1 2D gel electrophoresis 
 
Figure 17 Proteins identified by 2DE and LC/MS/MS 
A. Representative 2D gel region depicting spots 1713 and 1960 that were significantly upregulated in 
10 HD patients compared with 10 controls. B. Proteins identified by LC/MS/MS. Spot 1713 contained 
2 proteins, β-actin and ApoA-IV; spot 1960 contained the α and β chains of clusterin. (Data supplied 
by A Dalrymple and R Joubert.)  
1273 unique protein spots were analysed in total. In the first 2DE study, 2 spots (termed 1713 and 
1960) were significantly upregulated in HD patients compared with control plasma samples (Figure 
17A). LC/MS/MS confirmed that spot 1713 contained β-actin and ApoA-IV (7.3-fold change 
compared with controls; p=0.00007) and spot 1960 contained the α and β chains of clusterin (2-
fold change compared with controls; p=0.004) (Figure 17A and B). Whilst the LC/MS/MS data for 
spot 1960 provided direct evidence for glycosylation on the individual clusterin chains, it was not 
possible to elucidate the exact nature of the post-translational modification due to the limited 
sequence coverage. Several isoforms of clusterin were observed in the 2DE experiment: hence spot 
1960 represented a fraction of the total clusterin population. A representative control gel is given in 
Figure 18. 
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Figure 18 Representative control 2D gel region 
Gel depicts spots 1713 and 1960 that were significantly upregulated in 10 HD patients compared 
with 10 controls. C, Control; P, premanifest HD; E, Early HD; M, Moderate HD. (Data supplied by A 
Dalrymple and R Joubert.) 
The second 2DE study detected an additional 15 spots that were significantly different between 
control and HD plasma (Table 7). These included complement components C7 and C9, alpha-2 
macroglobulin and alpha-2 antiplasmin (all significantly upregulated in HD versus controls, Table 
7A); and afamin, insulin-like growth factor binding protein and plasma retinol binding protein (all 
significantly downregulated in HD versus controls, Table 7B). Increasing levels of clusterin, β-actin 
and ApoA-IV with advancing disease were not observed by 2DE following MARS column depletion: 
this was assumed to be an effect of the depletion as the first 2DE study was performed on less 
stringently depleted samples. However, the same sample cohort was used for immunoblotting, 
where clusterin is demonstrated to increase with disease progression (Figure 2).  
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A. Proteins increased with progressing HD clinical stage. 
Spot 
no. 
Protein or proteins in spot Observation Fold 
change 
p value 
(t-test) 
padj 
151 Complement component C7 precursor 
Alpha-2-macroglobulin precursor 
C < P 3.36 0.005 0.1 
357 Alpha-2-antiplasmin E < M 1.58 0.004 0.1 
376 Complement component C9 C < A 
P < A 
E < A 
M < A 
1.61 
1.99 
1.72 
1.51 
0.0004 
0.0001 
0.0001 
0.0003 
0.002 
0.002 
0.002 
0.007 
578 Fibrinogen gamma chain E < A 1.55 0.01 0.2 
660 Haptoglobin precursor C < A 
E < A 
2.58 
2.47 
0.003 
0.009 
0.07 
0.2 
661 Haptoglobin precursor C < A 
P < A 
E < A 
M < A 
3.77 
2.56 
2.78 
3.42 
0.006 
0.02 
0.03 
0.006 
0.1 
0.5 
0.7 
0.1 
725 Complement C4 precursor C < P 2.97 0.02 0.5 
789 Haptoglobin precursor C < A 
E < A 
M < A 
3.87 
4.68 
3.19 
0.009 
0.006 
0.01 
0.2 
0.1 
0.2 
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B. Proteins decreased with progressing HD clinical stage. 
Spot 
no. 
Protein or proteins in spot Observation Fold 
change 
p value 
(t-test) 
padj 
259 Afamin C > A 
P > A 
E > A 
1.86 
2.08 
1.80 
0.005 
0.0001 
0.004 
0.1 
0.002 
0.1 
283 Inter-alpha-trypsin inhibitor heavy chain 
H4 
Prothrombin 
P > A 
 
E > A 
2.29 
2.19 
0.0009 
0.003 
0.02 
0.07 
291 Insulin-like growth factor-binding protein 
complex acid labile chain 
Prothrombin 
E > A 
 
E > A 
3.25 0.0006 0.01 
297 Inter-alpha-trypsin inhibitor heavy chain 
H4 
P > A 2.26 0.0009 0.02 
608 Leucine-rich alpha-2-glycoprotein P > A 4.31 0.004 0.1 
614 Serum paraoxonase/arylesterase 1 P > A 1.63 0.0004 0.01 
699 Clusterin E > A 1.95 0.002 0.05 
703 Inter-alpha-trypsin inhibitor heavy chain 
H4 
E > A 3.44 0.004 0.1 
783 Plasma retinol-binding protein precursor C > A 
E > A 
M > A 
1.82 
1.60 
1.51 
0.0004 
0.003 
0.003 
0.01 
0.07 
0.07 
 
Table 7 Proteins identified by 2DE and MALDI-ToF to be regulated in HD patients and controls  
C, control; P, premanifest; E, early; M, moderate; A, advanced. Pcorr,, Bonferroni-corrected p-values 
adjusted for multiple inter-group comparisons (24 per protein). (Data supplied by A Dalrymple and R 
Joubert.) 
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III.4.2 Semi-quantitative immunoblotting 
Representative post-transfer gels are shown in Figure 19. 
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Figure 19 Post-transfer SDS-PAGE gels demonstrating equal protein loading of samples 
Gels are shown for (A) α-clusterin and (B) β-clusterin. Gels were stained with EZblue solution (Sigma) 
to determine protein loading. C, Control; P, premanifest HD; E, Early HD; M, Moderate HD. (Data 
supplied by A Dalrymple.) 
Semi-quantitative immunoblotting demonstrated increased levels of both α- and β-clusterin with HD 
progression (Figure 20). The trend for rising levels with increasing disease severity across all groups 
was statistically significant for both α-clusterin (p=0.000003) and β-clusterin (p=0.0007). These 
trends remained significant when allowing for any effect of age and sex on clusterin concentration 
in the regression analysis (p=0.0001 and p=0.0002 respectively). There were also significant 
differences between individual groups (ANOVA with post-hoc Tukey HSD analysis). For α-clusterin: 
early>control (p=0.0052); moderate>control (p=0.0001); moderate>premanifest (p=0.0073). For β-
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clusterin: moderate>control (p=0.0082). β-actin expression did not track with disease progression 
(data not shown). 
 
Figure 20 Semi-quantitative immunoblotting studies to determine α- and β-clusterin expression 
Representative western blots and box-and-whisker plots of band intensity values for α-clusterin (A and 
B) and β-clusterin (C and D). Samples were applied in pseudorandom order to avoid systematic error 
across gels. Mean values ± SD for α-clusterin: control (C) 44.9 ± 5.72; premanifest (P) 46.8 ± 3.47; 
early HD (E) 50.3 ± 4.14; moderate HD (M) 52.0 ± 3.16. Mean values ± SD for β-clusterin: C 86.2 ± 
5.79; P 90.0 ± 6.84; E 93.2 ± 7.75; M 95.1 ± 8.68. The overall trend for increasing clusterin across all 
groups, using linear regression analysis, was significant for both α- and β-clusterin (#####p=0.000003 
and ###p=0.0007 respectively). Significant differences between individual groups are shown (ANOVA 
with post-hoc Tukey HSD test: **p<0.01; ***p<0.001). (Raw data supplied by A Dalrymple.) 
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III.4.3 Clusterin ELISA 
 
Figure 21 Quantitative analysis of clusterin concentrations in HD plasma and CSF using ELISA 
A. Box-and-whisker plot showing clusterin concentrations in plasma samples from UK subjects. Mean 
concentrations ± SD: control (C) 121 ± 25.6; premanifest HD (P) 120 ± 29.2; early HD (E) 129 ± 26.7; 
moderate HD (M) 149 ± 32.2. B. Box-and-whisker plot showing clusterin concentrations in plasma 
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samples from Canadian subjects. Mean concentrations ± SD: C 192 ± 30.8; E 223 ± 30.0; M 248 ± 
52.4. C. Box-and-whisker plot showing clusterin concentrations in matched CSF samples from 
Canadian subjects. Mean concentrations ± SD: C 1.50 ± 0.7; E 2.02 ± 0.5; M 2.64 ± 0.5. The overall 
trend for increasing clusterin across all groups, using linear regression analysis, was statistically 
significant in all three studies (##p=0.0032 for UK plasma, ##p=0.0036 for Canadian plasma and 
####p=0.00009 for Canadian CSF). Significant differences between individual groups are shown 
(ANOVA with post-hoc Tukey HSD test: *p<0.05; ***p<0.001). (Raw data supplied by A Dalrymple.) 
Reliability of the clusterin ELISA assay was demonstrated by its low mean coefficient of variation 
(7.1%). 
ELISA experiments confirmed increased clusterin expression with HD stage in samples from both 
patient populations studied and in both plasma and CSF (Figure 21). Statistically significant increases 
across subject groups from control through progressing disease were found in the plasma from UK 
subjects (p=0.0032) and plasma and matched CSF from Canadian subjects (p=0.0036 and 
p=0.00009 respectively). These trends all remained significant when allowing for any effect of age 
and sex on clusterin concentration in the regression analysis (p=0.0146, p=0.0352 and p=0.00003 
respectively); clusterin concentration correlated only very weakly with age (R2=0.0429). There were 
also significant differences between individual groups (ANOVA with post-hoc Tukey HSD analysis). 
For UK plasma: moderate>control (p=0.0251); moderate>premanifest (p=0.0147). For Canadian 
plasma: moderate>control (p=0.0147). For CSF: moderate>control (p=0.0003). 
The apparent lower plasma clusterin concentration overall in UK plasma compared with Canadian 
plasma is likely due to the different blood fractionation techniques employed in the two 
populations. 
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III.4.4 IL-6 ELISA 
 
Figure 22 IL-6 ELISA quantification in HD patients and R6/2 mice 
A. Plasma IL-6 concentration (ng/L) with standard error bars in controls and HD patients. Mean 
concentrations ± SD: control (C) 1.45 ± 0.733; premanifest HD (P) 1.93 ± 1.12; early HD (E) 1.71 ± 
1.01; moderate HD (M) 2.89 ± 1.98. The overall trend for increasing IL-6 across all groups, using linear 
regression analysis, was statistically significant (###p=0.0004). Significant differences between 
individual groups are shown (ANOVA with post-hoc Tukey HSD test: *p<0.05; ***p<0.001). B. Serum 
IL-6 concentration (ng/L) with standard error bars from wild-type (WT) and R6/2 mice. n=15 for both 
groups at 4 weeks, 15 WT and 13 R6/2 at 8 weeks and 15 WT and 17 R6/2 at 12 weeks. Serum IL-6 
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was significantly elevated in R6/2 compared with controls at 12 weeks (**p=0.0013, t-test). (Raw data 
supplied by M Björkqvist and G Bates.) 
ELISA quantification of IL-6 in human plasma demonstrated a statistically significant trend to 
increase across advancing disease groups (p=0.0004) as well as significantly increased IL-6 in 
moderate HD compared with both controls and premanifest HD (Figure 22A). This trend remained 
significant when allowing for any effect of age and sex on IL-6 concentration in the regression 
analysis (p=0.0023); IL-6 concentration correlated only very weakly with age (R2=0.0700). There 
were also significant differences between individual groups (ANOVA with post-hoc Tukey HSD 
analysis): moderate>control (p=0.0004); moderate>premanifest (p=0.0227).  
ELISA data from R6/2 HD transgenic mice confirmed these findings, with mean serum IL-6 
concentration significantly higher in R6/2 than wild-type at 12 weeks (p=0.0013) (Figure 22B).  
III.5 Discussion 
III.5.1 Immune activation in HD identified by proteomic discovery 
While the proteomic discovery experiments revealed several candidate biomarkers, it should be 
noted that 2-dimensional gel electrophoresis has innate limitations in exploring the proteome. A 
eukaryotic cell is estimated to contain 50,000 proteins. The ~1300 protein spots identified here 
therefore represent a small fraction (~3%) of the complete proteome. 2DE is typically less successful 
in capturing proteins with low abundance, high or low mass, alkaline pH, hydrophobic properties or 
membrane localisation (Beranova-Giorgianni 2003). While positive findings from 2DE discovery are 
informative, therefore, useful information cannot be inferred from proteins not detected by the 
technique. 
Several of the 18 proteins identified by our 2 proteomic discovery techniques in human plasma that 
track with disease progression are involved in regulation of the innate immune system, which has 
been reported as activated in HD (Leblhuber et al. 1998).  
Alpha-2-macroglobulin (A2M) is an acute-phase protein, whose release is stimulated by IL-6 (Han 
1997). C7 and C9 are components of membrane attack complex (MAC), whose formation is 
modulated by clusterin (Choi-Miura et al. 1996). Clusterin, which was also shown to track with 
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disease progression by semi-quantitative immunoblotting and ELISA in plasma and CSF, is found in 
almost all mammalian tissues and biofluids but is differentially expressed by certain cell types, and 
tissue-specific isoforms exist. Its expression is upregulated in a variety of physiological and 
pathological states including apoptosis and response to injury. It is implicated in diverse 
mechanisms of cytoprotection, membrane recycling and regulation of membrane attack complex 
formation. A unified role has been proposed as a heat-shock or chaperone protein with 
cytoprotective properties (Jones et al. 2002). 
Our IL-6 ELISA findings in human plasma and the R6/2 mouse confirm, and may demonstrate a 
unifying trigger for, the presence of innate immune activation in HD. IL-6 is a pro-inflammatory 
cytokine that induces the release of acute-phase proteins including alpha-2-macroglobulin (Han 
1997). The acute-phase response leads to the activation of the complement cascade via C3 and 
hence the production of downstream factors (such as C7 and C9) and modulating factors such as 
clusterin (Han 1997). 
This peripheral immune activation may have important consequences. Inflammatory factors have 
profound physiological effects that may explain features of the HD phenotype. Il-6, for instance is 
involved in the regulation of energy balance by decreasing food intake and increasing energy 
expenditure, possibly through its action on the hypothalamus (Cancello et al. 2004).  Il-6 also 
triggers corticosteroid release by acting on the hypothalamic/pituitary/adrenal axis (Perlstein et al. 
1991), which may explain the derangement of the hypothalamic-pituitary-adrenal axis observed in 
R6/2 mice and humans (Björkqvist et al. 2006). Together, these effects may contribute to such 
phenotypic phenomena as the unexplained weight loss observed in HD (Sanberg et al. 1981). 
III.5.2 Neuroinflammation and HD pathogenesis 
Molecules produced by peripheral tissues as a result of disease processes may cross the blood-brain 
barrier and exert effects on the CNS. Neuroinflammation likely occurs as a result of locally and 
systemically produced factors. Complement activation and production of C7 have been 
demonstrated by microglia in the striatum of HD patients (Gasque et al. 2000). The classical 
complement pathway is activated by amyloid-β (Aβ) components; amyloid and complement 
proteins (including the MAC) colocalize in Alzheimer’s disease (AD) brain (Gasque et al. 2000); and 
MAC components introduced into the brain of live rats induce neurodegeneration (Xiong et al. 
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2003). Apoptotic cells bind complement, activating the classical pathway, suggesting a possible 
mechanism of complement activation and bystander damage in HD (Gasque et al. 2000). The 
importance of neuroinflammation in HD is underscored by human positron-emission tomography 
studies showing microglial activation in premanifest and early HD patients (Pavese et al. 2006; Tai et 
al. 2007). 
Clusterin and A2M are intimately involved in complement regulation and both have links to 
pathogenesis in neurodegeneration. Complement components are synthesized locally in AD brain, 
and brain-derived clusterin is an inhibitor of MAC formation (Choi-Miura et al. 1996; Tai et al. 2007). 
Clusterin and complement component mRNA are upregulated in HD brain and localize to sites of 
severe pathology including the caudate (Duguid et al. 1989; Hodges et al. 2006). In AD, clusterin 
colocalizes with amyloid β (Aβ) in neuritic plaques, is found reversibly complexed with Aβ in CSF 
and inhibits the aggregation of Aβ in vitro (Choi-Miura et al. 1996). Clusterin levels are elevated in 
CSF in AD (Nilselid et al. 2006). Clusterin has been shown to cross the blood-brain barrier (Duguid 
et al. 1989) and our data confirm that its concentration in CSF rises in parallel with that in plasma in 
HD.  
A2M is upregulated in reactive astrocytes during brain injury (Du et al. 1998). It binds strongly to 
Aβ, localizes to senile plaques in AD, is neuroprotective to cells exposed to Aβ toxicity and 
mediates Aβ degradation and clearance by Endocytosis (Narita et al. 1997; Du et al. 1998). A link 
with HD pathogenesis is plausible: both huntingtin fragments in HD and β-amyloid aggregates in 
AD are ubiquitinated (Gutekunst et al. 1999), and A2M-bound proteins are lysed intracellularly 
(Borth 1992). A2M, along with complement proteins, was recently shown by proteomic analysis to 
be significantly elevated in plasma in Alzheimer’s disease (Hye et al. 2006). 
Among the non-inflammatory proteins identified, alpha-2-antiplasmin is neuroprotective against 
excitotoxic neuronal death and has been suggested to have therapeutic potential in stroke 
(Campbell et al. 2004). Afamin, which showed decreased production with advancing HD stage, has 
binding affinity for vitamin E and has also been shown to be neuroprotective against oxidative stress 
(Heiser et al. 2002). 
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III.5.3 Identification of novel biomarker candidates 
The proteins identified by our discovery experiments may have the ability to function individually or 
together as biomarkers of HD. An ideal HD biomarker would directly measure a disease process 
occurring in the brain, but there is a valuable role for peripheral biomarkers of neurodegenerative 
diseases, over and above the ready accessibility of plasma compared with brain tissue or CSF. First, 
some of the changes seen in plasma may be due to CNS processes causing direct leakage into 
plasma. The possibility of identifying brain-specific isoforms in plasma to study this warrants further 
investigation. Second, a single mechanism arising from the HD triplet repeat expansion may 
produce parallel changes in both central and peripheral tissues, causing plasma levels of a protein to 
mirror those in the CNS. Third, as discussed above, peripherally produced molecules may exert 
central effects on the brain. 
In order to function as desired, to reduce duration, cost and sample size requirements for clinical 
trials of potential disease-modifying treatments, a candidate biomarker must be obtainable from 
easily accessible biofluid, must track linearly with disease progression and should have mechanistic 
links to disease pathogenesis in order to respond predictably to disease modification (Henley et al. 
2005). The proteins highlighted by this study appear to meet these basic requirements. Clusterin, in 
particular, which was evaluated by two techniques in two independent populations in both plasma 
and CSF, has promise as a biomarker for HD. The mouse IL-6 data also suggest a possible 
translational biomarker for testing therapeutic candidates across species, though the non-linear 
pattern of change in both human and mouse likely reflects the multifactorial regulation of 
neuroinflammatory pathways. 
For large scale validation and later clinical use, it is likely that a combination of several clinical, 
neuroimaging and biochemical biomarkers will be necessary to track disease progression in HD 
(Henley et al. 2005). The potential markers identified here warrant further investigation in large 
longitudinal cohort studies, as well as in concert with potential disease-modifying interventions. 
III.6 Publication relating to this chapter 
The work presented in this chapter was published as Dalrymple A / Wild EJ et al. (2007) Proteomic 
profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker 
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candidates. Journal of Proteome Research 6(7): 2833-2840. All figures in this chapter are 
reproduced from this article by permission of the American Chemical Society. 
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Chapter IV A pathogenic pathway of immune 
activation detectable before clinical 
onset in Huntington’s disease  
IV.1 Introduction 
UTANT HUNTINGTIN IS expressed ubiquitously (Sathasivam et al. 1999) and HD causes 
numerous abnormalities outside the central nervous system (CNS), including upregulation 
of immune proteins (Björkqvist et al. 2006; Robbins et al. 2006; Van Raamsdonk et al. 2007). The 
interactions between CNS pathology and changes detectable in peripheral tissues in HD are poorly 
understood, but may be of importance in measuring or slowing disease progression. The work 
presented in Chapter IV demonstrates evidence of immune activation in peripheral plasma in 
manifest HD identified using proteomic profiling but no significant differences between controls and 
premanifest mutation carriers have previously been shown.  
The nature of the immune activation in HD remains incompletely explored. It is not known whether 
the innate or adaptive arm of the immune system, or both, is activated in HD, and the alterations in 
each immunomodulatory cytokine at each disease stage are unknown. The cause of the immune 
activation peripherally is also unknown. IL-6, which triggers the acute phase response, is produced 
primarily by monocytes and lymphocytes but this could be due to dysfunction of these cells caused 
by expression of mutant huntingtin (i.e. a cell-autonomous effect) or in response to inflammation-
triggering events outside these cells, such as huntingtin-induced tissue damage or the mutant 
protein itself being interpreted as an antigen (i.e. non-cell-autonomous pathways). Of interest in this 
respect is the finding that the IκB kinase / NFκB signalling pathway that triggers IL-6 release is 
upregulated by mutant huntingtin and this may contribute to neurotoxicity (Khoshnan et al. 2004). 
Critically, the relationship between peripheral inflammation and CNS pathology in HD is unknown. 
Certain inflammatory proteins, such as complement proteins and clusterin, are also upregulated 
both peripherally and in the brain in HD (Gasque et al. 1995; Hodges et al. 2006 and chapter IV). In 
vivo imaging, in vitro and post-mortem studies have shown that microglia — the CNS counterpart of 
macrophages — are activated in premanifest (Tai et al. 2007) and manifest HD (Sapp et al. 2001), 
that microglial activation correlates with disease severity (Pavese et al. 2006) and that mutant 
huntingtin is expressed in microglia (Shin et al. 2005). Thus, inflammation is an established, though 
M 
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incompletely understood, feature of HD with likely pathogenic importance. Inflammatory changes 
in the CNS and peripheral tissues in HD may be due to independent effects of mutant huntingtin in 
both compartments, causing analogous derangements centrally and peripherally; or inflammatory 
activation may begin peripherally and spread to the CNS — or vice versa — through the passage of 
immunomodulatory molecules across the blood-brain barrier.  
Insights into CNS and peripheral immune system interactions in HD may provide new biomarkers 
and improve knowledge of key pathogenic mechanisms, possibly leading to novel therapeutic 
approaches. The present work seeks to elucidate further the nature of the peripheral inflammatory 
activation in HD, through quantification of levels of key inflammatory and immunomodulatory 
molecules in human plasma and serum from 3 different mouse models of HD. To investigate 
possible links between peripheral inflammation and neuronal dysfunction, associations were 
examined between individual inflammatory molecules and clinical features of HD. Targeted 
transcription profiling was used to examine expression of key immunomodulatory proteins in the 
HD striatum, to determine whether the inflammatory activation seen peripherally is mirrored in the 
CNS. Expression of huntingtin in its wild-type and mutant forms was examined in human monocytes 
to investigate the possibility that the immune activation is due to a disease-related cell-autonomous 
dysfunction of these cells. This was confirmed with functional studies of human monocytes, and 
macrophages and microglia from HD mouse models, demonstrating that there is disease-related 
dysfunction of CNS and peripheral inflammatory cells in HD. 
The chemokine system is a family of some fifty small molecules and twenty receptors, related to but 
distinct from cytokines and having in common roles as leukocyte chemoattractants. Chemokines 
are now recognised as central to many processes related to infection and immunity, including 
migration of leukocytes into the CNS and modulation of the function of the blood-brain barrier. 
Quantification of chemokine levels may shed light on the status of both the immune system as a 
whole and the function of specific immune components (Cardona et al. 2008). 
Chemokine levels were determined in plasma samples using the same multiplex ELISA platform. 
Associations with clinical scores were examined, and an analysis was performed to examine the 
possible utility of chemokines as cross-sectional biomarkers, both alone and as a source of 
additional information in combination with cytokines. 
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IV.2 Contributions and collaborations 
Multiplex ELISA and immunoglobulin quantification was performed by M Björkqvist and A 
Magnusson. RT-QPCR studies were performed by C Benn and G Bates. Monocyte sorting and 
stimulation experiments were performed jointly by the author with M Lowdell, R Andre and N 
Lahiri. R6/2 and knock-in animals were reared by B Woodman and G Bates. YAC128 husbandry 
and experiments were performed by J Thiele and B Leavitt. Microglial stimulation was performed by 
E Raibon, R Lee and T Möller. Striatal expression experiments were performed by A Sylvestroni and 
T Möller. Collection and processing of matched CSF and plasma was performed by B Leavitt. Figure 
36 was prepared by D Soulet. Subject recruitment and clinical characterisation, plasma processing, 
statistical analysis of all data, preparation of all other figures and drafting of the published 
manuscript were performed by the author. Study conception, design and interpretation was led by 
the author, M Bjorkqvist and S Tabrizi with contributions from all collaborators. Revision of the 
manuscript was shared between all collaborators including the author. 
IV.3 Subjects and methods 
IV.3.1 Ethical approval and subject recruitment 
Ethical approval (including animal experiments) and subject recruitment were as specified in 
Chapter II. 
IV.3.2 Inclusion and exclusion criteria 
Subjects with concomitant CNS disorders, significant medical comorbidity, known liver dysfunction, 
recent alcohol or substance abuse, and those taking medications or supplements suspected or 
known to interfere with the experimental methods used, and subjects with inflammatory or infective 
conditions were excluded. Patients with advanced HD were not included in this work.  
IV.3.3 Collection and processing of human plasma samples 
Subjects were classified as controls, premanifest HD or early or moderate manifest HD. Sample 
collection, fractionation and storage and CAG repeat sizing were carried out as outlined in Chapter 
II. A subset of subjects was assessed on the unified Huntington’s disease rating scale (The 
Huntington Study Group 1996) by a neurologist experienced in assessment of HD patients. 
Subjects’ demographic and clinical data are given in Table 8. 
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Experiment Disease stage Subject numbers Female:male Mean age 
(range) 
Control 69 43:26 42 (22-67) 
Premanifest 34 19:15 39 (23-54) 
Early 47 24:23 47 (25-80) 
Cytokine multiplex assay 
Plasma 
Moderate 44 30:14 52 (38-76) 
     
Control 26 18:8 46 (29-65) 
Premanifest 11 5:6 39 (27-49) 
Early 17 9:8 47 (31-61) 
IgA, IgM assay 
Plasma 
Moderate 18 14:4 50 (26-76) 
     
Control 19 11:8 40 (26-67) 
Premanifest 17 9:8 38 (27-47) 
Early 13 8:5 42 (25-60) 
IgG assay 
Plasma 
Moderate 20 11:9 51 (38-74) 
     
Control 24 20:4 37 (22-67) 
Premanifest 24 15:9 38 (27-54) 
Early 24 14:10 48 (25-80) 
GM-CSF assay 
Plasma 
Moderate 28 17:11 51 (26-77) 
     
Control 9 6:3 45 (25-66) 
Early 9 4:5 51 (38-64) 
IL-6 and IL-8 assay 
Matched CSF and 
plasma 
Moderate 11 1:10 53 (38-72) 
Control 34 22:12 44 (25-65) 
Premanifest 15 8:7 39 (23-54) 
Early 23 11:12 47 (31-65) 
Chemokine plasma assay 
Moderate 27 19:8 52 (26-76) 
Table 8 Clinical characteristics of subjects in each human biofluid study 
Plasma work was performed using a combination of overlapping and unique samples. There was also 
overlap with the plasma samples used for the work presented in the previous chapter. Paired 
CSF/plasma samples were from the same subjects as those used for the clusterin ELISA described in 
the previous chapter.  
 130 
IV.3.4 Collection of matched CSF and blood samples 
30 CSF donors were recruited (Table 8) and their CSF handled as detailed in chapter II.9. These 
subjects are the same as those reported in Chapter III. 
IV.3.5 Collection of mouse serum samples 
For the present experiments, HdhQ150/Q150 knock-in and R6/2 exon 1 models that develop 
comparable and widespread molecular phenotypes (Woodman et al. 2007) were used. R6/2 
(Mangiarini et al. 1996) and HdhQ150/Q150 mice (original nomenclature: CHL2) (Lin et al. 2001) were 
bred and serum samples collected as previously described (Woodman et al. 2007). All animals had 
unlimited access to water and breeding chow (Special Diet Services) under a 12h light:12h dark 
cycle. YAC128 mice were maintained on the FVB/N strain background (Slow et al. 2003).  Numbers 
and ages of animals are shown in Table 9.  
Experiment Mouse model Age of animals Number of WT 
animals 
Number of 
disease animals 
R6/2 12 weeks 20 20 Serum cytokine 
multiplex assay 
HdhQ150Q/Q150 22 months 10 9 
     
YAC128 12 months 3 4 Macrophage 
stimulation 
study and 
serum IL-6 
ELISA YAC18 12 months 4 4 
Microglial 
stimulation 
study 
R6/2 Neonatal 4 4 
Table 9 Details of animals used for murine experiments 
IV.3.6 Serum and plasma analyses 
Cytokine levels were quantified using Meso Scale Discovery (MSD) assays as per the 
manufacturer’s protocol and analyzed on a SECTOR™ 2400 instrument (MSD). The operator was 
unaware of the disease state of each sample during processing and statistical analysis was 
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performed independently. Serum levels of immunoglobulins (IgG, IgM and IgA) were determined by 
single radial immunodiffusion assays (The Binding Site Ltd), following the manufacturer’s protocol. 
IV.3.7 Human monocyte huntingtin expression study 
Whole blood was collected from HD patients and controls matched for age and sex (Table 10A). 
Leukocytes were isolated by density gradient centrifugation over Lymphoprep™ solution (Axis-
Shield). Monocytes were obtained by flow cytometry. Briefly, mononuclear cell suspensions were 
labelled with anti-CD45 FITC and anti-CD14 PE (BD) and viable monocytes sorted flow 
cytometrically by immunophenotype (CD45+/CD14+) and forward angle light scatter signals 
(FACSAria high speed cell sorter; BD) to at least 95% purity (see Figure 23A). 
A. Huntingtin 
expression study 
Sex Age Status Disease stage 
(Shoulson et 
al. 1979) 
CAG sizes 
C1 F 45.8 Control   
C2 M 43.8 Control   
HD1 M 41.9 HD 2 17/45 
HD2 F 44.2 HD 2 25/43 
HD3 F 61.4 HD 2 16/42 
       
B. Monocyte 
functional study 
N Female:male Mean age (SD) Mean expanded CAG 
repeat length (range) 
Controls 8 2:7 42.2 (10.3)  
Premanifest HD 9 4:4 38.8 (6.2) 43.5 (41-48) 
Table 10 Details of subjects whose blood was used for human monocyte studies 
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Figure 23 Representative flow cytometry plots 
Plots demonstrate purity of cells obtained by (A) flow cytometry and (B) magnetic sorting. Monocyte 
purities are shown as percentages. 
RNA was prepared from pellets of 5×106 cells using an RNeasy mini kit (Qiagen) according to 
manufacturer’s instructions. Quality and quantity of RNA was assessed using the RNA nanochip 
method on a BioAnalyzer (Agilent Technologies). Reverse transcription (RT) of 1μg of total RNA 
was performed in 50mM KCl, 10mM Tris–HCl (pH 9.0), 0.1% Triton X-100, 6.5mM MgCl2, 10mM 
DTT, 1mM dNTPs, 10ng/μL random hexamers with 0.35U/μL RNasin (Promega) and MMLV reverse 
transcriptase (Invitrogen) for 10min at 23°C then 40min at 37°C. The RT reaction was diluted 10-
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fold in nuclease-free water (Sigma) and 5μL was used in a 25μL reaction containing Precision 
Mastermix (PrimerDesign), 300nM primers and 200nM probe. Cycling conditions were: 2min at 
50°C, 15 min at 95°C, 44× (1min at 94°C, 1min at 60°C) using the Opticon 2 real-time PCR 
machine (MJ Research). The threshold used for the analysis was set at 0.05 and reactions were 
performed in triplicate for each sample. Primer and probe sequences are listed in Table 11. 
Expression of huntingtin was calculated using 2-ΔΔCT with beta-2-microglobulin (B2M) as the 
reference (Gabert et al. 2003). Positive control samples with known B2M expression levels 
produced consistent results under these experimental conditions. 
Gene Forward primer Reverse primer Probe (5’-FAM, 3’-
TAMRA) 
Abl TGGAGATAACACTCTA
AGCATAACTAAAGGT 
GATGTAGTTGCTTGG
GACCCA 
CCATTTTTGGTTTGGG
CTTCACACCATT 
Beta 2 
microglobulin 
GAGTATGCCTGCCGT
GTG 
AATCCAAATGCGGCA
TCT 
CCTCCATGATGCTGCT
TACATGTCTC 
Huntingtin GCTGCACCGACCGTG
AGT 
CGCAGGCTGCAGGG
TTAC 
CAGCTCCCTGTCCCG
GCGG 
CAG repeat 
sizing 
ATGAAGGCCTTCGAG
TCCCTCAAGTCCTTC* 
GGCGGCTGAGGAAG
CTGAGGA 
N/A 
Table 11 Primers used for human monocyte expression studies 
*FAM-tagged primer. 
 CAG repeats were measured in RNA using an ABI3730 automated sequencer and all 
instruments and materials were obtained from Applied Biosystems unless indicated. The p4G6E4.0 
plasmid, which expresses exon 1 of huntingtin with 18 CAG repeats, was used as a positive control. 
PCR was performed in AM buffer, 10% DMSO, 200μM dNTPs, 10ng/μL primer with 0.5U/μL Taq 
polymerase (Perkin Elmer). Cycling conditions were 90sec @ 94°C, 25 × (30sec @ 94°C, 30sec @ 
68°C, 90sec @ 72°C), 10min @ 72°C. The FAM-tagged PCR product (1μL) together with 
MegaBACE™ ET900 (Amersham Bioscience) internal size standard (0.04μL) were denatured at 94°C 
for 5min in 9μL of HiDi formamide. The run conditions were as follows: capillary size, 36cm, 
Polymer-PoP-7™. The run module was oven temperature, 66°C; buffer temperature, 35°C; pre-run 
voltage, 15kV; pre-run time, 180sec; injection voltage, 3kV; injection time, 20sec; first readout time, 
200msec; second readout time, 200 msec; run voltage, 10kV; voltage number of steps, 10; voltage 
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step interval, 20sec; voltage tolerance, 0.6kV; current stability, 10μA; ramp delay, 1sec; data delay, 
120sec; run time, 2700sec. Data analysis was performed using the plate manager application 
GeneMapper v5.2-3730XL. 
IV.3.8 Functional study of human monocytes 
Whole blood was collected in heparin (CP pharmaceuticals) from subjects as detailed in Table 10B. 
Leukocytes were isolated by density gradient centrifugation over Histopaque-1077 solution (Sigma). 
Monocytes were obtained by magnetic sorting to increase yield and minimize handling time. 
Mononuclear cell suspensions were labelled with anti-CD14 microbeads and sorted through 
magnetic cell separation columns (Miltenyi Biotech) to at least 95% purity (see Figure 23B). 
Monocytes were counted and 5×105 cells per well seeded into 24-well culture plates in RPMI 
culture medium supplemented with 5% FBS, 2mM L-glutamine and 1% penicillin/streptomycin 
(Invitrogen). Cells were incubated for 16 hours before stimulation. The medium was then changed 
to fresh cell culture medium, with or without 10ng/mL IFN-γ (R&D systems). For LPS stimulation, 
2μg/ml LPS was added to the medium (Sigma). After 24 hours, supernatants were harvested from 
two separate wells for each subject/condition. The cells remaining were lysed in 50 mM Tris (pH 8), 
150 mmol NaCl, 0.5% sodium deoxycholate and 0.5% Triton X-100, and assayed for total protein 
concentration using the BioRad protein assay kit following the manufacturer’s instructions (BioRad). 
IL-6 concentrations in supernatants were determined using the MSD assay and adjusted for total 
protein concentration. 
IV.3.9 Functional study of tissue macrophages 
Alveolar macrophages were isolated from 12-month-old WT, YAC18 and YAC128 mice, all 
maintained on a pure FVB/N strain background. The YAC128 (line 53) mouse line expresses high 
levels of full-length human huntingtin with ~128 polyglutamine repeats and is a well-established 
model of HD.  These mice develop an age-dependent phenotype similar to that seen in HD 
patients, including cognitive deficits, motor dysfunction, and selective neurodegeneration; 12-month 
mice are equivalent to early human HD (Slow et al. 2003). YAC18 mice (line 212) express 
transgenic human WT huntingtin and do not exhibit any disease phenotype relative to their WT 
littermates. They differ from YAC128 mice only in the length of the polyglutamine tract. 
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Animals were sacrificed using 10mg avertine i/p injection. Blood was drawn from the inferior vena 
cava and serum samples obtained by two-stage centrifugation. Alveolar macrophages were 
extracted by intratracheal infusion of ice-cold PBS (Gibco) followed by centrifugation and 
resuspension of extracted cells. Cells were counted and seeded at 1.5×105 cells/mL onto 96-well 
gelatin-coated plates and incubated in culture media containing 5% medium (RPMI 1640 (Gibco), 
5% FBS (Cansera) and 1% penicillin/ streptomycin (Gibco)). After 24 hours this was changed to 1% 
medium (RPMI 1640, 1% FBS, and 1% P/S). Functional studies were performed after a further 24 
hours. The medium was changed to fresh 1% medium, or 1% medium containing 10μg/L IFN-γ 
(R&D systems) with or without 100μg/L control standard endotoxin (Cape Cod). After 24 hours, IL-6 
concentrations were measured in supernatants from two independent wells from each animal for 
each condition, using a commercial mouse IL-6 ELISA kit following the manufacturer’s instructions 
(eBioscience). Numbers of animals used in each experiment are given in Table 9. 
IV.3.10 Functional study of microglia 
Mixed primary glial cultures were prepared from single brains of R6/2 mice (B6CBA-
Tg(HDexon1)62Gpb/3J; Jackson Labs) as previously described (Weydt et al. 2004). In brief, four-day 
old mice were decapitated; the brains were removed and submerged in ice-cold Hank’s saline. The 
meninges and blood vessels were removed before the tissue was trypsinized, carefully dissociated 
with a 5ml pipette, resuspended and filtered twice (100μm-diameter Falcon™ filter, BD) before 
seeding the cells in 5ml of medium per flask (1 brain/flask).  Cells were cultured in poly-ornithine-
coated 25cm2 flasks in DME and supplemented with 10% FBS (D10F). 
Littermate heterozygote R6/2 and WT mice were used; each brain was processed and cultured 
individually to prevent cross-contamination between animals. Genotype and CAG length repeat 
were determined by PCR from tail samples taken at the time of CNS culture preparation (Laragen). 
Once astrocytes reached confluence (5-7 days), D10F medium was supplemented with 2ng/mL of 
GM-CSF. Microglial cells were collected, pooled according to genotype, and seeded in 96-well 
Primaria™ plates (2.5x104 cells in 250μL D10F per well; BD). Cultures were >95% pure as assessed 
by CD11b immunostaining. For each experiment, WT and R6/2 microglial cells were processed in 
parallel. 
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24 hours after plating, the cells were serum-starved (MSFM- 0.2ng/ml GM-CSF) for an additional 24 
hours. They were then stimulated with IFN-γ (10U) ± LPS (10ng/ml) or carrier control. After 24h of 
stimulation, supernatant was collected and stored at -80°C for further analysis. 
IL-6 concentration was measured by Luminex bead array system (Qiagen). 60μL of supernatant of 3 
representative experiments (n=4 for each condition) was thawed and processed using the BioPlex™ 
platform (BioRad). 
IV.3.11 Striatal gene expression study 
Total RNA was isolated and purified from striatal samples obtained from The New Zealand 
Neurological Foundation Human Brain Bank and the New York Brain Bank at Columbia University 
(6 controls and 17 patients with pathological grades as shown in Table 12) with the RNeasy mini kit 
(Qiagen). mRNA was transcribed into cDNA with SuperScript III (Invitrogen). RT-QPCR was 
performed in triplicate with target-specific Roche Universal Library probes (FAM) and Roche 
universal master mix (Roche Diagnostics), and analyzed with an ABI PRISM® 7500 RT-QPCR 
System. Mitochondrial ribosomal protein S35 (MRPS35) expression was determined by duplex PCR 
(VIC) in the same sample to normalize target expression to a housekeeping gene. MRPS35 was 
chosen based on gene array data showing it not to be regulated in HD striatum (Dr. A. Strand, 
FHCRC, personal communication). The target/MRPS35 ratio was used to compare the relative 
target expression using the modified ΔΔCT method (Pfaffl 2001). Purity of mRNA was checked by 
performing qPCR without prior RT. Stability of expression of the housekeeping gene MRPS35 was 
confirmed by comparison with a second house keeping gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). 
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Relative RNA quantification, 
% of controls (SD) 
Group n Female: 
male 
Mean 
age at 
death 
(Range) 
Mean 
CAG 
repeat 
length  
(SD) IL-6 IL-8 TNF-α 
Control 6 0:6 59 
(42-74) 
 100 
(88.3) 
100 
(40.1) 
100 
(60.8) 
HD 17 3:14 54 
(40-74) 
45 
(5) 
1520 
(159) 
1110 
(125) 
208 
(110) 
VS1 4 0:4 50 
(41-58) 
41 
(3) 
4220 
(147) 
596 
(108) 
382 
(235) 
VS2 4 0:4 62 
(47-74) 
45 
(4) 
694 
(122) 
402 
(73.6) 
92.1 
(153) 
VS3 4 0:4 54 
(40-64) 
45 
(4) 
3210 
(195) 
1950 
(152) 
306 
(75.8) 
VS4 5 3:2 49 
(45-53) 
53 
(4)* 
775 
(218) 
2740 
(36.7) 
684 
(57.7) 
Table 12 Demographic, clinical and pathological characteristics of subjects in the post-mortem 
striatal expression study 
VS, Vonsattel pathological grade (Vonsattel et al. 1985). *CAG repeat lengths available for 2 samples 
only. 
IV.3.12 Statistical analysis 
For the human plasma cytokine and immunoglobulin data, inter-group differences were identified 
by one-way ANOVA with post-hoc Tukey HSD testing to allow for multiple comparisons. Linear 
regression analysis using coded variables for each subject group (control=1, premanifest=2, early=3, 
moderate=4), using age and sex as covariates, was used to identify significant change with 
advancing disease (Dalrymple et al. 2007). 
Calculations of estimated time to onset in premanifest subjects were made using the age- and CAG-
dependent conditional onset probability formula of Langbehn et al. (Langbehn et al. 2004). 
Correlations with clinical variables were examined using linear regression analysis and partial 
correlations. Because the distribution of UHDRS and TFC data was not Gaussian, bootstrapping 
with 1000 replications was used in order to enable linear regression analysis and the use of age as a 
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covariate. This analysis inevitably involved the use of multiple statistical tests, but because the 
associations under investigation were of independent scientific interest p-values were not corrected 
for multiple comparisons (see chapter II and Savitz et al. 1995). 
To examine for the ability of combinations of plasma cytokines to distinguish between different 
subject groups, stepwise logistic regression was used (Teunissen et al. 2003). The model tested the 
6 cytokines with statistically significant correlations across disease stage, in order of diminishing R-
value (IL-6, IL-8, IL-4, IL-10, TNF-α and IL-5; see Figure 24B); variables were removed from the model 
when p<0.05 for the logistic regression. The comparisons assessed were: controls versus 
premanifest HD; controls versus all HD expansion-positive subjects; and premanifest versus 
manifest HD. 
ROC curves were constructed using the same method to determine which combinations of 
chemokines best predicted membership of the same paired groups. For the subjects in whom 
chemokines were measured, chemokines alone, cytokines alone and the two marker types 
combined were tested. 
Unpaired two-tailed t-tests were used to identify significantly different serum levels for each cytokine 
in mouse serum and to compare mRNA levels (expressed as 2-ΔΔCT) between controls and HD 
patients in the two gene expression studies. Unpaired one-tailed t-tests were used to test the 
hypotheses that monocytes, macrophages and microglia produce more IL-6 than WT animals when 
stimulated with LPS. 
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IV.4 Results 
IV.4.1 Cytokine levels 
Control Premanifest HD Early HD Moderate HDA
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Figure 24 Altered immune profile peripherally in Huntington’s disease 
A. Multiplex ELISA quantification of cytokine levels in plasma from HD patients (premanifest, early and 
moderate HD stages) compared with control subjects. Graphs show mean concentrations with 
standard error bars. Significant differences between individual groups are shown (ANOVA with post-
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hoc Tukey HSD test). B. The overall trend for increasing levels of cytokines across all groups, analyzed 
using linear regression, was highly significant for IL-6 and IL-8 and significant for IL-4, IL-10, TNF-α and 
IL-5.  R-values (partial correlation coefficients) are corrected for age and sex. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. (Raw data supplied by M Björkqvist.) 
194 plasma samples were collected from HD mutation carriers ranging from premanifest to 
moderate HD and from control subjects (Table 8) and levels of key inflammatory and 
immunomodulatory molecules were quantified using multiplex sandwich ELISAs and single radial 
immunodiffusion assays. An altered profile of cytokine levels was found in HD patients (Table 13). 
The most striking increases across subject groups, from controls to progressing disease, were in IL-6 
and IL-8 (p<0.0001 in each case). In addition IL-4, IL-10 and TNF-α levels increased significantly with 
disease progression (Figure 24B). Moreover, IL-6 levels were significantly increased in premanifest 
subjects, who had an estimated mean of 16 years until motor onset (Figure 24A) (Langbehn et al. 
2004). Interestingly, the cytokines that were increased earliest in the disease course (IL-6 and IL-8) 
are involved in the innate immune response (Kindt et al. 2006).  IL-10 and IL-4, anti-inflammatory 
cytokines involved in the adaptive immune response, increased significantly in moderate stage 
disease. 
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 Control Premanifest HD Early HD Moderate HD 
 Mean (SD) n Mean (SD) N Mean (SD) n Mean (SD) n 
IL-6 3.06 (2) 69 5.26 (2.66) 34 5.3 (3.01) 47 6.65 (3.46) 46
IL-8 2.11 (1.03) 69 2.27 (0.97) 34 3.08 (1.47) 47 3.98 (2.67) 46
IL-4 0.32 (0.38) 68 0.58 (0.88) 34 0.63 (0.71) 45 0.84 (0.78) 45
IL-10 0.87 (0.87) 66 1.85 (2.75) 34 1.67 (1.68) 45 2.15 (3.06) 44
TNF-α 2.62 (1.25) 69 3.04 (1.51) 34 3.03 (1.27) 47 3.32 (1.05) 46
IL-5 0.34 (0.23) 66 0.38 (0.33) 34 0.49 (0.88) 45 0.53 (0.5) 46
IL-2 0.86 (0.99) 66 1.06 (0.79) 34 1.01 (0.96) 45 1.51 (4.63) 46
IFN-γ 0.54 (0.58) 66 0.38 (0.39) 34 0.44 (0.44) 45 0.77 (0.76) 46
IL-13 3.17 (2.62) 66 1.84 (1.46) 34 2.48 (2.23) 45 2.35 (12.49) 46
IL-12 1.38 (1.11) 66 1.31 (1.32) 34 1.97 (2.11) 45 0.85 (1.5) 45
IL-1β 0.83 (0.82) 69 0.81 (0.87) 34 0.85 (0.89) 47 0.74 (0.77) 46
GM-CSF 0.19 (0.16) 23 0.17 (0.12) 24 0.39 (0.48) 24 0.08 (0.1) 36
IL-6 3.06 (2) 69 5.26 (2.66) 34 5.3 (3.01) 47 6.65 (3.46) 46
IL-8 2.11 (1.03) 69 2.27 (0.97) 34 3.08 (1.47) 47 3.98 (2.67) 46
IL-4 0.32 (0.38) 68 0.58 (0.88) 34 0.63 (0.71) 45 0.84 (0.78) 45
IL-10 0.87 (0.87) 66 1.85 (2.75) 34 1.67 (1.68) 45 2.15 (3.06) 44
Table 13 Plasma cytokine levels in HD, by disease stage, measured by multiplex ELISA assay 
All cytokine levels are in ng/L. (Raw data supplied by M Björkqvist.) 
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IV.4.2 Immunoglobulin levels 
There was no difference in levels of immunoglobulins (IgG, IgA or IgM) at any disease stage (Figure 
25), arguing against widespread activation of the adaptive humoral immune system. 
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Figure 25 Plasma immunoglobulin levels are unchanged in HD 
Quantification of plasma IgG, IgA and IgM by single radial immunodiffusion assays revealed no 
difference in immunoglobulin levels across disease stages, arguing against widespread activation of the 
adaptive immune system. Graphs show mean concentrations and standard error bars. (Raw data 
supplied by M Björkqvist.) 
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IV.4.3 Associations between cytokines and clinical characteristics 
Associations were then examined between these cytokine changes and clinical characteristics. 
Plasma IL-8 levels increased markedly with disease progression (Figure 24) and correlated with 
clinical measures of HD. Levels of IL-8 correlated positively with worsening disease, as 
demonstrated by UHDRS chorea scores (R=-0.37, p<0.01) and total motor scores (R=0.27, p<0.05), 
as well as negatively with total functional capacity (TFC) scores where lower scores indicate more 
severe disease (R=-0.28, p<0.05) (Figure 26A). TNF-α levels in plasma correlated with UHDRS 
chorea scores (R=0.28, p<0.01) and UHDRS motor scores (R=0.26, p<0.05) (Figure 26B); a negative 
correlation with TFC was seen that approached statistical significance (R=-0.20, p=0.07). 
 
Figure 26 Correlations between plasma cytokine levels and clinical severity scores in premanifest 
and manifest HD gene carriers 
Levels of (A) IL-8 and (B) TNF-α correlated with worsening disease as demonstrated by increasing 
UHDRS chorea and total motor score, and decreasing total functional capacity score. (Raw cytokine 
data supplied by M Björkqvist.) 
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IV.4.4 Cytokines as potential biomarkers 
Objective markers of HD progression are needed to facilitate the conduct of clinical trials of 
disease-modifying therapies in HD. Stepwise logistic regression analysis was used to construct 
receiver operating characteristic (ROC) curves that demonstrated a strong ability of combinations of 
plasma cytokine levels to discriminate between disease groups (Figure 27). A combination of IL-6, 
IL-10 and IL-5 was found to discriminate optimally between premanifest HD and controls with an 
area under the curve (AUC) of 0.81. A combination of IL-6, IL-8 and IL-10 best discriminated all HD 
expansion carriers (premanifest and manifest) from controls (AUC 0.82). IL-6, IL-8 and IL-10 together 
best discriminated between premanifest and manifest HD patients (AUC 0.85). A detailed 
explanation of ROC curves is given in chapter II.11.11. 
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Figure 27 ROC curves demonstrating the ability of different combinations of plasma cytokine 
levels to discriminate between subject groups 
In a ROC curve plot, the ‘true positive’ diagnosis rate (sensitivity) is plotted against the ‘false positive’ 
diagnosis rate (1-specificity) for a test with a binary outcome. The area under the curve (AUC) 
summarizes the discrimination of the test, i.e. its ability to classify cases correctly. A perfect test would 
have an AUC of 1, a worthless test an AUC of 0.5. AUC values may be classified as follows: 0.9-
1=‘excellent’; 0.8-9=‘good’; 0.7-0.8=‘fair’, 0.6-0.7=‘poor’; 0.5-0.6=‘fail’ (Hanley et al. 1982). For the 
present analysis, optimum combinations were identified by stepwise logistic regression analysis using a 
threshold of p=0.05 for each cytokine removed from the model. A combination of IL-6, IL-10 and IL-5 
best discriminated between controls and premanifest HD; a combination of IL-6, IL-8 and IL-10 best 
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discriminated manifest from premanifest HD; and a combination of IL-6, IL-8 and IL-10 best 
discriminated controls from HD gene carriers (both premanifest and manifest). . (Raw cytokine data 
supplied by M Björkqvist.) 
IV.4.5 Huntingtin expression by human monocytes 
IL-6 triggers the acute phase response and is produced primarily by monocytes/macrophages and 
lymphocytes (Kindt et al. 2006). In order to define the possible source of peripheral cytokines, 
monocytes were purified from whole blood from HD patients and control subjects by flow 
cytometric and magnetic sorting. Using RT-QPCR, monocytes from HD patients were found to 
express mutant huntingtin (Figure 28). 
 
Figure 28 Human monocytes express wild-type and mutant huntingtin 
A. RT-QPCR studies of human monocytes obtained by flow cytometry demonstrated huntingtin 
expression in 100% of monocyte samples tested from controls (n=2) and HD patients (n=3). 
Expression ratios are relative to beta-2-microglobulin. Graph shows mean expression ratios with 
standard error bars. B. PCR amplification of CAG repeat tracts from huntingtin mRNA reveals that HD 
monocytes express both WT and mutant huntingtin, supporting the possibility of cell-autonomous 
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dysfunction resulting in immune activation. WT and mutant CAG repeat lengths are shown. +, 
p4G6E4.0 plasmid, expressing HTT exon 1 with 18 CAG repeats. . (qPCR  data supplied by C Benn.) 
IV.4.6 Functional study of myeloid cells in HD 
A series of stimulation experiments was performed to examine the function of myeloid cells in HD. 
Isolated monocytes from premanifest HD mutation carriers were stimulated with LPS and found to 
behave abnormally, displaying excess IL-6 production compared with cells from control subjects 
(Figure 29A). Mutant huntingtin thus appears to produce functional overactivity of monocytes. 
To determine whether the presence of the mutant protein causes this dysfunction, isolated 
macrophages from the YAC128 mouse model of HD were stimulated with LPS. Echoing the results 
seen in human HD monocytes, macrophages from the YAC128 responded with enhanced secretion 
of IL-6 in response to stimulation, compared with macrophages from wild-type mice (Figure 29B). 
YAC128 cells differ from WT cells in respects other than the presence of the mutant protein, so to 
test whether the presence of mutant huntingtin per se is sufficient to produce dysfunction, this 
stimulation experiment was repeated in macrophages from the YAC18 mouse, which differs from 
the YAC128 only in the length of the polyglutamine stretch: excessive IL-6 release was not seen in 
YAC18 cells (Figure 29C). 
To determine whether microglia — the CNS equivalent of monocytes/macrophages — are also 
dysfunctional in HD, LPS stimulation was performed in microglia isolated from the widely-used R6/2 
transgenic mouse model of HD (Mangiarini et al. 1996). HD microglia, too, demonstrated 
hyperactivity in response to stimulation (Figure 29D). 
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Figure 29 HD monocytes, macrophages and microglia are overactive when stimulated 
A. No IL-6 was detectable in the supernatant of monocytes from control (n=9) or premanifest HD 
subjects (n=8) in the unstimulated state or after priming with IFN-γ. Monocytes stimulated by addition 
of both IFN-γ and 2μg/mL LPS expressed IL-6, but expression levels were significantly higher from HD 
monocytes. B. Alveolar macrophages from the YAC128 HD mouse model have similarly altered 
function when stimulated. YAC128 macrophages stimulated by addition of both IFN-γ and 100ng/mL 
LPS expressed significantly more IL-6. n=3 WT and 4 YAC128. C. Macrophages from YAC18 mice, 
which differ from YAC128 cells only in the number of CAG repeats, behaved no differently from WT 
cells (p=0.231, n=4 per genotype) in response to stimulation at the same LPS concentration, suggesting 
that the hyperactivity is due to mutant huntingtin. D. Microglia isolated from neonatal R6/2 mice are 
also hyperactive when stimulated by 10ng/mL LPS (n=4 per group). Graphs show mean 
concentrations with standard error bars. ND, not detected. Unpaired t-tests: *p<0.05; *p<0.01. 
(Human data produced by the author, M Lowdell, R Andre and N Lahiri; YAC data supplied by J 
Thiele and B Leavitt; R6/2 data supplied by E Raibon, R Lee and T Möller.) 
 148 
IV.4.7 CNS expression of cytokines in HD 
Expression of inflammatory transcripts in post-mortem human striatal tissue was investigated using 
RT-PCR. Markedly increased expression of IL-6, IL-8 and TNF-α was found in HD striatum (Figure 
30), mirroring the key changes seen in plasma much earlier in the disease and suggesting in situ 
excess CNS production of these cytokines. Further work, currently under review for publication, has 
suggested increased striatal expression of IL-10 and, in contrast to the findings from plasma, IL-1β 
(Dr Thomas Möller, personal communication). Thus while the post-mortem striatum prominently 
echoes the changes seen in plasma from subjects earlier in the disease, it may not recapitulate them 
precisely. 
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Figure 30 Altered expression of inflammatory transcripts in post-mortem HD striatal tissue 
Levels of IL-6, IL-8 and TNF-α RNA were significantly higher in striatum of HD patients than in control 
striatum. Graphs show means with standard error bars. n=6 controls and 17 HD patients (see Table 
12). Unpaired t-tests: *p<0.05, ***p<0.001, ****p<0.0001. (Raw data supplied by A Silvestroni and T 
Möller.) 
IV.4.8 Cytokine levels in matched CSF and plasma 
To investigate the relationship between central and peripheral inflammatory processes, IL-6 and IL-8 
were measured in matched plasma and CSF samples from HD patients and controls using ELISA. 
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CSF and plasma levels of IL-6 and IL-8 correlated closely (Figure 31; R=0.74 and R=0.66 
respectively; p<0.0001 for both). 
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Figure 31 Correlations between matched CSF and plasma levels of IL-6 and IL-8 
ELISA-quantified levels in CSF and matched plasma samples correlated strongly for both IL-6 and IL-8. 
(Raw data supplied by M Björkqvist from samples provided by B Leavitt.) 
IV.4.9 Cytokine expression in HD mouse models 
Multiplex ELISA was used to determine whether peripheral immune activation is present in serum in 
HD mouse models. Increased levels of several cytokines were found in the R6/2 transgenic mouse 
and the full-length HdhQ150/Q150 knock-in model of HD (Woodman et al. 2007). In 12-week R6/2 
mice, IL-1β, IL-6, IL-10 and IL-12p70 were significantly increased (Figure 32A). In 22-month knock-in 
Hdh150Q/150Q mice IL-6, IL-10 and IL-12p70 were significantly elevated (Figure 32B). In the YAC128 
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mouse model of HD at 12 months of age, similar elevations in serum IL-6 and mKC — a murine 
functional homolog of IL-8 (Bozic et al. 1995) — were seen (Figure 32C). 12-month YAC128 animals 
are phenotypically equivalent to early HD (Slow et al. 2003), and these animals therefore model the 
human patients whose plasma was studied.  
 
Figure 32  Mouse models of HD recapitulate features of human immune dysfunction 
Serum levels of cytokines, measured by multiplex ELISA, are elevated in both (A) R6/2 and (B) 
HdhQ150Q/Q150 knock-in mouse models (n=9 per genotype) at end-stage. C. In 12-month YAC128 
animals (equivalent to early human disease), serum IL-6 and mKC — a murine functional homolog of 
IL-8 — are significantly increased (n=3 WT and 4 YAC128). Graphs show mean levels with standard 
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error bars. Unpaired t-tests: *p<0.05; **p<0.01. (Raw data supplied by M Björkqvist from samples 
provided by B Leavitt, B Woodman and G Bates.) 
IV.4.10 Study of chemokine levels 
Chemokine levels were tested in 99 subjects whose demographic characteristics are given in Table 
8. As shown in Figure 33, there were significant inter-group differences for all five chemokines 
tested. For three (eotaxin-3, eotaxin and MCP-4) there were significant differences between 
adjacent clinical groups. Three chemokines (eotaxin-3, MIP-1β and eotaxin) showed statistically 
significant increases across all subject groups with advancing disease. When associations between 
clinical scores and chemokine levels were examined, eotaxin-3 levels were found to correlate with 
UHDRS motor score (R=0.41, p<0.05). There were no statistically significant correlations between 
any other chemokine and UHDRS motor or chorea score or TFC (data not shown). 
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Figure 33 Altered chemokine profile peripherally in Huntington’s disease 
(A) Multiplex ELISA quantification of chemokine levels in plasma from HD patients and control 
subjects. Graphs show mean concentrations with standard error bars. Significant differences between 
individual groups are shown (ANOVA with post-hoc Tukey HSD test). Significant differences between 
adjacent clinical groups were seen with eotaxin-3 (early vs moderate HD), eotaxin and MCP-4 
(premanifest vs early HD). No chemokine levels differed significantly between controls and 
premanifest HD. (B) The overall trend for increasing levels of chemokines across all groups, analyzed 
using linear regression, was significant for eotaxin-3, MIP-1β and eotaxin.  R-values (partial correlation 
coefficients) are corrected for age and sex. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (Raw data 
supplied by M Björkqvist.) 
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Figure 34 Plasma levels of eotaxin-3 correlate with UHDRS motor score in premanifest and 
manifest gene carriers 
R, partial correlation coefficient corrected for age. (Raw chemokine data supplied by M Björkqvist.) 
Stepwise logistic regression analysis was then used to determine which combinations of plasma 
chemokine levels best predicted membership of different dichotomous subject groupings. The 
results of this analysis are shown in Figure 35. All five chemokines were used in the model. Each 
contrast was then repeated using the six ‘top’ cytokines identified in the previous work, for those 
subjects in whom both cytokine and chemokine levels were available. Finally, the model was 
applied using both chemokine and cytokine values, to determine the optimum combination of 
inflammatory markers for each contrast. For each of the three contrasts tested, the AUC value (a 
measure of the reliability of the test) was approximately the same as, or lower than, that obtained 
using cytokines. However, in each case, combining chemokines and cytokines resulted in an 
optimum combination of markers containing one or more molecules from each category, and an 
AUC higher than chemokines or cytokines alone. 
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Figure 35 ROC curves demonstrating that chemokine and cytokine levels can be combined to 
improve the ability of inflammatory markers to distinguish between different clinical groups 
The ability of different markers to categorise subjects in each of three pairwise clinical contrasts was 
tested. For each contrast, ROC curves were constructed using stepwise logistic regression to examine 
the discriminatory ability of cytokines alone, chemokines alone and both marker types combined. For 
each set of markers, in each contrast, the markers included in the model and the AUC are given. The 
threshold for removal from the model was p=0.05. In every contrast, combining chemokines and 
cytokines led to an AUC higher than that resulting from either set of markers tested individually. 
Cytokines tested: eotaxin-3, MIP-1β, eotaxin, MCP-1 and MCP-4. Chemokines tested: IL-6, IL-8, IL-4, 
TNF-α and IL-5, as above. (Raw chemokine and cytokine data supplied by M Björkqvist.) 
IV.5 Discussion 
Taken together, these data show that immune activation in HD is widespread and detectable in 
peripheral plasma across disease stages. Key cytokines of the innate immune system are 
upregulated both centrally and peripherally and robust changes even take place in premanifest HD 
mutation carriers many years before the onset of motor abnormalities. The elevated IL-6 level seen 
in premanifest subjects with a mean of sixteen years until predicted clinical onset represents the 
earliest plasma abnormality identified to date in HD. The peripheral changes correlate well with 
clinical variables and are accompanied by alterations in striatal gene expression. 
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Although cytokines such as IL-4 and IL-10 are increased later in the disease, normal immunoglobulin 
levels throughout the disease course suggest that there is no generalized activation of the adaptive 
immune response. While IL-6 and IL-8 production are triggered by NFκB activation (Fietta et al. 
2002; Khoshnan et al. 2004), IL-4 and IL-10 act to downregulate NFκB (Kindt et al. 2006). The late 
involvement of these cytokines may reflect an adaptive response to chronic immune activation, 
possibly involving altered interactions between monocytes/macrophages and TH2 cells. 
The correlation shown between plasma and CSF levels of IL-6 and IL-8 links the central and 
peripheral immune activation in HD. IL-6 and IL-8 are seen to be increased in plasma and the 
striatum. These cytokines are not thought to cross the healthy blood-brain barrier (BBB) in the acute 
setting (Steensberg et al. 2006; Billiau et al. 2007) and studies of brain penetration of specific 
molecules in HD have not identified alterations of the BBB (e.g. Hersch et al. 2006). Mutant 
huntingtin therefore probably induces parallel dysfunction in both compartments (Figure 36). The 
immune dysfunction demonstrated here in monocytes from premanifest HD gene carriers may 
reflect similar central changes in HD microglia, and therefore act as a window onto central disease 
pathogenesis at this very early stage in the disease process. Given the dramatic changes seen in 
striatal cytokine expression and the chronic nature of these changes, passage of cytokines from the 
CNS into blood is a possibility that cannot be excluded, though cytokines are rapidly broken down 
(Pan et al. 2007) and would likely be subject to considerable dilution in plasma. However, the 
presence of primary abnormalities of both peripheral and central cytokine-producing cells 
(monocytes/macrophages and microglia respectively) suggests that parallel disease-related 
derangements in the periphery and CNS are the simplest explanation for these CSF-plasma 
correlations. 
Microglia have previously been implicated in the pathogenesis of HD (Sapp et al. 2001; Pavese et 
al. 2006; Tai et al. 2007) and are increasingly seen as key players in the pathogenesis of 
neurodegenerative diseases (Lobsiger et al. 2007). The increased cytokine production observed in 
the CNS and peripherally could be caused by dysfunction of microglia and their counterparts, 
monocytes and macrophages. These data show that monocytes from HD patients express mutant 
huntingtin. Further, they demonstrate that microglia, monocytes and macrophages in HD are all 
hyperactive when stimulated. The NFκB signalling pathway that triggers IL-6 release is known to be 
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upregulated by mutant huntingtin (Khoshnan et al. 2004) and the microglial kynurenine 
monooxygenase pathway has been identified as a potential therapeutic target in HD, establishing 
immune dysfunction as a possible pathogenic pathway in HD (Giorgini et al. 2005).  
The functional overactivity of macrophages from 12-month YAC128 mice — corresponding to early 
human HD — was not seen in macrophages from YAC18 mice, which are identical to YAC128 
animals except for the length of the polyglutamine tract. This suggests that the presence of mutant 
huntingtin alone is sufficient to cause derangement of monocytes/macrophages. 
Interestingly, while IL-6 is undetectable in the supernatant of isolated human monocytes, levels of IL-
6 in plasma are not zero in control subjects and HD patients. The same is true of murine 
macrophages and serum. Thus, there is low-level background cytokine production in vivo, perhaps 
due to normal cell turnover or environmental immune challenges, that is absent in vitro. A primary 
dysfunction of monocytes is sufficient to explain the increased plasma cytokine levels in HD, as 
hyperactive HD monocytes will respond excessively to this physiological background stimulation. 
However, it is possible that HD also causes differences in the level of background immune 
stimulation, which could contribute to the later upregulation of the adaptive immune response 
cytokines IL-4 and IL-10. 
There is a need for markers of progression (‘state biomarkers’) in HD and other neurodegenerative 
diseases (Ray et al. 2007). These results suggest that inflammatory changes detected in peripheral 
plasma may be biologically relevant and mirror the neurodegenerative process occurring in the CNS 
(Figure 36). Indeed, combined peripheral markers of inflammation were recently suggested to be 
biomarkers for diagnosis and progression in Alzheimer’s disease (Ray et al. 2007). Remarkably, 
peripheral inflammatory changes may also reveal early pathogenic events in HD, occurring over 15 
years before the onset of neurological manifestations. The study of chemokine levels in HD reveals 
that levels of inflammatory molecules other than cytokines appear to track with progression and 
may be able to function as biomarkers, particularly when combined with cytokines, where they 
appear able to convey additional information and increase the discriminatory power of biomarker 
combinations. 
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The inflammatory changes seen in patients are echoed in mouse models of HD. Importantly, they 
may therefore provide translational biomarkers for the use of HD mouse models in the 
development of therapeutic interventions. Finally, the mechanism of early innate immune activation 
in HD warrants further study as a potential source of targets for disease-modifying therapies. 
 
Figure 36 Immune activation, induced by mutant huntingtin, occurs both peripherally and 
centrally in Huntington’s disease 
A cell-autonomous effect of the mutant protein may be responsible for the innate immune response. 
The NFκB signalling pathway that triggers IL-6 release is known to be upregulated by mutant huntingtin 
(Khoshnan et al. 2004) and microglia-derived toxicity can influence disease progression (Khoshnan et 
al. 2004; Giorgini et al. 2005). This work shows that the innate immune response detectable in plasma 
very early in the disease is strongly linked to disease progression and recapitulated in HD striatum, that 
human monocytes express mutant huntingtin and that monocytes, macrophages and microglia 
overexpress IL-6 when stimulated. Early innate immune activation could be a target in the 
development of disease-modifying therapies. (Figure prepared by D Soulet.) 
IV.6 Publication relating to this chapter 
The work presented in this chapter was published as Björkqvist M / Wild EJ et al. (2008) A novel 
pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. 
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Journal of Experimental Medicine 205(8): 1869-1877. This publication does not include the 
chemokine analysis, which is in preparation for submission. 
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Chapter V Plasma neurofilament levels in 
Huntington’s disease 
V.1 Introduction 
N CONTRAST TO the previous two chapters, this chapter focuses on the experimental testing of a 
specific hypothesis, derived from plasma biomarker work in other neurological diseases, relating 
to a single candidate biomarker. The need for objective measures that are easy to quantify reliably 
in accessible tissue or fluid, track linearly with disease progression and change in response to 
disease-modifying therapeutic interventions has already been discussed and plasma is particularly 
appealing as a source of biomarkers because it is readily accessible compared with cerebrospinal 
fluid.  
Neurofilament proteins are the dominant proteins of the axonal cytoskeleton. Three neurofilament 
isoforms (light, L; medium, M and heavy, H) form the neurofilament triple protein (Lee et al. 1996). 
Neurofilament proteins have been established as markers for axonal injury, degeneration and loss 
and their clinical use as biomarkers has been suggested in a range of acute and chronic neurological 
diseases including multiple sclerosis, Parkinson’s disease and Alzheimer’s disease (Petzold 2005). 
The early course of HD is characterised by neuronal dysfunction rather than neuronal loss 
(Leegwater-Kim et al. 2004). Neurofilament is released by dysfunctioning as well as dying neurons 
(Petzold 2005), and neuronal loss does occur by the symptomatic stage of HD (Leegwater-Kim et al. 
2004). Plasma is a desirable target for biomarker identification because of its ready accessibility 
compared with cerebrospinal fluid. Changes in neurofilament levels have been shown in plasma in 
other neurological diseases (Petzold 2005). It is therefore reasonable to hypothesise that 
neurofilament levels may be altered in plasma in HD. 
The aim of the present study was to determine whether neurofilament H (NfH) levels in plasma, 
assessed using enzyme-linked immunosorbent assay (ELISA), differ significantly from those in a 
control population or track with progression in HD. 
V.2 Contributions and collaborations 
The NfH ELISA was performed by Dr Axel Petzold. Subject recruitment, plasma processing, data 
analysis and interpretation and manuscript preparation were carried out by the author. 
I 
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V.3 Subjects and methods 
V.3.1 Ethical approval and subject recruitment 
Ethical approval and subject recruitment were as specified in Chapter II. 
V.3.2 Inclusion and exclusion criteria 
Subjects with concomitant central nervous system disorders, significant medical comorbidity, 
known liver dysfunction, recent alcohol or substance abuse, and those taking medications or 
supplements suspected or known to interfere with the experimental methods used, were excluded. 
In view of the likelihood of nutritional, infective and inflammatory disorders in advanced HD, such 
patients were not included in the study. 
V.3.3 Collection and fractionation of blood samples 
Subjects were classified as controls, premanifest HD or early or moderate manifest HD. Sample 
collection, fractionation and storage and CAG repeat sizing were carried out as outlined in Chapter 
II. 
Plasma NfH levels were determined using an in-house ELISA technique based on commercially 
available antibodies (Petzold et al. 2003). This ELISA has been optimised for the capture antibody 
SMI35 (Sternberger Monoclonals Inc., Lutherville, USA) which recognizes a range of NfH 
phosphoforms (170 kDa, pI 6.2 to 210 kDa, pI 5.1). The analytical sensitivity of the assay was 200 
pg/mL with an intra-assay variation of as little as 2.4% (Brettschneider et al. 2006). Values below 
200 pg/mL, but above the blank reading, were interpolated from the standard curve. Values which 
equalled the blank reading were defined as non-measurable (0 pg/mL). 
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V.4 Results 
Subject group Subject number (F:M) Median age (range) Mean NfH 
concentration ± SD 
(pg/mL) 
Control 29 (16:13) 43 (21-68) 341 ± 142 
Premanifest 29 (16:13) 41 (26-53) 343 ± 180 
Early 29 (15:14) 49 (25-66) 326 ± 177 
Moderate 30 (21:9) 52 (25-77) 398 ± 212 
Table 14 Demographic characteristics of subjects and mean plasma NfH concentrations 
(Raw NfH data supplied by A Petzold.) 
The demographic characteristics of subjects whose plasma was tested are shown in Table 1. The 
mean coefficient of variation of the assay for this experiment was 2.72. Mean NfH plasma 
concentrations are given in Table 1 and shown in Fig. 1. Though the mean plasma NfH level was 
higher in the moderate disease group, linear regression revealed no overall trend in NfH levels with 
advancing disease (p=0.2917) even when correcting for subject age (p=0.5423). Analysis of inter-
group differences using ANOVA revealed no significant differences between subject groups 
(p=0.4317). 
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Figure 37 Plasma NfH levels are unaltered in HD 
Mean values are shown in pg/mL with standard error bars. Though NfH levels were higher in 
moderate disease than other groups, the difference was not statistically significant and there was no 
significant correlation between disease stage and plasma NfH concentration. (Raw NfH data supplied 
by A Petzold.) 
There were no significant correlations between plasma NfH concentration and either calculated 5-
year probability of disease onset (Langbehn et al. 2004) in premanifest subjects (R2=0.0064, 
p=0.6850), or disease severity (Penney et al. 1997) in all mutation carriers (given by [CAG repeat 
length - 35.5] × age; R2=0.0044, p=0.5557). 
To examine whether plasma NfH levels reflect rate of progression in HD, an analysis of genotype-
phenotype discordance was carried out by identifying two subsets of mutation carriers. From their 
CAG repeat length, the age at which each subject would have a 50% probability of disease onset 
was calculated (Langbehn et al. 2004). The ‘late-onset’ group was defined as those premanifest 
subjects who had remained disease-free beyond this 50% probability-of-onset age (6 of 29 subjects), 
while the ‘early-onset’ group was defined as those subjects who developed manifest disease before 
the 50% probability-of-onset age (13 of 57 subjects). Plasma NfH levels (means ± SD, ng/L) were 
0.336 ± 0.159 in the ‘late onset’ group and 0.380 ± 0.139 in the ‘early onset’ group, with no 
significant difference between the groups (t-test, p=0.5502). 
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V.5 Discussion 
Using a highly sensitive ELISA assay, plasma concentrations of NfH were quantified in control 
subjects and HD mutation carriers from premanifest, early and moderate disease stages. Plasma 
NfH levels can be quantified in a robust and reproducible manner in these patients. However, a 
correlation between disease stage and plasma NfH level was not found, even when correcting for 
subject age. There was no significant correlation between plasma NfH and calculated parameters 
based on CAG repeat length, the major determinant of disease course in HD. Finally, no effect of 
genotype-phenotype discordance on plasma NfH levels was found to suggest that NfH may be a 
predictor of disease onset. 
These findings may be explained by the speed of disease progression in HD patients. Neurofilament 
proteins are released from degenerating neurons and axons into the extracellular fluid, from where 
they equilibrate with other fluids such as blood. Because the neurodegenerative process in HD is 
slow, it is likely that neurofilament proteins released into plasma will be removed too quickly to 
allow for a measurable increase compared with controls. 
Overall, plasma NfH does not fulfil the characteristics of a useful biomarker of onset or progression 
in HD. 
V.6 Publication relating to this chapter 
The work in this chapter was published as Wild EJ et al. (2007) Plasma neurofilament heavy chain 
levels in Huntington’s disease. Neuroscience Letters 417(3): 231-233. Figure 37 is reproduced from 
this article by permission of Elsevier. 
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Chapter VI Whole-brain atrophy as a biomarker of 
HD 
VI.1 Introduction 
HIS CHAPTER DESCRIBES the main outcome of the longitudinal imaging study: the measurement 
of whole-brain atrophy over two years in premanifest and early HD. HD usually begins 
insidiously in mid-adult life and progresses relentlessly, causing widespread impairment of brain 
function resulting in an unpredictable spectrum of clinical manifestations including movement 
disorders, cognitive impairment and psychiatric disturbances.  
The mutant huntingtin protein is expressed ubiquitously in both CNS and peripheral tissue (Aronin 
et al. 1995; Sathasivam et al. 1999; Björkqvist et al. 2008). Both post-mortem and in vivo, the most 
striking macroscopic change in HD brains is atrophy of the neostriatum with a preponderance for 
the caudate and putamen (Forno et al. 1979; Oliva et al. 1993). Nuclear and cytoplasmic aggregates 
of mutant huntingtin — the microscopic neuropathologic hallmark of HD — are found widely in gray 
and white matter but are relatively sparse in the striatum where degeneration is most prominent 
(Gutekunst et al. 1999). Moreover, the total loss of brain mass by end-stage HD is considerably 
greater than could be accounted for by striatal atrophy alone (Forno et al. 1979; Aylward et al. 
2004; Henley et al. 2006) and numerous studies have confirmed that, notwithstanding the clear 
early prominence of striatal involvement, HD ultimately affects the whole brain (Rosas et al. 2003; 
Rosas et al. 2005). 
Though there are no current treatments that slow the progression of HD in humans, several putative 
treatments have demonstrated a disease-modifying effect in animal models (Handley et al. 2006), 
and it has been further demonstrated that reversible neuronal dysfunction precedes cell death in 
HD (Yamamoto et al. 2000). A genetic test can reliably predict those people destined to develop 
the disease, and in such individuals, the slowing of pathology would be expected to delay the onset 
of disease symptoms. Because the disease progresses slowly and is heterogeneous, and because of 
the limitations of clinical rating scales, trials of possible disease-modifying treatments in humans are 
likely to be greatly facilitated by the availability of a panel of state biomarkers that can be used to 
track progression of the disease reliably and distinguish between symptomatic and disease-
modifying effects (see Chapter I). 
T 
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Numerous neuroimaging techniques for detecting changes in HD brains have been employed, with 
different abilities to capture aspects of the diverse effects of the mutant protein (reviewed in chapter 
I.2.2). Quantifying change in structures with well-defined anatomical boundaries may be more 
reproducible than measuring the volumes of less easily-defined regions. More importantly, perhaps, 
whole-brain atrophy would be expected to capture the totality of mutant huntingtin’s effects on 
brain volume, and is therefore less likely to overlook clinically important changes that may have 
significance for our understanding of either natural history or the effects of putative therapeutic 
agents. The brain boundary shift integral (BBSI), a semi-automated technique for quantifying whole-
brain atrophy (Freeborough et al. 1997) has improved reliability over manual measures (Schott et al. 
2005) and has been employed as an outcome measure in Alzheimer’s disease clinical trials (Fox et 
al. 2005). 
Whole-brain atrophy rates measured over a six-month period using the BBSI have previously been 
shown to be increased in early HD (Henley et al. 2006). Larger cohorts and longer inter-scan 
intervals are expected to produce stronger signal-to-noise ratios in disease-related measures, 
enabling more robust estimation of atrophy rates in HD. In addition, the study of mutation carriers 
prior to the diagnosis of manifest disease may reveal important early changes in the HD. 
Furthermore it is not known whether whole-brain atrophy proceeds at a constant rate in HD or 
whether it accelerates or decelerates, and to date this aspect of the disease has only been studied 
to a limited extent for regional atrophy (Aylward et al. 2000; Aylward et al. 2004), but has obvious 
implications for both our understanding of the disease and the conduct of future clinical trials 
involving putative disease-modifying therapies. 
A large cohort of patients with HD, premanifest mutation carriers and control subjects over two 
years was studied prospectively, with clinical assessment and volumetric MRI scans at baseline, and 
one and two years later. The BBSI technique was used to compare whole-brain atrophy between 
different disease stages, and used atrophy rates within subjects over consecutive intervals to 
determine whether atrophy accelerates in HD. 
VI.2 Contributions and collaborations 
The study was conceived by Dr N Fox and Dr S Tabrizi and the study protocol was designed by 
them with Ms S Henley and the author. Subject recruitment was shared equally between the author 
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and Ms S Henley. MRI scanning was overseen by Dr D MacManus. Whole-brain segmentations and 
were carried out equally by Ms S Henley, Ms N Hobbs and the author. Dr Chris Frost gave 
statistical advice. All other work, including clinical and behavioural characterisation of subjects, BSI 
optimisation, data analysis and interpretation and preparation of figures, was carried out by the 
author. 
VI.3 Ethical approval 
Ethical approval and overall study conduct were as described in chapter II.2, page 73. 
VI.4 Subjects 
Whole-brain atrophy rates were calculated for 70 subjects: 19 control subjects, 20 premanifest 
mutation carriers and 31 early HD patients. Demographic characteristics are given in Table 15. 
Controls were partners or spouses of mutation carriers, or individuals previously at risk of HD with a 
negative genetic test for the mutation.  Premanifest HD was defined as a diagnostic confidence 
score of <4 on the Unified Huntington’s Disease Rating Scale (UHDRS) (The Huntington Study 
Group 1996); early HD as a diagnostic confidence score of 4 with a UHDRS total functional 
capacity score of 7 or more (Shoulson 1981). No subjects were taking any medication known or 
suspected to influence brain volume and subjects with concomitant neurological illnesses were 
excluded. 
VI.5 Methods 
VI.5.1 Imaging 
VI.5.1.1 Overview 
Figure 38 gives an overview of the steps from scan acquisition to calculation of the BBSI. 
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Figure 38 Overview of image acquisition, preprocessing and analysis 
VI.5.1.2 Scan acquisition and preprocessing 
1.5T volumetric MRI scans were acquired and preprocessed as described in chapter II.7. 
VI.5.1.3 Whole-brain segmentation 
Whole-brain segmentation was performed using a semi-automated algorithm (Freeborough et al. 
1997) described in detail in Appendix H. Briefly, upper and lower thresholds were determined 
visually, to include all brain tissue and exclude as much non-brain tissue as possible. An axial cut-off 
slice was defined at the most caudal extent of the cerebellum. The region containing the brain was 
defined as the largest contiguous region. The region was eroded throughout by one or more voxels 
(in practice one erosion only was needed) to restrict the region to brain tissue. Remaining 
connections with non-brain tissue were deleted manually. The region was then dilated to the edge 
of the brain using intensity thresholds of 60% and 160% of the mean value. Where necessary, 
regions were manually edited for anatomical accuracy. Segmentations were performed by three 
investigators (including the author) whose intra- and inter-rater reliability was greater than 99%. 
VI.5.1.4 Registration of serial MRI 
Scan pairs were aligned using affine registration with 12 degrees of freedom, from which the BBSI 
was calculated (Freeborough et al. 1997; Woods et al. 1998). Registrations were carried out across 
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all three intervals from three timepoints: year one to baseline, year two to baseline and year two to 
year one. 
VI.5.1.5 Optimisation of BBSI parameters 
The BBSI algorithm uses values of upper and lower intensity thresholds, I1 and I2 (also expressed as 
the window centre, Ic = I1/2 + I2/2, and width, Iw = I1 - I2) which are used to determine the range of 
intensities over which the boundary shift is calculated, and should be selected such that it falls 
entirely within all of the intensity transitions (e.g. grey matter to CSF) associated with the boundaries 
of a structure. Adjustment of the parameters can alter the calculated BBSI substantially, while the 
optimum set of parameters depends largely on scan acquisition parameters, as well as on properties 
of the boundaries in question (Freeborough et al. 1997). A novel optimisation procedure developed 
by the author was therefore carried out to identify the parameters most likely to maximise the 
signal-to-noise ratio for the measure in this cohort over the longest interval studied. 
Optimisation took as its gold standard the manual measure of volume change derived from the 
subtraction of followup from baseline brain volumes. While this measure is typically less 
reproducible than the optimised BBSI, the mean volume changes resulting when it is applied to 
cohorts of scans tend to be accurate. The optimum set of parameters was defined as those which, 
when applied to a representative set of registered scan pairs, produced the set of differences 
between the manual and BBSI-derived measure with the lowest standard deviation. 
A subset of scans may be used to determine the optimum parameters for a larger set (Freeborough 
et al. 1997). Five scan pairs were selected in each subject group, such the subset matched as closely 
as possible the entire group. Scans were matched for mean and range of age, sex, CAG (in the 
premanifest and HD groups) and BBSI-derived atrophy rates using the default parameters. Because 
the BBSI operates on affine-registered scan pairs, it was necessary for the volume-subtraction 
measure to be performed on registered scans too. The whole-brain regions of the registered 
followup scans for these fifteen subjects were therefore re-segmented and volume changes were 
calculated from these re-segmented registered pairs. 
To identify the optimum combination of parameters, a script written in Microsoft VBA was used to 
generate BBSI commands using large numbers of different combinations of parameters. Pilot work 
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had shown that the default BBSI parameters of Ic = 0.5 and Iw = 0.5 tended to be rather higher than 
the optimum values. Accordingly, a range of values for window centre from 0.3 to 0.6 in increments 
of 0.01 was used, with a range of values for window width from 0.1 to 0.5 in increments of 0.05. 
Each possible combination of centre and width was tested, for a total of 279 combinations. The 
outcome of the comparisons is shown in Figure 39. 
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Figure 39 Outcome of BBSI optimisation process 
Surface plots showing, for combinations of window centre and width, the standard deviation of the 
total difference between the volume changes over two years derived from the BBSI and manual 
subtraction for fifteen subjects. The height and colour of the surface represents the SD. Lower SDs 
correspond to better agreement between the measures. A. Entire range of values tested. B. Narrower 
range of parameters containing the lowest SDs. Plots were prepared using Graphis software (Kylebank, 
Inc). 
Two clusters of parameters resulted in low SDs of the difference between measures: one around 
Ic = 0.57, Iw = 0.1 and another around Ic = 0.55, Iw = 0.2. Overall, the latter cluster contained a larger 
number of combinations with low SDs, in addition to having a window width less likely to miss 
important features that may not have been represented in the subset of scans chosen for 
optimisation. The final parameters chosen were therefore Ic = 0.55 and Iw = 0.2. These parameters 
were used to calculate atrophy rates using the BBSI over all intervals. 
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VI.5.2 Clinical assessment 
Clinical assessment, including neurological, behavioural and functional measures, was as specified in 
chapter II.5-II.6. In addition subjects underwent cognitive assessment as outlined in chapter II.10 
and Appendix H. 
VI.5.3 Statistical analysis 
VI.5.3.1 Correction for total intracranial volume 
To correct for differences in head size, brain volumes were standardised for baseline total 
intracranial volume (TIV) which was measured according to a standard protocol (Whitwell et al. 
2001). To derive the slope of the relationship between TIV and brain volume, log-transformed brain 
volumes were regressed on log-transformed TIVs for control scans.  The slope, β, was then used to 
adjust all baseline brain volumes for TIV using the following equation: 
β×⎟⎟⎠
⎞
⎜⎜⎝
⎛×=
TIVSubject
TIVMeanVV rawadjusted  
Followup brain volumes were calculated from baseline brain volume and BBSI-derived absolute 
brain loss. All brain volumes were normalized to mean TIV. 
VI.5.3.2 Atrophy rate calculation 
Brain volume change measured by the BBSI was also converted to percentage of baseline brain 
volume and annualized to generate atrophy rates.  All statistical analyses were carried out on log-
transformed values as described in chapter II.11.13.1. Results were converted back to annualised 
percentage rates. 
VI.5.3.3 Inter-group comparisons 
Linear regression models, adjusting for age at baseline and gender, were used to compare atrophy 
rates acceleration between groups. Separate linear regression models of the effects of age and sex 
across all subjects were used to produce adjusted values for atrophy rate and acceleration. 
VI.5.3.4 Clinical associations 
Linear regression models, adjusting for age at baseline and gender, were used to assess associations 
between atrophy parameters and clinical variables. 
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VI.5.3.5 Genetic associations 
Five-year conditional onset probabilities, and estimated time to a 60% probability of motor 
diagnosis were calculated using a standard formula (Langbehn et al. 2004). 
VI.5.3.6 Sample size calculations 
Sample size requirements for clinical trials were calculated using a standard approach (Campbell et 
al. 1993) based on estimating the subject numbers required to achieve a 90% chance of detecting a 
30% reduction in both the absolute atrophy rate in early HD and the excess of atrophy in early HD 
with respect to the control rate, at a significance level of 0.05. Sample sizes were compared using 
atrophy rates from baseline to year one, and from baseline to year two. 
VI.5.3.7 Linear change over two years 
For the ‘direct’ measures of change (clinical, behavioural and functional scores), a generalised 
estimating equation (GEE) analysis was used to incorporate all available data over the three 
timepoints, as described in chapter II.11.13.2. The BSI, an ‘indirect’ measure of change, was 
analysed using linear regression over the longest available interval, from baseline to two years. 
VI.5.3.8 Linearity of progression 
To examine non-linearity within each group, paired t-tests within groups were used to compare rates 
of change in each variable of interest between the first and second year. For inter-group 
comparisons of non-linearity, difference scores were calculated by subtracting the first- from the 
second-year annualized rate of change. A linear regression model was then used to compare these 
difference scores between groups, adjusting for age and sex. 
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VI.6 Results 
VI.6.1 Subject disposition 
Baseline to year-two BBSI
C PM HD Total
10 17 21 48
Recruited
C PM HD Total
23 22 50 95
Attended baseline 
assessment
C PM HD Total
21 22 46 89
Excluded before baseline 
assessment
C PM HD Total
2 0 4 6
Excluded during baseline 
assessment
C PM HD Total
1 1 6 8Completed baseline 
assessment
C PM HD Total
20 21 40 81 Dropout during year one
C PM HD Total
2 2 0 4
Completed year-one 
followup assessment
C PM HD Total
18 19 40 77
Dropout during year two
C PM HD Total
6 3 14 23
Attended year-two but not 
year-one assessment
C PM HD Total
1 1 0 2
Completed year-two 
followup assessment
C PM HD Total
13 17 26 56
Baseline to year-one BBSI
C PM HD Total
18 17 27 62
Year-one to year-two BBSI
C PM HD Total
7 10 17 34
Baseline to year-one and
year-one to year-two BBSIs
C PM HD Total
7 10 12 29
 
Figure 40 Subject disposition over the course of the study 
C, control; PM, premanifest; HD, early HD. 
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As shown in Figure 40, a total of 95 subjects initially agreed to participate in the study. Six subjects 
did not attend the initial assessment, and of the 89 that did, eight were excluded after failing to 
meet the inclusion criteria when assessed in person, leaving a definitive cohort size of 81 subjects 
with a complete baseline assessment. During the first year of followup, four subjects dropped out (a 
retention rate of 95%) leaving 77 with two full assessments. Of these scan pairs, 62 produced good-
quality registrations for calculation of the 12-month BBSI.  During the second followup interval, a 
further 23 subjects dropped out, but two who missed the one-year assessment returned, so 56 
subjects were assessed at the year-two timepoint. This final timepoint generated 48 successful scan 
registrations from baseline to two years, and 34 from one to two years. Analysis of atrophy 
acceleration requires registrations over both one-year intervals to be successful: this was the case 
for 29 subjects. 
VI.6.2 Demographic data 
Demographic data are given in Table 15 for the entire cohort at baseline. In addition, the sections 
below give separate demographic data for the subset of subjects undergoing each analysis. Overall, 
the groups were well-matched for IQ (t-tests), gender and handedness (Fisher’s exact tests). The 
premanifest group was significantly younger than both controls and early HD (t-test, p=0.01 and 
p<0.001 respectively), but age was corrected for statistically in all analyses. The early HD group had 
significantly higher CAG repeat lengths than did the premanifest group (p=0.01). 
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 Control Premanifest Early HD 
N 20 21 40 
Gender, M:F 7:13 10:11 11:20 
Age at baseline assessment, years 45.3 (10.5) 37.7 (7.9) 49.0 (9.6) 
CAG repeat length - 42.2 (1.8) 43.7 (2.4) 
Years to predicted motor onset 
(Langbehn et al. 2004) - 17.7 (7.1) - 
Disease duration - - 4.6 (2.7) 
Total functional capacity 13 (0) 13 (0) 10.9 (1.8) 
Handedness, R:L 19:1 20:1 36:4 
IQ 106 (11.6) 103 (9.2) 105 (13.0) 
UHDRS motor score 1.1 (0.9) 3.6 (4.0) 28.9 (12.6) 
Beck depression inventory score 5.55 (3.9) 6.8 (6.3) 8.35 (8.7) 
SBA score 7.1 (5.7) 8.9 (6.1) 10.5 (7.2) 
Table 15 Subject demographic characteristics for the entire 81-subject imaging cohort at the 
baseline assessment 
VI.6.3 Clinical progression 
Clinical and behavioural scores at baseline are discussed in Chapter VII in the context of the VBM 
analysis of associations with regional atrophy. This section examines the longitudinal trends in 
clinical, behavioural and functional scores over the full course of the study, using a generalised 
estimating equation analysis. The analysis of clinical progression employs the whole cohort as 
described in Table 15. The results are given in Table 16. In early HD, UHDRS motor score increased 
by a mean of 3.9 points per year and TFC declined at a mean of 0.54 points (both p<0.01) but 
neither measure changed significantly in controls or premanifest HD subjects. Scores on the Beck 
depression inventory (BDI) worsened significantly in controls (1.64 points per year, p<0.01) and 
early HD (1.70 points per year, p=0.02) but not premanifest subjects; the difference between 
controls and early HD was not statistically significant however. There were no significant changes or 
intergroup differences (over one year only) in mean SBA score. 
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 Rates of change, points per year (95% confidence intervals) 
 Control Premanifest Early HD 
N 20 21 40 
UHDRS motor 
score 
0.01 (-0.34 to 0.37) 0.40 (-0.41 to 1.23) 2.79 (1.50 to 4.08) 
(all subjects) p=0.95 p=0.33 p<0.01a,b
UHDRS motor 
score 
0.17 (-0.23 to 0.62) 0.46 (-0.45 to 1.37) 3.90 (2.71 to 5.08) 
(single rater) p=0.46 p=0.32 p<0.01a,b
TFC -0.02 (-0.09 to 0.05) -0.02 (-0.08 to 0.04) -0.54 (-0.80 to -0.29) 
 p=0.53 p=0.58 p<0.01a,b
Beck score 1.64 (0.62 to 2.67) -0.49 (-1.42 to 0.44) 1.71 (0.27 to 3.15) 
 p<0.01 p=0.32a p=0.02b
SBA score* 0.22 (-2.69 to 3.13) -1.43 (-4.48 to 1.62) 1.49 (-0.80 to 3.77) 
 p=0.88 p=0.36 p=0.20
Table 16 Annual rates of change of clinical variables. 
GEE analysis is adjusted for age, gender and, for UHDRS motor score in all subjects, motor rater. Mean 
rates are given with 95% CIs. p values indicate whether this change was significantly different from 
zero.  The superscripts indicate where the change per year differed between groups: achange different 
from that in controls; bchange different from that in premanifest HD (both at p<0.05). *SBA scores at 
the two-year timepoint were not included because of a change in the assessment tool (see chapter 
II.6). 
Assessment of linearity of change in clinical scores, not including SBA, was carried out in the 56 
subjects who attended all three assessments. Their demographic data and the results of the analysis 
of non-linearity by paired t-test within groups are given in Table 17. 
There appeared to be a significant slowing of progression of motor score in the premanifest group 
(year one change +2.0; year two change -0.4; p=0.03). However, when the intra-group comparison 
was limited to those subjects assessed by the principal motor rater, the change was not significant 
(year one change +1.7, year two change -0.1; p=0.19) and when analysed in the entire premanifest 
group with the effect of motor rater adjusted for statistically, again there was no evidence of 
significant change in the rate of progression (p=0.47).  
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For the other clinical variables, there was no evidence of significant non-linearity within any subject 
group, or when compared between groups (data not shown), and non-linearity scores were not 
significantly associated with baseline disease duration, TFC, motor score, conditional onset 
probability or CAG repeat length (after adjustment for age). 
 Control Premanifest Early HD 
N 12 16 28 
Gender, M:F 5:7 8:8 13:15 
Age at baseline assessment, years 45.3 (7.4) 39.1 (8.1) 48.3 (10.0) 
CAG repeat length - 41.9 (1.6) 43.4 (2.3) 
Years to predicted motor onset at 
baseline 
(Langbehn et al. 2004) 
- 15.7 (7.2) - 
Disease duration, years - - 4.9 (2.7) 
UHDRS motor 
(all subjects) 
0.9 (2.4) 
-0.8 (1.5) 
p=0.13 
2.0 (3.7) 
-0.4 (1.4) 
p=0.03 
4.8 (7.4) 
1.1 (8.1) 
p=0.13 
UHDRS motor 
(single rater) 
2.2 (3.9) 
-1.5 (2.5) 
p=0.33 
1.7 (3.9) 
-0.1 (1.4) 
p=0.19 
4.8 (7.9) 
3.5 (6.8) 
p=0.64 
TFC 0 (0) 
-0.1 (0.2) 
p=0.33 
0 (0) 
0 (0.2) 
p=0.33 
-0.6 (1.1) 
-0.7 (1.1) 
p=0.88 
Change in clinical 
scores: 
year 1 (SD) 
year 2 (SD) 
p-value for non-linearity 
BDI 2.1 (5.5) 
1.3 (4.2) 
p=0.88 
0.7 (4.6) 
-1.0 (5.1) 
p=0.77 
-0.6 (6.6) 
2.7 (6.2) 
p=0.46 
Table 17 Demographic data and outcomes of intra-group tests for non-linearity in rates of change 
of clinical scores. 
Groups were well-matched for gender. The premanifest group was significantly younger than controls 
and early HD and had significantly shorter CAG repeat lengths than the early HD group. 
VI.6.4 Whole-brain atrophy rates over two years 
VI.6.4.1 Overview 
In order to present the whole-brain outcomes visually for as much of the cohort as possible, TIV-
corrected baseline brain volumes and subsequent atrophy values were used to generate TIV-
corrected followup brain volumes, which are shown in Figure 41 for all subjects for whom a 
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minimum dataset of a baseline TIV and at least one value for whole-brain atrophy (from baseline to 
years one or two) was available. The demographic data of these subjects are given in Table 18. 
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Figure 41 Whole brain MRI findings in this cohort 
All brain volumes (vertical axis) are normalized to TIV. Each subject’s baseline brain volume is joined 
to the BBSI-derived followup brain volume over the longest assessment interval. In HD gene carriers, 
line colour represents the pathological CAG repeat length. In controls (grey), a slow decline in brain 
volume reflects normal age-related atrophy, and the slopes (atrophy rates) are largely within the range 
expected for such age-related atrophy. Premanifest carriers generally lie within the control range for 
brain volume and atrophy rate, but several lie outside the control range for one or both measures. 
Two premanifest subjects who underwent motor onset during the study are highlighted with asterisks 
at the point of onset diagnosis. In early manifest HD, brain volumes and atrophy rates generally lie 
outside the control range, with higher CAG repeat length subjects tending to undergo pathological 
atrophy earlier and to a greater extent. 
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 Control Premanifest Early HD 
N 19 20 31 
Gender, M:F 7:12 9:11 16:15 
Age at baseline assessment, years 45.6 (10.7) 37.5 (8.1) 49.4 (9.1) 
CAG repeat length - 42.3 (1.8) 43.4 (1.7) 
Years to predicted motor onset 
(Langbehn et al. 2004) 
- 15.6  
Disease duration - - 4.9 (2.7) 
Total functional capacity 13 (0) 13 (0) 11.2 (1.7) 
UHDRS motor score 1.1 (0.9) 3.6 (4.1) 27.6 (11.7) 
Interval between baseline and 1-year 
scan, years 
1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 
Interval between baseline and 2-year 
scan, years 
2.2 (0.1) 2.3 (0.1) 2.3 (0.1) 
Table 18 Baseline demographic data for the subjects whose whole-brain atrophy findings are 
shown in Figure 41 
The groups were well-matched for gender. The premanifest group was significantly younger than both 
controls (p=0.01) and the early HD group (p<0.001) and had significantly lower CAG repeat lengths 
(p=0.02). There were no significant inter-group differences in inter-scan duration for either interval. 
VI.6.4.2 Improved signal-to-noise ratio 
Overall the quality of scan registrations was higher over the two-year period than over one year, 
and the BBSI technique appeared to be better able to capture true atrophy over the period. 
Examples of whole-brain atrophy in an HD patient and a control subject measured by the BBSI over 
one and two years, highlighting both the disease-related increase in atrophy and the improved 
detection of atrophy over two years, are given in Figure 42. 
 180 
A
C D
B
1-year interval 2-year interval
Ea
rly
 H
D
C
on
tr
ol
 
Figure 42 Whole-brain atrophy in HD quantified by the BBSI technique 
Parasagittal views of baseline MRI scans with overlays showing areas of volume loss (red) and gain 
(green) detected by BBSI. A. Early HD patient aged 33 with 47 CAG repeats, showing change over 
one year. B. Change over two years in the same patient, with clearer evidence of atrophy. 
C-D. Equivalent images from a 40-year old control subject, showing little atrophy over either interval. 
VI.6.4.3 Atrophy rates 
Whole-brain atrophy rates over two years were calculated for 48 subjects, whose demographic data 
are given in Table 19. 
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 Control Premanifest Early HD 
N 10 17 21 
Gender, M:F 6:4 8:9 11:10 
Age at baseline assessment, years 44.2 (10.0) 38.2 (8.7) 48.5 (9.7) 
CAG repeat length - 42.0 (1.7) 43.1 (1.9) 
Years to predicted motor onset 
(Langbehn et al. 2004) 
- 16.0 (7.0) - 
Disease duration - - 4.8 (2.6) 
Total functional capacity 13 (0) 13 (0) 11.6 (1.5) 
UHDRS motor score 1.1 (0.9) 2.8 (3.2) 26.0 (10.6) 
Interval between baseline and 2-year 
scan, years 
2.2 (0.1) 2.3 (0.1) 2.3 (0.1) 
Table 19 Baseline demographic data for the 48 subjects whose whole-brain atrophy rates were 
calculated over the two-year interval 
The groups were well-matched for gender. The premanifest group was significantly younger than the 
early HD group (p<0.01) but not controls (p=0.11). The two gene-positive groups did not differ 
significantly in CAG repeat length (p=0.055). 
Whole-brain atrophy rates by group are given in Table 20 and Figure 43. Mean atrophy rate was 
about five times higher in the HD group than in both controls and the premanifest HD group and 
the inter-group differences were statistically significant (p<0.001 in both cases). In this cohort far 
from predicted disease onset, the mean atrophy rate in the premanifest group did not differ 
significantly from the control mean (p=0.55). 
 Control Premanifest HD 
N 10 17 21 
Mean atrophy rate, % per year (SD) 0.16 (0.25) 0.22 (0.23) 0.88 (0.50) 
95% CI -0.02 to 0.34 0.10 to 0.34 0.65 to 1.10 
Table 20 Whole-brain atrophy rates by group, adjusted for age and sex 
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Figure 43 Whole-brain atrophy is increased in early HD 
Whole-brain atrophy rates, adjusted for age and sex, were increased in early HD patients compared 
with both controls and premanifest HD. ***p<0.001 by linear regression. Horizontal bars show group 
means. 
As shown in Figure 43, there was a statistically significant association between age- and gender-
adjusted whole-brain atrophy rate and CAG repeat length (p=0.009). On average, a single triplet 
increase in repeat length was predicted to increase the whole-brain atrophy rate by 0.12% (95% CI 
0.03% to 0.22%, p=0.009, R=0.42). As shown in Table 21, over the two-year interval, whole-brain 
atrophy rates were not significantly associated with baseline disease duration, onset probability in 
the premanifest group or change in any clinical variable, though the association with change in 
UHDRS chorea score was close to statistical significance (p=0.06). 
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Predictor Group R p 
Slope of association, % 
per year per unit (95% 
CI) 
CAG repeat length PM & HD -0.4247 0.009 0.12% (0.03% to 0.22%) 
5-year onset probability PM -0.2042 0.48 0.63% (-1.26% to 2.49%) 
Baseline motor duration HD -0.2465 0.23 0.05% (-0.03% to 0.13%) 
Change in UHDRS motor 
scorea 
HD 0.1054 0.68 -0.02% (-0.09% to 0.06%) 
Change in UHDRS chorea 
scorea 
HD 0.3213 0.06 -0.14% (-0.28% to 0.01%) 
Change in TFCb HD 0.1967 NS -0.15% (-0.45% to 0.49%) 
Change in BDI scoreb PM & HD 0.2793 NS -0.01% (-0.11% to 0.09%) 
Table 21 Associations between whole-brain atrophy and clinical variables over two years 
a Motor rater was used as a covariate in the analysis of associations with clinical scores. 
b Bootstrapping was used to analyse these non-normally distributed variables, so a p-value is not 
obtained directly; NS, not significant at the 5% level. 
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Figure 44 Association of whole-brain atrophy rate with CAG repeat length across premanifest 
and early HD 
This relationship is partly explicable by the fact that the premanifest group had more subjects with low 
repeat lengths and fewer with high repeat lengths, while HD subjects have higher rates of atrophy 
than premanifest subjects. On average, a single triplet increase in repeat length was predicted to 
increase the whole-brain atrophy rate by 0.12%. 
Sample size estimations were calculated for putative clinical trials using whole-brain atrophy as an 
outcome measure, to determine the number of early HD subjects per arm required for trials of a 
treatment reducing atrophy rate by 30%, both in absolute terms and with respect to the difference 
between early HD and controls. For a one-year trial calculated using absolute atrophy reduction, the 
requirement would be 120 subjects; for a two-year trial, 78 subjects. For the same trial based on 
relative reduction, the requirements would be 322 and 116 subjects respectively. 
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VI.6.4.4 Atrophy acceleration 
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Figure 45 Whole-brain atrophy accelerates in early HD, and acceleration increases as motor 
onset approaches in premanifest HD and correlates with pathological CAG repeat length 
A. Whole-brain atrophy rates by group, with each subject’s first- and second-year atrophy rates joined, 
such that accelerating atrophy is indicated by an upward slope. Atrophy rates did not increase 
significantly in controls and premanifest HD but did so in early disease (*p<0.05, paired t-test). B. Age- 
and sex-adjusted atrophy acceleration rates, showing the difference in atrophy rate between the 
second and first years. Values above zero represent atrophy acceleration. Horizontal bars show group 
means. C. Age- and sex-adjusted atrophy acceleration rates show a strong positive association with 5-
year conditional onset probability in the premanifest group. A 10% increase in onset probability 
predicts a 1.4% annual acceleration in atrophy (95% CI: 1.0% to 1.8%). D. Age- and sex-adjusted 
atrophy acceleration rates show a positive association with CAG repeat length: on average, a one-unit 
increase in CAG repeat length is associated with a predicted increase in annual atrophy acceleration 
of 0.4% (95% CI: 0.2% to 0.6%). R, partial correlation coefficient. 
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Annualized atrophy rates were calculated for a subset of 29 subjects across the two consecutive 
one-year intervals (Figure 45 and Table 22). Comparison of the first and second year atrophy rates 
within each group (Figure 45A) revealed significant acceleration of atrophy in the early HD group 
(p=0.048) but not in controls or premanifest HD (p=0.38 and 0.28 respectively). The acceleration of 
atrophy remained statistically significant in the early HD group (p=0.045) if determined using 
absolute volume loss (ml per year), rather than relative loss (% per year). When acceleration was 
compared between groups, the HD group tended to accelerate compared with controls, though the 
difference was not statistically significant (p=0.055).  
 Control PM HD 
N 7 10 12 
Gender, M:F 4:3 5:5 6:6 
Age at baseline assessment, years 46.7 (8.7) 40.0 (8.9) 46.4 (9.1) 
CAG repeat length - 42.0 (1.6) 43.5 (1.8) 
Years to predicted motor onset 
(Langbehn et al. 2004) 
- 14.3 (6.8) - 
Disease duration - - 5.5 (3.0) 
Total functional capacity 13 (0) 13 (0) 11.6 (1.7) 
UHDRS motor score 0.9 (0.9) 3.1 (3.6) 27.0 (11.1) 
Interval between baseline and 1-year 
scan, years 
1.0 (0.0) 1.0 (0.0) 1.0 (0.1) 
Interval between 1-year and 2-year 
scan, years 
1.2 (0.1) 1.3 (0.1) 1.3 (0.1) 
0-1 year atrophy rate (SD) 0.20 (0.60) -0.03 (0.49) 0.58 (0.66) 
1-2 year atrophy rate (SD) 0.03 (0.47) 0.36 (0.67) 1.27 (0.79) 
Mean annual atrophy acceleration rate 
from year 1 to year 2 (SD) 
-0.17 (0.88) +0.39 (1.10) +0.69 (1.08) 
95% CI -0.99 to +0.64 -0.40 to +1.18 +0.01 to +1.37 
Table 22 Assessment of whole-brain atrophy acceleration by group. 
Units are % of baseline whole brain volume per year. There were no significant inter-group differences 
in sex, age, CAG repeat length or inter-scan interval. 
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Despite the absence of evidence for an overall acceleration of atrophy in the premanifest group, 
there was a striking association between these subjects’ 5-year onset probability and acceleration of 
whole-brain atrophy, such that a 10% increase in onset probability predicted a 1.4% annual 
acceleration in atrophy (95% CI 1.1 to 1.7 Figure 45C; p<0.001). This suggests that significant 
acceleration of whole-brain atrophy occurs as manifest disease onset approaches. 
Across all gene carriers (Figure 45D), there was a positive association between annual acceleration 
of atrophy and CAG repeat length, after correction for age and sex, such that, on average, a single 
triplet increase was associated with a 0.4% annual acceleration in atrophy (p=0.001). 
Apart from onset probability in the premanifest group and CAG repeat length in all gene carriers, 
atrophy acceleration was not associated with other disease features (namely baseline disease 
duration, TFC or baseline motor score). 
VI.7 Discussion 
VI.7.1 Clinical change 
As expected, UHDRS motor, TFC and Beck depression inventory scores, analysed by generalised 
estimating equation analysis, declined significantly in early but not premanifest HD (Table 17). The 
rate of decline in motor scores in this cohort is slightly slower than that seen in other cohorts (e.g. 
The Huntington Study Group 1996), probably reflecting the early stage of the disease in these 
patients, as well as perhaps the availability of antichoreic medications which may affect the motor 
score. 
The addition of a second motor rater for some subjects at the two-year timepoint (because of 
integration of the study with TRACK-HD) has some interesting consequences. To an extent, the 
effect of inter-rater variability can be corrected for by using the motor rater as a covariate (as in 
Table 16). However, if the rates of progression are analysed excluding subjects assessed by the 
second rater, the values are rather different (3.9 points/year decline in early HD, as opposed to 2.8). 
This highlights a shortcoming of the generalised linear model: it can only model and correct for 
effects of nuisance variables where those effects are linear between groups and across timepoints. 
However it is likely that the effect of motor rater differed between groups (here, the second rater 
appears to give disproportionately lower scores in early HD) and between timepoints (the second 
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rater was only involved at the year two timepoint). The differential effect of motor rater is echoed 
by the findings for the analysis of linearity of UHDRS motor score (Table 17), where an unexpected 
finding appears to arise in the premanifest group: that UHDRS motor scores rose in the first year 
and fell in the second, with the difference between the two changes being statistically significant. 
However, once the analysis is limited to those subjects scored by the primary rater, the difference is 
non-significant, as it is when the whole cohort is examined with motor rater as a covariate.  That the 
UHDRS motor score varies considerably between raters is well known (The Huntington Study 
Group 1996) but these findings emphasise the crucial importance of consistency in motor rater, 
both cross-sectionally and longitudinally, for studies such as this, as well as the incomplete ability of 
statistical models to correct for differences between motor rater, even when these have been 
expected in advance, and training has been given to seek to minimise inter-rater variability. 
The rate of functional decline in this early HD cohort was rather slower than that previously 
reported: 0.59 units per year decline, compared with typical figures of around 1 unit per year in 
stages I and II (The Huntington Study Group 1996; Marder et al. 2000). There are two likely reasons 
for this. Firstly, the contexts of this study — with its MRI scanning and neuropsychological 
assessment in addition to clinical testing — is more intensive from previous, purely clinical studies; 
faster-progressing subjects may be less likely to volunteer for an intensive study such as this, and 
more likely to drop out after fewer than three assessments. Second, to an extent it likely reflects 
improvements in clinical care in the past decade, especially given the multidisciplinary HD clinic 
setting from which the early HD patients were mostly recruited. 
Interestingly, while advancing HD was associated with significant worsening in the BDI score, the 
early HD group did not differ significantly from controls in rate of change of BDI, because control 
subjects’ scores worsened significantly too, at a rate comparable to that seen in early HD. As most 
of our controls were partners or spouses of premanifest or manifest subjects, this likely reflects the 
growing psychosocial burden on them, and perhaps, in addition, the reduced availability of support 
for carers and partners compared with patients themselves. 
The short behavioural assessment could not be applied at all timepoints, but was available at 
baseline and one year. Rates of change of SBA were not significantly different from zero in any 
group over this interval, and did not differ significantly between groups. This is interesting, especially 
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given the suggestion (discussed in Chapter VII) that the SBA is better able to detect genuine disease-
related behavioural features when applied cross-sectionally. The lack of significant change over time 
is likely due to a combination of factors. First, the availability of effective treatments for behavioural 
features of HD, which may be able to stave off progression selectively in HD, but will tend to be 
less available to control subjects (even though the partners of HD patients tend to have a 
progressive behavioural phenotype, as attested by SBA scores). Second, the broader scope of the 
SBA means that, while it may be better able to capture the full range of behavioural deficits in HD, 
it is perhaps less likely to progress linearly when examined within or between groups, since it is 
likely to be more variable between subjects or within a given subject over time, as different 
behavioural problems emerge and recede. 
In contrast to whole-brain atrophy, there was no evidence of significant non-linearity in the key 
clinical measures over the two-year interval studied. This may reflect a true absence of linearity in 
the disease over this period. However, the apparent acceleration in atrophy in the early HD group, 
plus the association between atrophy acceleration and onset probability in the HD group, suggests 
that there may be an acceleration of underlying pathology that was not reflected in the clinical 
scores, highlighting the need for alternative measures. 
VI.7.2 Whole-brain atrophy 
Quantification of whole-brain atrophy over two years in this large cohort confirms that atrophy rate 
is significantly increased in early HD, to about 5 times the rate associated with normal aging. A 
significant increase in brain atrophy was not seen overall in this group of premanifest subjects but, 
given that they are relatively far from onset as a group (mean 17.6 years), this is not altogether 
surprising. 
This study also confirms a significant association between whole-brain atrophy rate and CAG repeat 
length across both premanifest and manifest mutation carriers. That this association is present after 
correction for age indicates that the increased atrophy rate is not simply due to the tendency of the 
disease to be more severe with aging for a given repeat length. The association is in keeping with 
our work using other analysis techniques and the imaging, clinical and neuropathological findings of 
others (Penney et al. 1997; Rosas et al. 2001; Kassubek et al. 2004; Ravina et al. 2008). These 
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findings may be of importance for subject stratification for clinical trials, where the effect of CAG 
repeat length needs to be considered in addition to stratification according to clinical disease stage. 
The rate of atrophy in early HD is consistent with our previous findings over shorter intervals 
(Henley et al. 2006), but in this longer study, the signal-to-noise ratio of the measure is considerably 
improved, probably because over longer time intervals, variability due to MRI acquisition or image 
analysis has relatively less impact on measured atrophy rates. This improvement in signal-to-noise 
ratio is highlighted by the calculated sample size requirements for clinical trials using atrophy rate as 
an outcome measure, which are about 35% lower over two years than one year, whether 
calculated using absolute rates or excess atrophy relative to controls. Dropout rates from cohort 
studies are unlikely to reach 35% over two years, indicating that a three-timepoint study over two 
years, allowing calculation of both atrophy rate and an assessment of atrophy acceleration, is 
practicable and may require fewer subjects at enrolment. 
Post-mortem studies have revealed 10-20% loss in brain mass by end stage in HD, (Forno et al. 
1979) equating to about 180ml for a typical brain. If the annual atrophy rate of 0.9% seen in early 
HD were sustained year-on-year, this volume of atrophy would be reached after about 17 years, 
roughly corresponding to the typical period of 15-20 years between onset and death (Roos et al. 
1993). On the face of a single-interval measurement, it is therefore tempting to suggest that atrophy 
rate proceeds linearly at a fixed annual percentage rate. However, our data suggest that such 
assumptions of linearity of whole-brain atrophy rate may not be valid. Within-subject comparisons of 
atrophy rates in this cohort suggest that atrophy does accelerate in early HD (by about 0.7% of 
brain volume each year, albeit with wide 95% confidence intervals, from 0.01% to 1.4%), while 
acceleration precedes onset in premanifest HD and is not seen in controls. The fact that the rate of 
atrophy in the manifest group is about five times higher than that seen in the premanifest group or 
controls, means that there must have been acceleration in the rate of atrophy. What is unclear is 
whether the rate of loss, once established, it is sustained at that rate through to the final stages of 
disease. 
These preliminary findings therefore merit further study in larger cohorts over multiple timepoints. 
Such studies are now underway, most notably in the form of TRACK-HD (TRACK-HD Steering 
Committee 2006-8). 
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Defining linearity of atrophy rate is not without difficulty: atrophy proceeding at the same number 
of millilitres each year would appear to accelerate if expressed as a percentage of brain volume, 
because atrophy reduces brain volume. There is no firm neuropathologic basis for deciding whether 
atrophy acceleration is best defined as an increase in absolute or relative atrophy rate. However, in 
this study, atrophy rates accelerated significantly, whether rates were expressed in terms of annual 
percentage loss or annual volume loss, suggesting that the whole-brain atrophy rate in early HD 
increases significantly year-on-year according to either definition of linearity. 
The absence of measurable acceleration in the premanifest group as a whole may again be 
explicable by the fact that the premanifest group is generally many years from predicted onset. 
However, the striking correlation between acceleration of atrophy and estimated 5-year onset 
probability in the premanifest group strongly suggests that atrophy acceleration is seen in the years 
before clinical diagnosis in HD.  Further work in larger premanifest cohorts with subjects closer to 
predicted motor onset is required to investigate whether year-on-year acceleration of whole-brain 
atrophy is a predictor of clinical onset. 
Linearity of whole-brain atrophy rate in HD has not previously been studied, but multi-interval 
longitudinal measurement of other brain structures has been carried out. Aylward and colleagues 
found that caudate volume was stable until 11 years prior to motor onset, then atrophy of the 
caudate proceeded linearly at 0.24cm3 per year in premanifest subjects, while putaminal volume 
was stable until 9 years before motor onset then volume loss occurred at 0.23cm3 per year 
(Aylward et al. 2004). In previous work, caudate atrophy rates in mild and moderate HD were 
determined to be 4.9% and 7.2% respectively, suggesting acceleration with progressing disease. 
However, because of the small volume of the caudate, these percentage changes corresponded to 
roughly equal absolute annual rates of atrophy of 0.16 cm3 and 0.18cm3 respectively (Aylward et al. 
2000). It is difficult to assess whether this represents a true acceleration of pathology, for the 
reasons of definition discussed above, and because cross-sectional comparison of single intervals 
between disease stages is a less reliable indicator of atrophy rate linearity than are serial observation 
of individuals over multiple intervals. Recent cross-sectional data from the large Predict study appear 
to confirm the findings of Aylward and colleagues (Paulsen et al. 2008). 
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In summary, quantification using the BBSI over two years confirms whole-brain atrophy rates to be 
increased in early HD with acceleration year-on-year, whereas the rate of atrophy is not increased 
overall in far-from-onset premanifest HD, but does accelerate as motor onset approaches. In HD 
mutation carriers, both rate and acceleration of atrophy tend to be greater at a given age for 
subjects with larger CAG repeat lengths. Study of whole-brain atrophy has the potential to inform 
our understanding of the neurobiology of HD and may provide one means of assessing the 
outcomes of future clinical trials of putative disease-modifying treatments. 
VI.8 Publications relating to this chapter 
A draft manuscript containing the work presented here is under preparation for submission. 
The one-year longitudinal data for this study have been published as: Henley SMD / Wild EJ et al. 
(2009) Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s 
disease. Movement Disorders, published online ahead of print. 
A discussion of the BBSI as a potential biomarker for HD is included in a review article by the 
author as: Wild EJ and Fox NC (2009) Serial volumetric MRI in Parkinsonian disorders. Movement 
Disorders, accepted for publication. 
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Chapter VII Clinical-neuroanatomical associations 
in early HD 
VII.1 Introduction 
HE PRIMARY FOCUS of the longitudinal imaging study was on atrophy measured summatively 
across the whole brain using the BBSI technique, with its accuracy, reproducibility and ability 
to capture the full extent of structural brain change, as a biomarker of progression in premanifest 
and early HD. But as has been alluded to, the study of biomarkers is at its core a study of natural 
history, since no measure that is not linked to pathogenesis can be considered a true biomarker, 
and the most useful biomarkers are likely to be those with the closest and best-understood links 
with the disease process. Outwardly, this is likely to be reflected by associations between biomarker 
levels and established clinical measures as discussed in chapter II.11.9. Lack of association between 
a potential biomarker and one or more established clinical measures is likely to undermine its 
potential utility. 
The assertion of Chapter VI that HD is a whole-brain disease has the corollary that all brain atrophy 
is fundamentally regional, and crucially, the BBSI technique is a quantitative one with no localising 
ability. BBSI-derived overlays such as those shown in Figure 42 can highlight the areas where the 
brain boundary has moved by the greatest amount, but the atrophy underlying these shifts may be 
structurally remote from the boundary (Freeborough et al. 1997). Nonetheless, it is of interest to ask 
which brain regions the atrophy measured by the BBSI is most pronounced, and what the clinical 
associations of such regional atrophy are.  Furthermore, the demonstration that extrastriatal areas 
undergo atrophy in HD is an insufficient argument for the adoption of whole-brain atrophy 
measures as biomarkers: it must be further demonstrated that such extrastriatal atrophy is of clinical 
relevance. Thus, study of regional as well as whole-brain atrophy is an important step in the 
evaluation of whole-brain atrophy measures as potential biomarkers. In addition, examining the 
clinical correlates of regional atrophy is of interest per se in enhancing our understanding of the 
neurobiological basis of HD. 
Voxel-based morphometry (VBM) is an unbiased, automated technique for analysing regional 
volume changes across the whole brain (Ashburner et al. 2000). Unlike region-of-interest 
approaches, it requires no a priori hypotheses about regionalisation. In a sense, VBM is somewhat 
T 
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analogous to the ‘omics’ techniques for laboratory biomarker discovery, in that it performs many 
comparisons on a macro-scale to drill down to specific foci of greatest disease-related difference. 
Like these techniques, VBM is not without its potential problems of interpretation, most notable 
among which are methods of accounting for multiple comparisons (its statistical parametric maps 
(SPMs) are essentially the outcome of thousands of pairwise t-tests, one for each voxel in the brain), 
variations in its technical implementation and concerns about a lack of standardisation in 
performing and reporting analyses (Bookstein 2001; Apostolova et al. 2007; Ridgway et al. 2008). 
Nonetheless, the technique and its reporting have improved over time and it has become a widely-
established and well-validated technique for studying disease-related changes in brain structure, 
albeit with the caveat that it is perhaps most appropriately used as a tool for generating hypotheses 
about regionalisation that can then be tested with a directly focused approach. 
As reviewed in chapter I.2.2, VBM has been applied to Huntington’s disease and, though findings 
have not been entirely consistent between studies, most studies have confirmed the presence of 
striatal atrophy (Thieben et al. 2002; Peinemann et al. 2005) with a general consensus that extra-
striatal areas also undergo atrophy in early HD (Kassubek et al. 2004; Douaud et al. 2006). 
In addition to groupwise contrasts, comparing regional brain volumes in, say, HD patients versus 
controls, VBM may be used to examine associations between regional atrophy and phenotypic 
measures, typically clinical scores. 
In one such study of the structural correlates of motor dysfunction in HD, a subgroup analysis of 
patients with mild and severe motor involvement revealed associations with volume in the striata, 
opercula and hypothalamus (Kassubek et al. 2004). In a more recent study, higher UHDRS motor 
score was shown to correlate with reduced grey-matter volume in both caudate nuclei, the right 
hippocampus, the calcarine fissure and the left cerebellum, with several regions also displaying 
decreased white-matter volume in association with motor score (Jech et al. 2007). In addition, 
cortical thickness measurement has revealed apparently extensive cortical involvement in early HD, 
while distinct motor phenotypes (bradykinetic and choreic) appear to be differentially associated 
with atrophy of different areas, with the more common hyperkinetic phenotype affecting both 
parietal, frontal (specifically the precentral gyri) and occipital regions (Rosas et al. 2008). 
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The regional morphometric associations of the behavioural / psychiatric phenotype of HD, in 
contrast, have not previously been reported. Such associations are of interest, however. Behavioural 
changes are highly complex, involving functions associated with a diversity of brain areas, so might 
be expected to be associated with extrastriatal pathology to a greater extent than motor features. 
Psychiatric disorders are among the aspects of HD most amenable to treatment, but predicting 
which patients will develop psychiatric dysfunction is challenging, and the identification of 
consistent structural correlates of such dysfunction could be of value in supporting clinical risk 
stratification. 
A cross-sectional VBM analysis of volumetric MRI data was therefore carried out on baseline MRI 
scans from the longitudinal imaging study cohort. This analysis aimed to examine associations 
between regional grey matter volume and clinical disease measures, focusing on motor and 
behavioural dysfunction, using strict correction for multiple comparisons across the whole brain. 
Cross-sectional whole-brain VBM analyses of raw regional volume differences between the subject 
groups in this cohort have been published elsewhere (Henley et al. 2008) and are therefore not 
discussed here. In addition, the use of the novel Short Behavioural Assessment (SBA) in parallel with 
the Beck depression inventory (BDI) in all subjects in the study enables a preliminary analysis of the 
degree of concordance of the newer behavioural measures in comparison with the more 
established tool. 
VII.2 Contributions and collaborations 
Subject recruitment and characterisation and MRI scanning were as for the work presented in the 
previous chapter. Image processing was carried out by Ms Susie Henley. All other work, including 
data analysis and interpretation and preparation of figures was carried out by the author. 
VII.3 Subjects and methods 
VII.3.1 Subjects 
The analysis included subjects from the baseline assessment of the longitudinal imaging study, 
whose MRI scans were of sufficient quality. This amounted to 81 subjects whose demographic 
characteristics were as shown in Table 15, page 175. 
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VII.3.2 Clinical assessments 
Motor features were assessed using the UHDRS motor score (chapter II.5.1, page 79 and Appendix 
D). The behavioural measures analysed were the Beck depression inventory (Appendix F) and the 
Short Behavioural Assessment (Appendix G). 
VII.3.3 MR imaging 
1.5 Tesla T1 volumetric MRI scans were acquired and preprocessed as described in chapter II.7.1, 
page 81. Images were processed using MATLAB 7.0 (The MathWorks, Inc, Natick, Massachusetts, 
USA) and SPM2 (Wellcome Department of Cognitive Neurology, ION, London).  VBM was 
performed following a modified version of the optimised method (Good et al. 2001). 
VII.3.4 Analysis of clinical scores 
Total scores for the SBA were calculated by summing the frequency and severity scores in each 
domain. Differences in clinical scores across groups were analysed using linear regression models as 
described in II.11.7, page 89, with age and gender as covariates. Initial comparison of the BDI and 
SBA assessments was performed by examining the correlation between them in a given subject; 
because the units of both scales are arbitrary, comparing the two measures against a line of unity is 
not meaningful, so a regression fit line was plotted. Since the strength of a correlation between two 
measures is not necessarily the best indicator of their ability to measure a given feature, a Bland-
Altmann analysis (Bland et al. 1986) was also performed: for each subject, the difference between 
the two measures was plotted on the vertical axis against the mean of the measures on the 
horizontal axis. Values for the bias (mean difference between the measures) and limits of agreement 
(mean ± two standard deviations of the difference) were calculated. 
VII.3.5 Image analysis 
Initial processing used a modified version of the script provided by Christian Gaser (Gaser 2008). 
Native space images were affine-registered using the standard SPM2 T1 template, and underwent 
initial segmentation.  Normalisation parameters were estimated for warping the resulting grey 
matter segments onto the SPM2 grey matter template.  These normalisation parameters were then 
used to warp the original native space images.  Normalised images were then segmented into grey 
matter, white matter and cerebrospinal fluid (CSF) and these segmentations were modulated using 
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the volume changes from the normalisation.  White matter and CSF segments were not used in any 
further analysis as the primarily focus was on grey matter changes.  
Preliminary work showed that normalising grey matter to a grey matter template resulted in better 
alignment of the grey matter segments compared with standard normalisation (judged visually and 
by looking at the ‘reverse contrast’, i.e. assessing where patients appear to have more grey matter 
than controls).  This was achieved with the standard SPM templates; using customised (study-
specific) templates for normalisation and segmentation did not produce any additional 
improvement.  Each grey matter segment then had spurious non-brain tissue removed according to 
a brain mask derived from the corresponding original image using MIDAS semi-automatic 
segmentation software (Freeborough et al. 1997).  Finally the images were smoothed using an 8mm 
full width half-maximum Gaussian kernel. 
VII.3.5.1 Analysis of grey matter volume associations  
A regression model, using age, gender and TIV as covariates, was used to examine associations 
between grey matter volume and the clinical variables of interest. The model used was of the form 
εμββββ +++++= TIVgenderagexVolume 4321  
where x is the clinical measure of interest, μ is a constant term and ε represents between-subject 
variability. The contrast of interest was β1<0, i.e. regions where there was a significant negative 
association between grey matter volume and x. 
An explicit mask was applied to SPMs to exclude any voxels for which more than 10% of the 
images had a value of less than 0.1.  This was preferred to the default ‘absolute’ mask option in 
SPM, which would exclude any voxels for which one or more images had a value of less than 0.1 
and thus perhaps be unduly influenced by a single poorly-registered scan.  All SPMs were 
thresholded using a false discovery rate (FDR) of q<0.05 to correct for multiple comparisons and 
displayed as overlays on a smoothed version of the MNI-152 T1 template.  In order to localise 
regions of atrophy, MNI coordinates were converted to Talairach space and localised to anatomical 
regions using a publicly available online atlas (International Neuroimaging Consortium 2008). 
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The associations examined were behavioural scores (BDI and SBA) across all gene carriers, and 
UHDRS motor score in the manifest HD group. 
VII.4 Results 
Demographic and clinical characteristics of subjects, and inter-group matching, were as shown in 
Table 15 (chapter VI.6.2, page 175). 
UHDRS motor score (Figure 46A) was significantly higher in the early HD group than both controls 
and premanifest subjects (p<0.001 for both) but did not differ significantly between controls and 
premanifest subjects (p=0.16). Despite a trend to increase, there were no significant differences 
between groups in BDI score (Figure 46B: controls v. premanifest, p=0.48; controls v. early HD, 
p=0.14; premanifest v. early HD, p=0.55). Total SBA scores (Figure 46C) were significantly higher in 
early HD than in controls (p=0.041) but the premanifest HD (p=0.20) did not differ significantly 
from controls (p=0.57) or early HD (p=0.20). 
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Figure 46 Clinical scores by group 
Graphs show group means while error bars represent standard deviation. A. UHDRS motor score. B. 
Beck depression inventory score. C. Short behavioural assessment score. *p<0.05, ***p<0.001 by 
linear regression. 
VII.4.1 Comparison of BDI and SBA 
Comparisons of each subject’s Beck depression inventory and short behavioural assessment score 
are given in Figure 47. The scatter plot (Figure 47A) reveals a moderate correlation (R=0.67); the 
 199 
Bland-Altmann plot (Figure 47B) did not reveal an obvious relation between the difference and the 
mean, indicating a lack of systematic magnitude-related bias; the mean bias was +2.0 (95% CI 0.7 to 
3.2) and the limits of agreement (mean ± two standard deviations) were -9.4 to 13.3. 
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Figure 47 Analysis of the agreement between Beck depression inventory and Short behavioural 
assessment scores 
A. Scatter plot of subjects’ SBA scores against Beck scores, with linear regression best-fit line. B. Bland-
Altmann plot, showing difference between the two scores (SBA - BDI) on the vertical axis against mean 
of the two scores on the horizontal axis. The grey region depicts the mean ± two standard deviations. 
VII.4.2 VBM analysis of clinical features 
In manifest HD subjects, there were significant associations between grey-matter volume and 
UHDRS motor score in both caudate nuclei. The largest area of association was in the right 
precentral gyrus, corresponding to the primary motor cortex (Figure 48). VBM analysis revealed no 
brain regions where score on either of the behavioural scales in all HD gene carriers was associated 
with grey-matter volume after correction for multiple comparisons (data not shown). 
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Figure 48 Statistical parametric maps (SPMs) showing regions where grey matter volume was 
negatively correlated with UHDRS motor score in early HD patients 
Significant associations are seen in both caudate nuclei and the right primary motor cortex (crosshair 
and arrows). The colour bar shows t-score. The SPM is thresholded using false discovery rate (FDR) 
correction for multiple comparisons with q<0.05. A, anterior; P, posterior; L, left; R, right. 
The finding that lower grey-matter volume in the right, but not left, primary motor cortex was 
associated with higher UHDRS motor score led to the development of a hypothesis that this 
asymmetry may be reflected in the clinical phenotype of manifest HD, the expectation being that 
left-sided motor signs may be more severe in a given patient. 
 201 
Left
Right-handers
Right
0
2
4
6
8
C
om
po
un
d 
m
ot
or
 s
co
re
Left
All subjects
Right Left
Left-handers
Right
A B C
 
Figure 49 Post-hoc analysis of asymmetry of motor signs in the early HD group 
A. All subjects. B. Right-handed subjects only. C. Left-handed subjects only. Graphs show mean 
compound upper limb motor score with standard deviation error bars. Two-tailed paired t-tests: NS, 
not significant; *p<0.05; **p<0.01. 
Accordingly, a post-hoc analysis was performed to test this hypothesis. Compound motor scores for 
the left and right upper limbs were constructed for each subject by adding the rigidity, pronate-
supinate, finger-tapping, dystonia and chorea scores for each limb, such that the maximum score 
per limb was 20 points. A paired two-tailed t-test was then used to test whether, within each 
subject, there was a significant difference in motor severity between the upper limbs. Scores for the 
left upper limb were significantly higher than those for the right (Figure 49A and Table 23; p=0.01). 
When the analysis was restricted to right-handed subjects (Figure 49B), the difference was more 
pronounced (p=0.002). In the four left-handers (Figure 49C), the trend was reversed, though the left-
right difference was not significant (p=0.22). In control subjects, there were no significant 
differences in motor score between left and right upper limbs in all subjects or right-handers only 
(p=0.33 for both). 
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Compound upper limb motor score, 
mean ± SD 
Early HD patient 
subgroup 
N 
Left Right 
Paired t-test, p 
All 40 4.53 ± 2.30 4.05 ± 2.33 0.01 
Right-handers 36 4.72 ± 2.24 4.11 ± 2.25 0.002 
Left-handers 4 2.75 ± 2.36 3.50 ± 3.32 0.22 
Table 23 Post-hoc analysis of asymmetry of motor signs in the early HD group 
To test whether this apparent effect of hand dominance, rather than left-right lateralisation per se, on 
asymmetry of motor signs was statistically significant, two scores were produced for each subject: a 
left-right difference score, calculated by subtracting the right from the left compound motor score; 
and a nondominant-dominant difference score, calculated by subtracting the compound motor 
score in the dominant limb from that in the nondominant limb. A paired t-test was then used to test 
whether these scores were significantly different, i.e. whether hand dominance has a greater effect 
on motor asymmetry than does pure left-right lateralisation. The mean difference was higher for the 
dominance score than the left-right score (0.63 ± 1.05 versus 0.48 ± 1.14 respectively) but the 
difference was not statistically significant (p=0.18). Comparing the difference scores between HD 
patients and controls, the patients displayed significantly more asymmetry than controls in the 
dominance score (p=0.038) but not the left-right score (p=0.16) 
VII.5 Discussion 
The analysis of cross-sectional motor abnormalities confirmed the expected findings in the three 
groups, showing a lack of significant difference in total UHDRS motor score between controls and 
premanifest HD, but with early HD subjects having significantly higher scores than the other two 
groups. This is in keeping with the definition of manifest HD and the findings of others in 
premanifest and early HD (Marder et al. 2000; Witjes-Ane et al. 2007). 
The parallel administration of the BDI and SBA allows a preliminary analysis of the degree of 
concordance of the two measures. For both measures, as expected, there was a trend for scores to 
increase, indicating more severe behavioural disturbance, from control to premanifest to early HD. 
For BDI, there were no significant differences in score between any groups, but for the SBA score 
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the early HD group had significantly higher scores than controls. This is likely to indicate that the 
SBA is better able to detect the broad spectrum of behavioural features in HD, whereas the BDI 
focuses only on the affective domain, and also has the potential to be confounded by physical 
manifestations of HD. Of course, it is possible that the significant difference in SBA in early HD is 
erroneous, and the BDI is giving a truer measure of behavioural dysfunction but this does not seem 
likely given that the SBA is derived from the larger, well-validated and HD-specific Problem 
Behaviours Assessment (Craufurd et al. 2001). 
Comparing the two measures directly is difficult for several reasons. Firstly, the scores on both 
scales are arbitrary and cannot be compared directly. Secondly, as alluded to above and in chapter 
II.11.9, in the absence of a ‘gold standard’, in a situation where the outcomes of an existing and a 
new measure are found to correlate, it is impossible to determine objectively whether any 
discrepancy between them means that the new measure is better or worse at evaluating the 
underlying disease: additional information about the nature of the tests and their ability to access 
known disease features is required. Moreover, as Bland and Altmann point out, examining the 
correlation between two such measures is unlikely to be informative alone unless the correlation is 
exceptionally poor, since any two measures of the same feature are likely to correlate well (Bland et 
al. 1986). The Bland-Altman plot (Figure 47) is a more informative means of comparing agreement 
between two tests, since it enables examination of the difference between the two scores over the 
range of (mean) scores, highlighting any tendency for systematic differences and showing the 
spread of differences more clearly than a scatter plot. Note that the absolute value of the difference 
is not meaningful for the comparison between BDI and SBA scores, since the values are arbitrary. 
Nonetheless it is encouraging that there is no obvious tendency for the difference between the 
scores to be influenced by their mean value. 
Overall, it seems reasonable to conclude from these data that the SBA is capable of capturing a 
disease-related signal of behavioural abnormality in early HD that was not detected by the BDI and 
that it does not appear to introduce any systematic bias into behavioural assessment over the range 
of behavioural phenotypes in this cohort. These conclusions are of course highly preliminary, but 
further study of the intra-and inter-rater reliability of the SBA and its ability to detect behavioural 
disturbance that is clinically important is warranted. 
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The VBM analysis of behavioural score in HD gene carriers highlighted no areas where behavioural 
dysfunction on either scale was significantly associated with regional grey-matter volume. The 
regional neuroanatomical correlates of behavioural dysfunction in HD have not previously been 
studied. Some attention has focused on the somewhat overlapping field of cognitive dysfunction: 
for instance, in a complementary VBM study based on this same longitudinal imaging cohort, 
Henley and colleagues found that poorer performance on tests of facial emotion recognition was 
associated with reduced volume in the striata for all emotions and, in addition, defective fear 
recognition was associated with additional atrophy of the right insula and both lateral orbitofrontal 
cortices, implying that atrophy of both generic and localised regions may underlie the emotion 
recognition deficits in HD (Henley et al. 2008) In contrast to both specific neuropsychological 
functions and motor impairment, however, psychiatric and behavioural features are such complex 
and integrated phenomena that association with specific brain regions seems unlikely. Nevertheless, 
some authors have asserted that involvement of frontal-subcortical circuits is likely to be a main 
contributor to behavioural disturbance in HD (Bonelli et al. 2007), with some support from 
functional studies showing that deficits of functional connectivity show associations with measures 
of behavioural dysfunction in the basal ganglia (Wolf et al. 2008). 
In this context, there are three possible interpretations for the lack of significant associations of 
regional atrophy. The first possible explanation is that there is a true, single regional basis to the 
behavioural dysfunction of HD that was missed by this analysis, perhaps through a lack of statistical 
power. The second is that different structural deficits may underlie different forms of behavioural 
dysfunction in HD (by analogy to the differential structural associates of facial fear recognition), but 
that the population under study, and their behavioural deficits, were too heterogeneous to allow a 
subgroup analysis of individual behavioural deficits. The final possibility is that the behavioural 
dysfunction is caused by deficits in neural networks too disseminated to produce specific regional 
volume changes detectable by such a whole-brain analysis. A priori, it is likely that each of these 
possible explanations contributes to the lack of regional signal in this analysis: subcortical-frontal 
networks, which are known to be dysfunctional in HD, probably do contribute a significant 
component to behavioural problems but, because of the heterogeneity of behavioural dysfunction, 
atrophy in these specific areas may not correlate closely with specific measures of behavioural 
performance; finally there may be more widespread cortical networks whose dysfunction (or 
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atrophy) may superimpose significant additional burdens on behaviour. Because of a lack of 
regional associations with either behavioural scale in total, it was not felt appropriate to examine for 
associations with different subscales. Overall, the negative outcome from this analysis suggests the 
identification of neuroanatomical substrates of behavioural dysfunction in HD is likely to require 
further study in much larger patient cohorts. 
In the analysis of motor function, higher UHDRS motor scores were associated with lower grey 
matter volumes in both caudate nuclei and the right precentral gyrus. Bilateral caudate involvement 
has been a consistent finding from previous VBM studies of motor associations but the extrastriatal 
associations have been difficult to synthesise between studies, partly because of their significant 
methodological differences. The precentral gyrus has not previously been implicated in a VBM 
analysis of motor features of HD, and previous work has generally highlighted regions such as the 
hippocampi and hypothalamus, which have little direct connection with motor function, above 
areas with plausible motor roles such as the cerebellum (Kassubek et al. 2004; Jech et al. 2007). The 
related morphometric technique of cortical thickness measurement is perhaps a more statistically 
powerful way of examining cortical involvement and suggests that, with the exception of the 
temporal lobes, widespread cortical atrophy contributes to the motor phenotype in HD, without 
highlighting either precentral gyrus as being differentially affected. Neuropathological studies do 
little to clarify matters: the prefrontal cortex has consistently been shown to display more severe 
neuropathological abnormalities than the motor cortex (e.g. van Roon-Mom et al. 2006), though of 
course neuropathology and relative functional impairment need not be strongly associated. 
Nonetheless, the present VBM study used conservative analysis techniques with robust whole-brain 
compensation for multiple comparisons, so its findings may be considered to reflect genuine 
structural associations with motor impairment, after correction for the effects of age, and do suggest 
that disease-related atrophy of this critical motor region may contribute directly to the motor 
phenotype of HD. As the site of the primary motor cortex, with its critical role in the execution of 
voluntary movements, the finding of significant association here between atrophy and motor 
dysfunction is of interest. Moreover the existence of direct glutamatergic excitatory projections from 
the primary motor cortex to the striatum (Albin et al. 1989) raises the possibility that degeneration in 
the two regions identified by this VBM analysis may be linked, perhaps by glutamatergic 
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excitotoxicity which has been proposed as a major contributor to cell dysfunction and death in the 
striatum (Estrada Sanchez et al. 2008). 
The asymmetry of the cortical findings in this analysis is of interest as well: atrophy of the left, but 
not the right precentral gyrus (governing movement of the right side of the body) was associated 
with motor impairment. While this study was not powered for a direct comparison of left versus 
right asymmetry in grey-matter volume, this would be an interesting analysis for future work. 
Previous studies have identified asymmetries in neuroimaging abnormalities in HD. A recent 
morphometric study of the basal ganglia found significantly more atrophy on the left (Muhlau et al. 
2007) and proposed that this was due to an increased lifetime’s use of the dominant hemisphere 
leading to increased excitotoxicity; while an MR spectroscopy study revealed elevated lactate levels 
that were markedly higher on the left (Jenkins et al. 1998). In the present analysis, it was the right-
sided cortex that displayed an association with motor score which is in contrast to the previous left-
sided findings of others in the basal ganglia. While Muhlau and colleagues showed that that the 
degree of asymmetry in the basal ganglia correlated with the total UHDRS motor score, no study 
has attempted to investigate whether asymmetry of atrophy is matched by a corresponding 
asymmetry in motor function. 
The post-hoc analysis of the hypothesis (based on the VBM results) that left-sided upper limb motor 
function would be more impaired than that on the right revealed that in the early HD group, left-
sided compound motor scores were significantly worse than those on the right, when compared 
within each subject. This difference remained significant when confined to right-handed subjects 
only, and in left-handed subjects the trend was reversed but the difference was not significant, 
probably because there were only four such subjects. Nonetheless, this initial analysis confirms that 
the lateralisation of atrophy-motor associations changes was reflected by an asymmetry of the 
motor phenotype. It also raises the suggestion that the non-dominant limb, rather than the left limb 
per se, may be differentially affected in early HD, though this was not significant when the two 
differences were compared directly. 
It could be argued that all functions will be less well-performed with the non-dominant limb, and 
that the difference in the HD group is not HD-related. However, in control subjects, there were no 
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significant asymmetries in motor score and when the difference in motor score between the 
dominant and nondominant limbs for each subject was compared between subject groups, the 
early HD patients displayed a significantly greater degree of asymmetry than did controls. Overall, 
therefore, based on the post-hoc asymmetry analysis of upper limb motor function in this cohort, it 
can be concluded that the VBM findings of left-sided primary motor cortex asymmetry across the 
cohort correspond to an underlying tendency for the nondominant limb to have significantly worse 
motor function in a given HD patient. 
On the face of it, these findings may seem incompatible with the previous left-sided (i.e. dominant 
hemisphere) structural and MRS findings of others. However, one possible explanation is a 
dissociation between upper limb motor function and striatal pathology, such that motor cortical 
atrophy is leftward-biased, corresponding to worse right-sided limb dysfunction, while striatal 
pathology may be rightward-biased but does not cause limb motor asymmetry. This does not imply, 
of course, that the striatum does not contribute to motor dysfunction but that the motor cortex may 
be a greater contributor to limb asymmetry than is the striatum. 
In addition, this VBM analysis and that of its motor correlates affirms the importance of extrastriatal 
atrophy in the clinical manifestations of HD, arguing in favour of further investigation of the regional 
correlates of clinical dysfunction as well as the clinical necessity for the inclusion of atrophy 
measures incorporating all brain regions in the repertoire of potential biomarkers for progression in 
HD. 
VII.6 Publications relating to this chapter 
The work presented here is under preparation for submission. VBM analyses of these baseline data 
for the cohort, focusing on genetic and psychological measures, have been published as: 
• Henley SMD, Wild EJ et al. (2008) Defective emotion recognition in early HD is 
neuropsychologically and anatomically generic. Neuropsychologia 46(8): 2152-2160. 
• Henley SMD, Wild EJ et al. (2009) Relationship between CAG repeat length and brain 
volume in premanifest and early Huntington’s disease. Journal of Neurology In press. 
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Chapter VIII  Conclusions and future work arising 
from this thesis 
VIII.1 The need for biomarkers 
N DESCRIBING THE clinical features of Huntington’s disease, the introductory chapter of this thesis 
set out the pressing need for treatments that will slow its progression, and indicated how such 
treatments, if offered judiciously to the premanifest gene carriers most likely to benefit from them, 
could ultimately lead to a cure for HD. The introduction went on to argue that because of the 
disease’s relative rarity, slow progression, long premanifest phase and clinical heterogeneity, the 
shortcomings of our clinical assessment tools, and the large number of competing potential 
therapeutic approaches, a conventional approach to the establishment of disease-modifying 
therapies is likely to be inadequate, and biomarkers that may be able to enhance the speed, 
efficiency, economy and robustness of clinical trials will be needed. In the remainder of the chapter, 
the literature on imaging, biofluid and quantitative clinical biomarker candidates to date was 
reviewed, laying the foundation for the subsequent chapters. 
VIII.2 Immune activation and plasma biomarkers 
The work presented in chapters III and IV, taken together, describes the identification and 
elucidation of a novel pathogenic pathway in HD. This work began as a proteomic discovery 
project without specific a priori hypotheses beyond the proposal that there may be significant, 
disease-related differences in protein expression between HD and control plasma detectable by 
careful proteomic profiling, and the principle, set out in Chapter I, that a plausible mechanistic 
connection with the pathogenesis of a disease is a sine qua non for the establishment of biomarker 
candidates. The study identified eighteen proteins with significantly differential disease-related 
expression. Three of these candidate proteins were further studied for their ability to behave as 
biomarkers and the most promising, clusterin, was shown to behave in human plasma and CSF to 
track with disease severity in HD. 
The specific proteins most easily identified by whole-proteome discovery techniques may not be 
those best suited for use as possible biomarkers, because of the incomplete coverage of the 
proteome that any such technique can offer. However, when viewed together, such findings can 
I 
 209 
offer an overall impression of the nature of the plasma protein profile of HD. Strikingly, almost all of 
the proteins identified as having altered expression were components of the innate immune system 
and acute phase response, raising the possibility of a widespread and progressive inflammatory 
derangement in HD. The study of this possibility formed the basis for the ensuing work, with a focus 
maintained on the possible utility of inflammatory changes as possible biomarkers. Using an ELISA 
technique, levels of IL-6 were shown to increase significantly with advancing HD and were shown 
to be elevated by 12 weeks in the R6/2 mouse. IL-6 is a key pro-inflammatory cytokine whose 
regulation is governed by the NFκB pathway, which has previously been implicated in the cellular 
pathobiology of HD (Khoshnan et al. 2004). The work presented in Chapter IV demonstrates that 
cytokines and chemokines are dysregulated in HD and that a direct effect of mutant huntingtin, 
acting within the myeloid cell, is sufficient to explain this immune activation, which was also seen in 
three different HD mouse models. The elevation of IL-6 levels in plasma from premanifest HD 
subjects suggests that it may be a very early event related to neuronal dysfunction in HD. 
The exploration of inflammatory molecules such as cytokines as possible biomarkers must be 
treated as preliminary data only, and its findings interpreted with caution, as it is based on samples 
derived from a single population, studied cross-sectionally only. However, these initial findings do 
appear promising. Several cytokines and chemokines tested appear to track with disease stage and 
clinical severity. The early elevation of IL-6 levels suggests a possible use for IL-6 as a cross-sectional 
state biomarker of the kind represented in Figure 10A-B: a therapy aimed at reducing expression of 
mutant huntingtin or modulating the NFκB pathway could be monitored for intracellular effect by 
studying whether treatment was associated with a return of IL-6 levels towards those seen in the 
control population. Meanwhile, the stepwise logistic regression and ROC curve analyses presented 
suggest a means for identifying and comparing combinations of biomarkers, both within and 
between modalities, and suggests that doing so is likely to result in combinations with greater ability 
to detect clinically significant differences than single markers. 
Three key aspects of this novel pathogenic pathway require further study: further characterisation of 
the pathway; inflammatory biomarkers; and its therapeutic potential. 
First, though the present work demonstrates that mutant huntingtin causes hyperactivity of myeloid 
cells, and the work of Khoshnan and colleagues suggests that the NFκB pathway may be a possible 
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means by which such dysfunction is mediated, the exact link between the mutant protein and the 
functional overactivity of monocytes requires systematic investigation. A followup project is already 
underway to investigate whether the stimulation of monocytes from HD gene carriers results in 
increased nuclear entry of NFκB. Meanwhile, the IκB kinase / NFκB signalling pathway is not the 
only means by which IL-6 release is triggered in myeloid cells: the JAK/STAT pathway is a capable of 
producing independent cytokine production, but is also linked to the NFκB pathway via SOCS 
protein regulation. Work is underway using novel fluorescent flow cytometry techniques in HD 
monocytes to determine whether components of the JAK/STAT pathway are dysregulated in HD. 
Second, before inflammatory molecules can be used as biomarkers, greater knowledge is required 
of how they behave in HD. Significant insight can be gained from full dissection of the pathogenic 
pathways involved, as described above. Specific studies to evaluate the feasibility of inflammatory 
markers will also be required. The present work deals only with cross-sectional changes, but 
longitudinal evaluation of biomarker candidates is required. The changes seen in cytokine levels are 
small — only one- or two-fold differences in level between clinical disease stages it would usually 
take an individual HD patient several years to progress to. Longitudinal study is required to establish 
the intra-subject variability and whether each subject’s cytokine profile tends to increase linearly 
with progression and, if so, over what interval such changes may be detected and with what clinical 
changes they correspond. Work is underway to amass a suitably large collection of plasma samples 
obtained longitudinally from well-characterised subjects, and analyse them using the multiplex ELISA 
platform according to the principles set out in Chapter II.11.13. In addition, validation of the present 
cross-sectional findings from one or more independent populations is required, to ensure that the 
findings presented are not partially or wholly artifactual, due to such factors as genetics, diet, 
environmental exposure, or medications. 
Both of these aims are best achieved in the context of large, multi-centre biomarker studies of the 
kind that are already in progress. One such study, TRACK-HD, has been designed with the 
evaluation of plasma biomarker candidates specifically in mind, and incorporates rigorously 
standardised plasma collection, processing and storage requirements to yield high quality and highly 
consistent plasma samples from four sites internationally, both cross-sectionally and longitudinally.  
Furthermore, the multimodal phenotypic assessment of subjects, with clinical, imaging and 
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quantitative motor evaluation, will greatly enhance our ability to evaluate inflammatory markers, 
both alone and in combination with other markers from both plasma and other assessment 
modalities. 
Third, but perhaps most importantly, if excessive inflammation is present both centrally and 
peripherally in HD, and is due to myeloid cell overactivity in the presence of mutant huntingtin, it is 
likely overall to be more harmful than beneficial, and the possibility of therapeutic interventions to 
suppress such inflammation warrants further study. Pharmacological anti-inflammatory treatments 
are already widely available and licensed for use in humans. Such treatments could be tested 
relatively easy in mouse models of HD; however, they are generally rather non-specific inhibitors of 
the activity of immune cells, typically lymphocytes. An innovative approach would be to examine 
the effect of bone marrow transplantation in HD animals, to see whether the replacement of mHtt-
expressing monocytes and microglia with wild-type cells can result in an immune response centrally 
and peripherally that is more conducive to neuronal survival. The permanence and transferability to 
humans of such an approach is highly appealing and preparations for such work are underway. 
Finally, from Chapter V it is apparent that plasma levels of neurofilament heavy chain protein are 
not biomarkers for HD. However, the study of neurofilament protein in CSF and brain remains of 
interest. 
VIII.3 Global and regional brain atrophy 
Chapter VI described the use of volumetric MR imaging techniques to measure whole-brain atrophy 
rate, and assess acceleration of atrophy, over two years in premanifest and early HD. In premanifest 
subjects far from onset, whole-brain atrophy rates do not appear to be significantly elevated, but 
from the cohort studied it cannot be concluded whether this is the case closer to onset. Rates of 
atrophy in early HD are significantly elevated, with atrophy occurring around five times higher than 
in control subjects. 
What are the implications of these findings for the potential utility of whole-brain atrophy as a 
biomarker? First, because of the a priori advantages of whole-brain imaging over caudate volumetry 
— namely its ability to capture all clinically relevant brain atrophy, and the higher reproducibility of 
quantifying change in the whole brain, with its well-defined anatomical boundary — the finding of a 
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statistically significant increase in any subject group suggests that it will be valuable to apply the 
technique to future therapeutic trials involving subjects in that group. Measurement of caudate 
atrophy alone may be more sensitive to change in premanifest subjects, but further study of whole-
brain atrophy using the BBSI is warranted to determine whether the technique is capable of 
measuring significant change in those subjects closer to disease onset, and whether atrophy rate 
ultimately predicts motor onset or other clinical features. 
Acceleration of atrophy, meanwhile, is seen in early HD and appears to be associated with 
proximity to onset in premanifest subjects. These preliminary findings are based only on a small 
subset of subjects with two one-year image registrations, and therefore require study in larger 
populations. 
Chapter VII presented a cross-sectional VBM study of the volumetric MR scan data from the cohort 
presented in the preceding chapter, adding information about regional atrophy to the whole-brain 
atrophy findings. Significant change in UHDRS motor score was significantly associated with 
atrophy in both caudate nuclei and the right precentral gyrus, and a post hoc analysis of 
lateralisation of motor signs confirmed a tendency for left-sided signs to be worse, in keeping with 
the pattern of atrophy. In contrast, there were no regions where behavioural scores were associated 
with atrophy rate, likely because of a lack of statistical power, the more distributed neural basis for 
behavioural symptoms, and the heterogeneity of such features in HD. This work argues that 
regional, as well as whole-brain approaches to volumetric imaging are likely to be of value in future 
observational and interventional studies in HD. Further, it suggests that a region-of interest approach 
to the study of motor features in HD, and indeed therapies expected to alter the motor phenotype, 
would be wise to focus on the basal ganglia and non-dominant motor cortical areas. Finally, if a 
regional basis for behavioural change exists and is capable of detection, very large cohorts of 
subjects are likely to be needed to unveil it. 
VIII.4 Future directions 
The search for biomarkers for HD has gained momentum in the past few years as we prepare for 
future disease-modifying therapeutic trials, and the vast amount of progress that has been made 
since then in the molecular neurosciences, combined with recent advances in neuroimaging, 
‘omics’ discovery technologies and quantitative motor assessment, has fuelled a recent flood of 
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promising biomarker candidates. The challenges now faced include eliminating less useful 
candidates as well as identifying further candidates. 
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Figure 50 Pipeline for the establishment of biomarkers for HD as surrogate endpoints for clinical 
trials of disease-modifying therapies 
The pipeline presented in Figure 50 highlights the series of steps required for a potential marker to 
become an approved surrogate endpoint in a clinical trial of a putative disease-modifying therapy. 
Most of the findings discussed in the previous section are small cross-sectional or longitudinal 
studies. To date, few studies have evaluated multiple biomarker candidates under the same 
conditions, particularly in a longitudinal design. Differences in study design such as followup 
interval, sample preparation techniques, scan parameters, acquisition of clinical data and techniques 
for analysing and presenting data between studies make direct comparison of the relative ability of 
each marker to measure and predict the disease process impossible. Head-to-head comparison of 
candidate markers within and between modalities is now essential. 
Unlike much of the work that has been performed to date, such direct comparisons require large 
sample sizes necessitating multi-centre projects, carefully standardised study design and monitoring, 
and multivariate statistical analysis. The infrastructure for such studies is already in place and several 
large longitudinal studies are ongoing. Each of these studies employs a large number of sites each 
carrying out a core of standardised assessments. The TRACK-HD study aims to act as an interface 
between small-scale biomarker discovery projects and these large-scale longitudinal trials, by 
comparing a large number of novel measures head-to-head in a few closely regulated centres. The 
most promising markers will then be carried forward into the more widely distributed longitudinal 
studies (TRACK-HD Steering Committee 2006-8). 
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It is to be anticipated that the first biomarker-powered multi-centre trials of disease-modifying 
treatments expected to delay onset in HD will begin within the next decade. The impressive results 
of candidate biomarker discovery to date must now be matched by rigorous mechanistic evaluation 
and systematic head-to-head comparison of biomarkers to maximise readiness for these trials. The 
author hopes that the work presented in this thesis may contribute in some small way to this 
pathway, as the global community of HD researchers inches towards the identification and 
adoption of successful disease-slowing treatments and towards the ultimate aim of all HD research: 
the cure. 
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Appendices 
Appendix A Demographic questionnaire 
1. Status (Control, premanifest, HD) 
2. Control status (partner/spouse, non-gene carrier) 
3. Date of birth 
4. Gender 
5. Ethnicity: 
− Asian or Asian British 
− Bangladeshi 
− Indian 
− Pakistani 
− Other 
− Black or Black British 
− Black African 
− Black Caribbean 
− Black other 
− Chinese  
− White 
− White British 
− White Irish 
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− White other 
− Mixed 
− White/Asian 
− White/black African 
− White/black Caribbean 
− Other 
− Other 
6. Handedness (left, right, mixed) 
7. Education level (None, CSE, O-level/GCSE, A-level, Technical diploma, University 
Entrance Diploma, College, Professional school degree, University degree, Higher 
degree, Other degree) 
8. Years in education 
9. Occupation 
10. Occupation grade (Higher managerial/professional, Lower 
managerial/professional, Intermediate, Small employers, Self-employed, Lower 
supervisory/technical, Semi-routine, Routine, Never worked, Long-term 
unemployed, Medically retired) 
11. Marital status (Single, partnership, married, divorced, widowed) 
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Appendix B Medical history questionnaire 
1. Height (m) 
2. Weight (kg) 
3. History of birth or neonatal illness 
4. History of childhood illness (<12 years) 
5. History of adolescent illness (13-17 years) 
6. History of adult illness 
7. Major surgery 
8. Units of alcohol per week 
9. History of alcohol abuse (>21 units/week for males, >14 units for females: current, 
previous, never) 
10. History of recreational drug use (current, previous, never) 
11. Tobacco use (current, previous, never) 
12. Cigarettes per day equivalent 
13. Years of smoking 
14. Date gave up smoking 
15. Allergies 
16. Current medications (name, dose, indication, duration) 
17. Current comorbid conditions 
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Appendix C Huntington’s disease history questionnaire 
1. Affected parent (mother, father, both, unknown) 
2. Estimated parental age of motor onset 
3. Affected parent’s current age or age at death 
4. Patient’s age at onset according to patient 
5. Patient’s age at onset according to family members 
6. Patient’s age at onset according to rater 
7. Age at genetic test 
8. First manifestation according to patient (None, Motor, Cognitive, Psychiatric, 
Oculomotor, Other, Mixed) 
9. First manifestation according to family members (None, Motor, Cognitive, 
Psychiatric, Oculomotor, Other, Mixed) 
10. First manifestation according to rater (None, Motor, Cognitive, Psychiatric, 
Oculomotor, Other, Mixed) 
11. Small CAG repeat length 
12. Large CAG repeat length 
13. Analysing laboratory 
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Appendix D UHDRS motor scale 
Motor scale 
Item Instruction Score Subsections 
Gait Observe the participant walking 
approximately 9 meters (10 yards) as 
briskly as they can, then turning and 
returning to the starting point. 
 0 normal gait, narrow 
base 
 1 wide base and / or 
slow 
 2 wide base and walks 
with difficulty 
 3 walks only with 
assistance 
 4 cannot attempt 
Single score 
Tandem gait The participant is requested to walk ten 
steps in a straight line with the foot 
placed (accurately but not quickly) such 
that the heel touches the toe of the other 
foot. Deviations from a straight line are 
counted. 
 0 normal for 10 steps 
 1 1 to 3 deviations 
from straight line 
 2 More than 3 
deviations 
 3 cannot complete 
 4 cannot attempt 
Single score 
Retropulsion 
test 
The participant’s response to a sudden 
posterior displacement produced by a 
pull on the shoulder while the participant 
is standing with eyes open and feet 
slightly apart is assessed. The shoulder 
pull test must be done with a quick firm 
tug after warning the subject. The 
participant should be relaxed with feet 
apart and should not be leaning forward. 
If the examiner feels pressure against 
his/her hands when placed on the 
participant’s shoulders, the examiner 
should instruct the participant to stand up 
straight and not lean forward. The 
examiner should instruct the participant 
to take a step backward to avoid falling. 
Examiners must catch subjects who begin 
to fall. 
 0 normal 
 1 recovers 
spontaneously 
 2 would fall if not 
caught 
 3 tends to fall 
spontaneously 
 4 cannot stand 
Single score 
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Item Instruction Score Subsections 
Tongue 
protrusion 
Ask participant to open their mouth wide 
while you inspect it using a torch. Then 
ask participant to protrude their tongue 
well beyond their front teeth while 
keeping their mouth wide open and to 
keep it out as long as it takes you (as the 
examiner) to count aloud from 1 to 10. 
Participants should be made aware that 
they are not allowed to prevent their 
tongue from slipping back into the mouth 
by biting on it. 
0 can hold tongue fully 
protruded for 10 sec 
1 cannot keep fully 
protruded for 10 sec 
2 cannot keep fully 
protruded for 5 sec 
3 cannot fully protrude 
tongue 
4 cannot protrude 
tongue beyond lips 
Single score 
Ocular 
pursuit 
Should be assessed over a range of 
approximately 20° with a slowly moving 
target taking about 2 seconds to move 
from one shoulder to the other. 
0 complete (normal) 
1 jerky movement 
2 interrupted pursuits / 
full range 
3 incomplete range 
4 cannot pursue 
Horizontal 
and vertical 
Saccade 
initiation 
Should be tested over a 20° range, as for 
ocular pursuits. Saccade movement 
should be elicited by a sound (snapping 
fingers) or movement (wiggle fingers), 
but not by a verbal command to look to 
the right or left. If any head movements 
are made, subject should be prompted to 
keep head still. 
0 normal 
1 increased latency 
only 
2 suppressible blinks or 
head movements to 
initiate 
3 unsuppressible head 
movements 
Horizontal 
and vertical 
Saccade 
velocity 
Should be tested at a larger range of 
approximately 30° so as to be able to 
detect incomplete range. 
0 normal 
1 mild slowing 
2 moderate slowing 
3 severely slow, full 
range 
4 incomplete range 
Horizontal 
and vertical 
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Item Instruction Score Subsections 
Rigidity Rigidity is judged on passive movement 
of the arms with the participant relaxed in 
the sitting position. 
0 absent 
1 slight or present only 
with activation 
2 mild to moderate 
3 severe, full range of 
motion 
4 severe with limited 
range 
L and R 
Finger taps Participant taps thumb with index finger 
in rapid succession with widest amplitude 
possible, each hand separately. Count the 
full-size taps made over 5 seconds. 
0 normal (≥15 in 5 
sec.) 
1 mild slowing, 
reduction in 
amplitude (11-14 in 
5 sec.) 
2 moderately impaired 
(7-10 in 5 sec.) 
3 severely impaired (3-
6 in 5 sec.) 
4 can barely perform 
task (0-2 in 5 sec.) 
L and R 
Pronate/ 
supinate 
Requires the participant to alternately hit 
the palmar and dorsal surface of one 
hand against the palm of the opposite 
hand. Use the palm of the opposite hand 
as a target. The participant should do this 
task as quickly as possible over a five-
second interval. The task is graded 
according to the degree of slowing and 
irregularity. 
0 normal 
1 mild slowing and / or 
irregular 
2 moderate slowing 
and irregular 
3 severe slowing and 
irregular 
4 cannot perform 
L and R 
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Item Instruction Score Subsections 
Luria Fist-hand-palm sequencing - Say ‘Can you 
do this?’ Examiner puts hand into fist on 
flat surface and sequences as follows: fist, 
side, flat (do not repeat this out loud). 
Watch to make sure that participant can 
mimic each step. When participant is 
able to join you then say ‘Very good, 
now keep going, I am going to stop. Rest 
hand and start timing participant’s 
sequences. A sequence is considered 
correct only if it is unaided by examiner 
and in the correct order. If participant is 
unable to complete any sequences over 
a 10-second period, then continue as 
follows. Say ‘Now lets try it again. Put 
your hands like this. FIST; SIDE; FLAT’. 
Watch to make sure the participant can 
mimic each step. Using the verbal labels, 
begin the sequences again and ask the 
participant to ‘Do as I do, Fist, Side, Flat’ 
(repeat this as you continue). Continue to 
perform Luria 3-step. When participant is 
able to join you say ‘Very good, now 
keep going, I am going to stop’. Rest 
hand and start timing participant’s 
sequences. A sequence is considered 
correct if it is unaided by examiner model 
and in the correct order. Count 
completed sequences and score as 
above. 
0 ≥4 in 10 sec, no cue 
1 <4 in 10 sec, no cue 
2 ≥4 in 10 sec with 
cues 
3 <4 in 10 sec with 
cues 
4 cannot perform 
Dominant 
hand only 
Bradykinesia Observe the participant during 
spontaneous motion such as walking, 
sitting down, arising from a chair, and 
executing the tasks required during the 
examination. This rating reflects the 
examiner’s overall impression of 
bradykinesia. 
0 normal 
1 minimally slow 
(?normal) 
2 mildly but clearly 
slow 
3 moderately slow, 
some hesitation 
4 markedly slow, long 
delays in initiation 
Single score 
Maximal 
dystonia 
Maximal dystonia is defined here as a 
tendency toward a posture, posturing 
along an axis. Observe the participant 
during the examination; i.e., no particular 
manoeuvres are required to elicit these 
features. Maximal dystonia are typically 
observed during demanding motor tasks 
such as tandem gait. When rating 
dystonia facial dystonia (blepharospasm, 
jaw opening and closing) should be 
included in your assessment of the 
truncal region. 
0 absent 
1 slight / intermittent 
2 mild / common or 
moderate / 
intermittent 
3 moderate / common 
4 marked / prolonged 
Trunk, 
R upper limb, 
L upper limb, 
R lower limb, 
L lower limb 
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Item Instruction Score Subsections 
Maximal 
chorea 
Maximal chorea is defined here as 
movement, not posture. Observe the 
participant during the examination; i.e., 
no particular manoeuvres are required to 
elicit these features. Maximal chorea is 
typically observed during demanding 
motor tasks such as tandem gait. 
0 absent 
1 slight / intermittent 
2 mild / common or 
moderate / 
intermittent 
3 moderate / common 
4 marked / prolonged 
Face, 
Buccal-oral-
lingual, 
Trunk, 
R upper limb, 
L upper limb, 
R lower limb, 
L lower limb 
Dysarthria Observe speech throughout encounter 0 normal 
1 unclear, no need to 
repeat 
2 must repeat to be 
understood 
3 mostly 
incomprehensible 
4 anarthria 
Single score 
 
Diagnostic confidence score 
Description Score 
Normal (no abnormalities) 0 
Non-specific motor abnormalities (less than 50 % confidence) 1 
Motor abnormalities that may be signs of HD (50 - 89 % confidence) 2 
Motor abnormalities that are likely signs of HD (90 - 98 % confidence) 3 
Motor abnormalities that are unequivocal signs of HD (≥ 99 % confidence) 4 
 
(The Huntington Study Group 1996; Euro-HD Network REGISTRY Steering Committee 2003-8) 
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Appendix E UHDRS functional scales 
(The Huntington Study Group 1996; Euro-HD Network REGISTRY Steering Committee 2003-8) 
Total functional capacity (TFC) 
Occupation 
0 = unable, 1 = marginal work only, 2 = reduced capacity for usual job, 3 = normal 
The participant’s capacity to engage satisfactorily in gainful or voluntary works is assessed regardless 
of whether or not the participant is actually working. Normal refers to gainful employment, actual or 
potential, with usual work expectations. Reduced capacity refers to full or part-time gainful 
employment with lower than usual work expectations (relative to the participant’s training and 
education), but with satisfactory performance. Marginal refers to a capacity only for part-time 
employment, actual or potential with low work expectations. Unable refers to a participant who 
would be unable to carry out these tasks, even with considerable assistance and supervision. 
Finances 
0 = unable, 1 = major assistance, 2 = slight assistance, 3 = normal 
Assessed by surveying the participant’s involvement in personal and family finances including 
balancing a chequebook, paying bills, budgeting, shopping, etc. Normal capacity refers to 
satisfactory handling of these basic financial tasks. Requires slight assistance refers to mild difficulties 
which would require the assistance / supervision of a family member or financial advisor. Requires 
major assistance refers to a participant who would require extensive supervision in handling routine 
financial tasks. Unable refers to a participant who would be unable to carry out these financial tasks, 
even with considerable assistance and supervision. 
Domestic chores 
0 = unable, 1 = impaired, 2 = normal 
Refers to the participant’s capacity to carry out routine domestic tasks such as cleaning, laundry, 
dishwashing, table-setting, cooking, lawn care, answering mail, maintaining a calendar, etc. Normal 
capacity refers to a full capacity without assistance. Impaired refers to impaired capacity requiring 
only slight assistance or supervision. Unable refers to marked incapacity requiring major assistance. 
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Activities of daily living 
0 = total care, 1 = gross tasks only, 2 = minimal impairment, 3 = normal 
Refers to the traditional areas of ‘activities of daily living’ (ADL) including eating, dressing and 
bathing. Normal refers to full capacity. Minimal impairment refers to impaired capacity requiring 
only slight assistance. Gross tasks only refers to impaired capacity requiring moderate assistance 
and supervision. Total care refers to major incapacity requiring total assistance and supervision. 
Care level 
0 = full time skilled nursing, 1 = home or chronic care, 2 = home 
Refers to the most appropriate care environment to meet the participant’s capacity, whether at 
home, at home or chronic care facility or full skilled nursing care (24 hours a day supervision). 
Functional Assessment 
Could the subject (one point each): 
1.      engage in gainful employment in accustomed work? 
2.      engage in any kind of gainful employment? 
3.      engage in any kind of volunteer or non-gainful work? 
4.      manage finances without help? 
5.      shop for groceries without help? 
6.      handle money as a purchaser in a simple cash transaction? 
7.      supervise children without help? 
8.      operate an automobile safely and independently? 
9.      do own housework without help? 
10.      do own laundry without help? 
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11.      prepare own meals without help? 
12.      use the telephone without help? 
13.      take own medications without help? 
14.      feed self without help? 
15.      dress self without help? 
16.      bathe self without help? 
17.      use public transport without help? 
18.      walk to places in neighbourhood without help? 
19.      walk without falling? 
20.      walk without help? 
21.      comb hair without help? 
22.      transfer between chairs without help? 
23.      get in and out of bed without help? 
24.      use toilet / commode without help? 
25.      be cared for at home? 
Independence Scale (IS) 
100% No special care needed 
90% No physical care needed if difficult tasks are avoided 
80% Pre-disease level of employment changed or ended; cannot perform household chores to 
pre-disease level; may need help with finances 
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70% Self-care maintained for bathing; limited household duties (cooking, knives); cannot drive; 
unable to manage finances 
60% Needs minor assistance in dressing, toileting, bathing; food must be cut 
50% 24 hour supervision appropriate; assistance required for bathing, eating and toileting 
40% Chronic care facility needed; limited self feeding, liquefied diet 
30% Minimal input into own feeding, bathing, toileting 
20% No speech, must be fed 
10% Tube-fed, total bed care 
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Appendix F Beck depression inventory 
(Beck et al. 1996) 
Instructions 
Read each item carefully, and tick the number next to the answer that best 
describes how you have been feeling the past week including today. 
Please tick only one answer in each group.  
 
 
I do not feel sad.  0 
I feel sad.  1 
I am sad all the time and can’t snap out of it.  2 
A 
I am so sad or unhappy that I can’t stand it.  3 
 
I am not particularly discouraged about the future.  0 
I feel discouraged about the future.  1 
I feel I have nothing to look forward to.  2 
B 
I feel that the future is hopeless and that things cannot improve.  3 
 
I do not feel like a failure.  0 
I feel I have failed more than the average person.  1 
As I look back on my life, all I can see is a lot of failure.  2 
C 
I feel I am a complete failure as a person.  3 
 
I get as much satisfaction out of things as I used to.  0 
I don’t enjoy things the way I used to.  1 
I don’t get real satisfaction out of anything anymore.  2 
D 
I am dissatisfied or bored with everything.  3 
 
I don’t feel particularly guilty.  0 
I feel guilty a good part of the time.  1 
I feel quite guilty most of the time.  2 
E 
I feel guilty all of the time.  3 
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I don’t feel I am being punished.  0 
I feel I may be punished.  1 
I expect to be punished.  2 
F 
I feel I am being punished.  3 
 
I don’t feel disappointed in myself.  0 
I am disappointed in myself.  1 
I am disgusted with myself.  2 
G 
I hate myself.  3 
 
I don’t feel I am worse than anybody else.  0 
I am critical of myself for my weaknesses or mistakes.  1 
I blame myself all the time for my faults.  2 
H 
I blame myself for everything bad that happens.  3 
 
I don’t have any thoughts of killing myself.  0 
I have thoughts of killing myself, but I would not carry them out.  1 
I would like to kill myself.  2 
I 
I would kill myself if I had the chance.  3 
 
I don’t cry any more than usual.  0 
I cry more now than I used to.  1 
I cry all the time now.  2 
J 
I used to be able to cry, but now I can’t even cry even though I want to.  3 
 
I am no more irritated by things than I ever am.  0 
I am slightly more irritated now than usual.  1 
I am quite annoyed or irritated a good deal of the time.  2 
K 
I feel irritated all the time now.  3 
 
I have not lost interest in other people.  0 
I am less interested in other people than I used to be.  1 
I have lost most of my interest in other people.  2 
L 
I have lost all of my interest in other people.  3 
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I make decisions about as well as I ever could.  0 
I put off making decisions more than I used to.  1 
I have greater difficulty in making decisions than before.  2 
M 
I can’t make decisions at all anymore.  3 
 
I don’t feel that I look any worse than I used to.  0 
I am worried that I am looking old or unattractive.  1 
I feel there are permanent changes in my appearance that make me look 
unattractive.  
2 
N 
I believe that I look ugly.  3 
 
I can work about as well as before.  0 
It takes an extra effort to get started at doing something.  1 
I have to push myself very hard to do anything.  2 
O 
I can’t do any work at all.  3 
 
I can sleep as well as usual.  0 
I don’t sleep as well as I used to.  1 
I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.  2 
P 
I wake up several hours earlier than I used to and cannot get back to sleep.  3 
 
I don’t get tired more than usual.  0 
I get tired more easily than I used to.  1 
I get tired from doing almost anything.  2 
Q 
I am too tired to do anything.  3 
 
My appetite is no worse than usual.  0 
My appetite is not as good as it used to be.  1 
My appetite is much worse now.  2 
R 
I have no appetite at all anymore.  3 
 
I haven’t lost much weight, if any, lately.  0 
I have lost more than five pounds.  1 
I have lost more than ten pounds.  2 
S 
I have lost more than fifteen pounds.  3 
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I am no more worried about my health than usual.  0 
I am worried about physical problems like aches, pains, upset stomach or 
constipation. 
1 
I am very worried about physical problems and it’s hard to think of much 
else.  2 
T 
I am so worried about my physical problems that I cannot think about 
anything else.  
3 
 
I have not noticed any recent change in my interest in sex.  0 
I am less interested in sex than I used to be.  1 
I am much less interested in sex now.  2 
U 
I have lost interest in sex completely.  3 
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Appendix G Short behavioural assessment 
(After Thompson et al.) 
Orientation (time) 
 Time of day morning  /  afternoon  /  evening; Day of week; Date; Month; Year 
0 Fully oriented: knows time of day, day of week, date (within  3 days), month, year. 
1 Partially disoriented 
2 Disoriented: completely mistaken about time and day  /  date 
3 Unable to respond because mute or cognitive deterioration too advanced 
Orientation (place) 
 Name of venue; Approximate address of venue; Type of establishment 
0 Fully oriented: knows name, approximate address, type of establishment 
1 Partially disoriented 
2 Disoriented: cannot correctly identify type of establishment 
Orientation (person) 
 Identify 2 people 
0 Fully oriented: identifies people known by name, and function of others; forgetting names 
acceptable unless known very well 
1 Partially disoriented 
2 Disoriented: wrongly identifies functions of people in the room 
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Depression  
In the past month have you been feeling sad? (or down or blue?) Has your mood affected your daily 
activities? Have you found yourself doing something you would ordinarily enjoy and realised you are 
not having fun? Behavioural persuasion: sad voice or expression, tearfulness Start the interview with an 
open ended question. Additional questions re depressive syndrome: appetite, change in weight; 
difficulty or disturbance in sleeping? Does the depressed mood come and go or does it seem always 
to be there? Is there any change throughout the day? 
Severity 
0 Absent 
1 Questionable or trivial 
2 Low mood present intermittently but does not interfere with everyday function; rate 2 if 
subject can easily enjoy amusing activities or visits from friends 
3 Feels sad much of the time, takes no pleasure from things that he / she usually enjoys, still 
able to cheer up sometimes with a big effort; low mood has definite effect on lifestyle, e.g. 
unable to enjoy company of friends or amusing diversions 
4 Subject feels utterly miserable all day 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
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Anxiety  
In the past month have you found yourself getting worried about things? Evidence of anxiety includes 
worrying, panic, feeling frightened or fearful for no apparent reason. Have you worried a great deal 
since your last visit? What is it like when you worry? Have you often felt on edge, or keyed up, or 
mentally strained? Have you had difficulty in relaxing? Do your muscles feel tensed up? When people 
get anxious they often feel their heart beating fast or they start shaking or sweating or can’t get their 
breath. Have you had feelings like that? 
Severity 
0 Never 
1 Questionable, vague unease (also rate 1 if subject's only worry or anxiety is about 
prognosis of HD) 
2 Intermittent worry or anxiety, not severe enough to cause significant distress or interfere 
with everyday activities; rate 2 for mild anticipatory anxiety prior to social events or 
unfamiliar activities 
3 Unpleasant anxiety present much of the time, significant impact on behaviour (e.g. avoids 
places or events associated with provoking anxiety) 
4 Anxiety present all the time, major impact on lifestyle (e.g. agoraphobia, cannot leave home 
without an escort); rate 4 if regular panic attacks 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
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Suicidal thoughts  
In the last month have you found yourself thinking that life is not worth living or that you would be 
better off dead? Have you thought about hurting yourself or killing yourself? Are you planning to hurt 
yourself or kill yourself? Have you taken any steps towards carrying out your plan? In the past four 
weeks, have you felt that life was not worth living or that you wouldn’t care if you didn’t wake in the 
morning? Have you thought about harming yourself or even making an attempt at suicide? 
Severity 
0 Absent 
1 Questionable; also rate 1 if subject plans suicide at a later date when disease is more 
severe but obtains comfort from this as means to retain control of destiny 
2 Sometimes very pessimistic with fleeting suicidal ideation 
3 Pervasive and distressing feelings of hopelessness and more prolonged or frequent suicidal 
ideation, but has not yet acted on this in any way 
4 Subject has attempted suicide or has made preparations such as saving up tablets or 
planning ways to avoid discovery when doing it 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
Disruptive / aggressive behaviour  
In the last month have you had any emotional or temper outbursts? Have you had times when you 
lost control of yourself? Have you hit, shoved or thrown things or expressed your temper in a physical 
way? Have you used threats or hostile words? 
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Severity 
0 Normal 
1 Questionable or trivial; within normal limits but worse than he / she used to be 
2 Verbal outbursts outside socially acceptable limits, not causing significant problems  /  
distress for other household members; becomes angry with self or inanimate objects when 
confronted with frustrating situations due to disability; violence towards property 
3 Tantrums causing significant distress for household members or practical difficulties caring 
for subject; verbal hostility directed towards another person; explicit verbal threats of 
violence or behaviour causing a justifiable fear of personal violence 
4 Temper tantrums so severe that relationship with carers is compromised, creating risk that 
subject will be rejected; any kind of actual physical assault 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
Perseveration 
Within the last month have you found yourself getting stuck on certain ideas? Within the past month 
have you been bothered by thoughts, images or fears that keep coming back even if you try not to 
have them? 
Severity 
0 Symptom absent 
1 Questionable or trivial 
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2  Mild perseverative behaviours  /  abnormal preoccupations present; do not interfere with 
everyday life or cause significant distress to subject  /  carers; comes out with comments 
referring to  earlier topic of conversation; rater observes perseverative phenomena during 
consultation 
3  Abnormal preoccupations occupy significant proportion of subject's attention, cause 
significant distress to subject or practical problems for carers; eg subject won't let matter 
drop after an argument  /  keeps returning to the same issue all day. 
4 Abnormal preoccupations occupy most of subject's attention and cause major problems 
and distress for subject and carers; may be preoccupied with the topic for several days at a 
time 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
Delusions  
I am going to ask you about unusual experiences that people sometimes have. Has it seemed like 
people are out to get you or perhaps controlling you? Has it seemed like you have special powers or 
importance or that books, TV and radio statements are referring to you? Are there any other unusual 
things you experience that I have not asked you about? Have you felt that people were unduly 
interested in you or that things were arranged to have special meaning or even that harm might come 
to you? Have there been any other odd or unpleasant experiences of any kind recently? 
Severity 
0 Symptom absent 
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1 Questionable or trivial 
2 Overvalued ideas (not true delusions) present for part of the day; do not affect behaviour 
3 Overvalued ideas present for much of day; behaves as if these beliefs true; can be 
persuaded with difficulty that mistaken 
4 Delusions: false beliefs, held with unshakeable conviction, not shared by social  /  cultural 
group, present continuously for ≥ 7 days 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
Hallucinations  
Have you heard things that other people could not hear such as noises or voices of people whispering 
or talking? Did you ever have visions or see things that other people could not see? How about any 
other strange sensations in your body, skin, smell or taste? We ask this question of everyone and 
would like to ask you; do you ever seem to hear voices or noises when there is nobody about and no 
ordinary explanation seems possible, or see or feel things other people can’t? What about any other 
unusual experiences or talents that some people have such as having second sight or being aware of 
strange presences? 
Severity 
0 Symptom absent 
1 Questionable or trivial 
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2 Reports hallucinations when asked but do not appear to cause any distress or affect 
subject's behaviour; experiences hallucinations but is aware that they cannot be real. 
3 Hallucinations affecting behaviour eg looking for source of voices, but not appearing to 
cause much distress 
4 Clearly distressed by hallucinations and preoccupied with them 
Frequency 
0 Never, or almost never 
1 Seldom: <1 times a week 
2 Sometimes: 1-4 times a week 
3 Frequently: 5-6 times a week 
4 Every day or almost every day 
Apathy 
Within the last month have you ever found that you have lost interest in things that used to be 
important to you? Do you sit around a lot doing nothing? Are you just as interested as always in trying 
new things, starting new projects? If apathy and depression are both felt to be present it would be 
important to differentiate clearly with reasons between the two. 
Severity 
0 Symptom absent 
1 Questionable or trivial 
2 No longer tries new things; gentle prompting to initiate pastimes which usually enjoys; less 
effort to keep up with friends  /  relatives; puts off household tasks previously part of daily 
routine, gentle prompting to do these things 
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3 Overt prompting to take part in pastimes  /  carry out daily household tasks; little / no effort 
to keep up with friends, left to others to initiate social contacts; takes part in & enjoys 
conversation; tends to follow, less likely to initiate a change of subject 
4 Performs no household tasks even if prompted repeatedly; never initiates activities, no 
interest in pastimes; impoverished speech, rarely initiates new conversation topics except re 
own needs; active choices limited to selecting TV programmes; switches on  /  changes 
channel 
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Appendix H Cognitive battery 
Cognitive tasks were administered by the same investigator at each visit, in a single session lasting 
about 1½ - 2 hours.  The order of tasks was kept constant. The tasks were: 
• Pre-morbid IQ: National Adult Reading Test (NART) (Nelson et al. 1991) 
• UHDRS cognitive tests: 
− Stroop colour-reading, word-reading and colour-word interference (Delis et al. 2001) 
− Letter fluency (Benton 1976) 
− Symbol Digit Modalities Test (SDMT) (Smith 1968) 
• Other executive / psychomotor tasks: 
− Category fluency (animals) (Delis et al. 2001) 
− Homophone Meaning Generation Test (HGMT) (Warrington 2000) 
− Trail-Making Test A and B, A cancellation 
• Memory: 
− Hopkins Verbal Learning Test-Revised (Brandt et al. 2001) 
− Digit span forward and backward, with 3 trials at each length (Wechsler 1981) 
− Recognition Memory Test (RMT) (Warrington 1984) 
• Naming: the Graded Naming Test (GNT) (McKenna et al. 1983) 
• Visuo-spatial: 
− Silhouette subtest of the Visual Object and Space Perception Battery (VOSP) 
(Warrington et al. 1991) 
− Benton Facial Recognition Test (Benton et al. 1983) 
 244 
• Emotion recognition: 24 faces from the Ekman and Friesen battery were used (Ekman et al. 
1976) 
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Appendix I Semi-automated segmentation of whole brain 
(Adapted from Dementia Research Centre Standard Operating Procedure and reported by 
Freeborough et al. 1997) 
Introduction 
The aim of the segmentation is to label all voxels that are predominantly brain while excluding non-
brain, for example, CSF, dura and the superior sagittal sinus. In some cases, whole brain 
segmentation can be accomplished in four steps: 
• Intensity thresholding to exclude voxels outside the intensity range for brain. 
• Erosion to break connections between brain and non-brain. 
• Dilation to restore eroded brain. 
• Rethresholding to include missing voxels within brain.  
NB: All steps operate on all slices in a three-dimensional fashion. At each stage, the current 
segmentation is reviewed through the whole volume. 
Intensity thresholding 
Intensity thresholds are set to exclude voxels brighter than brain (e.g. scalp) and darker than brain 
(e.g. CSF). 
The upper threshold should be set first. Anything brighter than the upper threshold will be excluded. 
Leaving the lower threshold on zero, increase the upper threshold until there is no green signal 
intensity within brain. 
Secondly, the lower threshold is set initially to lower than half the value of the upper threshold and 
then adjusted to include as much of brain as possible while minimising the inclusion of non-brain. 
The green intensity region should include most of the brain. 
The area around the cerebellum and temporal lobe are checked to ensure that most of the bridges 
— signal intensity connections linking brain to dura or superior sagittal sinus — are broken. 
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Ideally the lower threshold should be taken to a high enough value so that in the next step only one 
erosion is needed to remove non-brain. 
Finally, the axial cut-off slice is selected. This removes any structures below the inferior edge of the 
cerebellum. The coronal slice in which the cerebellum extends most inferiorly is the cut-off. Other 
slices are checked to ensure that all cerebellum is included. 
After ‘Accept’ is pressed, MIDAS searches for the largest connected three-dimensional object in the 
current region (i.e. brain) and removes any smaller unconnected objects. 
 
Thresholded image with voxels lighter and darker than brain excluded, and with the axial cut-off 
slice set to the lower extent of the cerebellum 
Erosion — breaking remaining connections between brain and non-brain 
The erosion removes a layer of edge-voxels from all surfaces of the region. The purpose is to break 
thin connections between brain and scalp. After each erosion, the program retains only the largest 
connected region. The minimum number of erosions necessary to isolate brain from non-brain are 
used. The usual range of erosions is 0-3. High numbers of erosions remove significant quantities of 
brain from the region that cannot be recovered in the dilation stage. In this case, the thresholds may 
be at fault or the image may be artefactual or noisy. 
Eroded voxels have a signal intensity below the upper threshold value. 
The number of erosions is increased one at a time until all non-brain structures are removed. If the 
edges of the brain region are still within grey matter, erosions can be increased by one. If the edges 
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of the brain region are within white matter, another erosion may remove too much. There are two 
ways to proceed. 
• Often the brain remains connected to scalp on only a few slices, often around the temporal 
lobes. If connections can be identified visually, then they can be broken interactively at this 
stage by striking through them with the mouse while holding down the middle button. 
Areas where connections have been interactively broken appear orange. When all 
connections between brain and non-brain have been removed, all parts of the region 
external to brain are removed automatically. The width of the interactive connection 
breaker can be set by adjusting the cursor width slider bar from 1-6. The right mouse 
button will remove the connection breaker and the left will add in additional region. 
• Further erosions can be performed, but the upper threshold can be lowered so that the 
white matter of brain is not eroded. This can break lower intensity connections between 
brain and scalp or dura without eroding any more brain. 
 
Eroded region showing disconnection from non-brain tissue 
Dilation — restoring eroded brain 
The purpose of this step is to recover the brain voxels that have been removed by erosion. Each 
dilation grows out from the edges of the current brain region but only into voxels within the 
currently defined range of intensities that represent brain. The intensity thresholds that appear at this 
point are automatically set by calculating the mean signal intensity over the whole brain region 
taking 60% and 160% of this value. These percentages have been determined to be suitable for T1-
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weighted volumes. These thresholds are re-calculated after each dilation as more voxels are 
recovered. 
The number of dilations that are needed to recover all brain voxels depends on the number of 
erosions (typically number of erosions plus 1 or 2). The number should be kept low enough so that 
no dura or sagittal sinus are included even if this results in a small proportion of brain not being 
included. Regions around the eyes are checked to ensure that the region has not extended into this 
area. 
The connection breaker can also be used at this stage to remove any final areas of scalp  /  dura 
which are attached. 
 
Dilated image showing disconnection from non-brain tissue 
Rethresholding — reclaiming remaining excluded areas 
This step is generally not required. However if there are small areas missing from the brain region 
this may remove the need for manual editing. It will also remove any tissue outside the thresholds 
within the brain. This step completes the segmentation. The rethresholding box is a box of voxels 
that moves across the outlined brain region and fills in any area within that region that has been 
omitted by step 3 subject to the following constraints: 
• The omitted area must be smaller than the box. 
• Only those voxels that have a signal intensity of between 60% and 160% of the mean brain 
intensity will be included. 
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• The missing area must already be internal to the region.  
Generally, a rethresholding box size of 6 will be large enough to recover any areas that have 
previously been excluded. 
Manual editing 
In cases where either some non-brain tissue remains in the segmentation, or brain tissue has been 
omitted, manual editing is required. Unlike the automated whole brain segmentation, editing is 
limited to the slice being viewed — manual editing does not work on the 3D volume. 
The brain region generated by the automated segmentation process above is highlighted (which 
should turn from blue to red), and manual editing mode is activated. Another window gives any one 
of two orthogonal views to that in the main window. Slices where the segmentation needs editing 
are selected, with particular attention to the temporal lobes and cerebellum, as these are areas 
where editing is most often required. If brain tissue has been excluded, the border can be deleted 
and a new border redrawn. 
New regions can be included by placing a seed in the appropriate area. Either a border can be 
drawn manually around the structure, or alternatively upper and lower thresholds can be selected to 
delineate the structure automatically. 
Finally, the new region is viewed in all planes to ensure that the manual editing process has not 
introduced new errors into the segmentation. The region is saved in the database. 
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